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Thrombosis is the pathologic formation of a blood clot within the vascular lumen. 
Intravascular clotting should always be regarded as pathologic, because blood 
clots physiologically form only at the sites of vascular wall injury. Thrombotic 
diseases constitute the main primary cause of death and disability worldwide and 
are the second most frequent secondary cause of death in patients with cancer.1 
Thrombosis may occur in virtually any vessel of the blood circulation and 
therefore thrombotic diseases are classified according to the type and location of 
the vessel that is occluded (Figure 1). Thrombosis in the vessels of microscopic 
caliber (terminal arterioles and capillaries) is the defining characteristic of 
thrombotic microangiopathies. Thrombotic microangiopathies are a group of 
diseases or clinical syndromes with overlapping clinical characteristics and 
heterogeneous etiology, highlighting the multicausal nature of microvascular 
thrombotic disease.2 Classifying thrombotic microanciopathies is difficult. There 
are many possible classification criteria (by clinical symptoms, by associated 
clinical condition, by pathophysiology, by any other characteristic), and we 
propose a reasonable classification in Table 1. Idiopathic thrombotic 
thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome 
(aHUS) are the two most important forms of idiopathic thrombotic 
microangiopathy. From a clinical standpoint, the two diseases are characterized 
by acute episodes of thrombocytopenia and microangipathic hemolytic anemia 
(Coombs negative hemolytic anemia with signs of red blood cell fragmentation). 
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Atypical HUS has prominent renal involvement with acute renal failure (which is 
a required criterion for the diagnosis of HUS), whereas TTP frequently (but not 
invariably) displays neurological manifestations. From a pathophysiological 
standpoint, aHUS is characterized by hyperactivation of the alternative 
complement pathway.3 Hyperactivation of the alternative pathway is usually 
caused by rare nonsynonymous mutations in complement factor or complement 
regulation genes.3 The patterns of inheritance of aHUS are articulated and 
characterized by variable penetrance, considerable locus heterogeneity and 
epistasis. Idiopathic TTP is characterized by a severe deficiency of the von 
Willebrand factor (VWF) cleaving protease, ADAMTS13. This form of 
microvascular thrombosis is the main focus of this thesis. 
Thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency 
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic 
microangiopathy characterized by acute episodes of widespread microvascular 
thrombosis causing severe ischemic organ damage.4 In the late 1990s it was 
discovered that the plasmatic activity of the von Willebrand factor (VWF) 
cleaving protease, ADAMTS13, is severely deficient in individuals with TTP. 
This discovery represented a turning point in the understanding of the 
pathophysiology of the disease.5 ADAMTS13 (a disintegrin and 
metalloproteinase with a thrombospondin type 1 motif, member 13) is the 
thirteenth member of the ADAMTS family of metalloproteases. Severe 
ADAMTS13 deficiency (i.e., a plasmatic activity of the protease below 10% of 
normal) is either due to circulating anti-ADAMTS13 autoantibodies (i.e. acquired 
deficiency)6 or, less frequently, to recessively inherited mutations of ADAMTS13 
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(i.e. congenital deficiency).7 Although not all of the patients with a clinically 
defined TTP present with severely reduced ADAMTS13, the finding of severe 
ADAMTS13 deficiency has been shown by several studies to define a distinct 
etiologic subgroup of the disease.5 In TTP patients with severe ADAMTS13 
deficiency, the pathologic presence in the circulation of uncleaved ultralarge 
VWF multimers is considered as the mechanism responsible for VWF-mediated 
platelet aggregation and thrombosis.4 The clinical severity of TTP is 
heterogeneous both in terms of short and long term prognosis. The studies 
presented in this thesis investigate the pathophysiology of TTP with ADAMTS13 
deficiency, in an effort to better understand the clinical heterogeneity that 
characterizes TTP patients. 
We studied both congenital (Section I, Chapters 1-4) and acquired (Section II, 
Chapters 5-9) forms of TTP in order to identify factors influencing clinical 
heterogeneity. 
In Chapter 1, we sought to compile a catalog of all genetic variants in the 
ADAMTS13 gene that are associated with congenital TTP. We systematically 
studied the type and location of these variants, the results of functional studies 
and their association with disease phenotype. The aim was to discover whether 
genotype-phenotype relationships existed. We found that ADAMTS13 genotype is 
a determinant of clinical heterogeneity. 
In Chapter 2, we expanded these observations and conducted a study measuring 
residual ADAMTS13 activity in 29 patients with congenital TTP. The goal was to 
find whether a residual ADAMTS13 activity exists in congenital TTP patients 
and if that activity is associated with phenotype severity. We found that residual 
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ADAMTS13 activity is a determinant of clinical heterogeneity and we described 
genotype-phenotype relationships. 
In Chapter 3, we described a case of congenital TTP. By measuring residual 
ADAMTS13 we sought to determine if ADAMTS13 activity is abolished during 
acute TTP in patients with congenital TTP who have measurable activity in 
remission.  
In Chapter 4, we summarized all recent studies on residual ADAMTS13 activity 
in TTP, discussing their pathophysiologic implications. 
In Chapter 5, we introduced acquired TTP, summarizing knowledge on the role 
of anti-ADAMTS13 autoantibodies in the disease. 
In Chapter 6, we compared the clinical severity of acquired TTP in first episodes 
and recurrences, in order to determine whether clinical episode number is 
associated with disease severity. We found that episode number is a determinant 
of clinical heterogeneity in TTP. 
In Chapter 7, we studied VWF-related measurements during acute disease and 
remission of TTP. The goal was to see if changes of VWF properties (e.g. its 
conformation) were associated with the onset of thrombosis in patients with TTP 
and if these properties were associated with the disease severity. We found that 
multimeric VWF pattern is associated with acute severity of TTP. 
In Chapter 8, we studied several ADAMTS13- and anti-ADAMTS13 
autoantibody-related measurements in acquired TTP patients, in order to 
determine their association with acute disease severity and with the occurrence of 
disease recurrence. We found several associations between study measurements 
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and clinically relevant endpoints, such as number of plasma exchange procedures 
needed to achieve remission or the development of recurrence. 
In Chapter 9, we reported the case of a patient with a history of acquired TTP 
who was safely treated with thienopyridines (i.e. drugs associated with the 
development of drug-induced-TTP). The report demonstrates that these drugs do 




Figure 1. Localization of thrombotic diseases. 




TTP, thrombotic thrombocytopenic purpura; TMA, thrombotic microangiopathy; 
DVT, deep vein thrombosis. 
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Tables 
Table 1. Classification of thrombotic microangiopathies. 
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a HELLP is classified as secondary TMA because it develops in pregnant women with 
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b Disseminated intravascular coagulation is secondary to many different 
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Abstract 
Congenital thrombotic thrombocytopenic purpura (TTP) (also known as Upshaw-
Schulman syndrome, USS) is a rare, life-threatening disease characterized by 
thrombocytopenia and microangiopathic hemolytic anemia. The disease is caused 
by a deficiency of the von Willebrand factor-cleaving protease (ADAMTS13) 
due to mutations in the corresponding gene. The spectrum of clinical phenotypes 
in congenital TTP is wide, encompassing neonatal-onset disease and adult-onset 
disease, forms with a single disease episode and chronic-relapsing forms.  
In this article, we review ADAMTS13 gene variants associated with inherited 
ADAMTS13 deficiency and congenital TTP. To date, 76 mutations of 
ADAMTS13 are reported in the literature. Missense mutations, which constitute 
nearly 60% of ADAMTS13 mutations, preferentially localize in the 5’-half of the 
gene encoding the N-terminal half of the protein, where the domains that are 
indispensable for ADAMTS13 catalytic function are situated. In vitro expression 
studies in cell cultures have shown that defects in protein secretion and catalytic 
activity are the main mechanisms responsible for the deficiency of ADAMTS13 
in congenital TTP patients. Even though data from the literature suggest the 
existence of genotype-phenotype associations, a clear relationship between the 
type and the effect of ADAMTS13 genetic defects with disease manifestations 
remains to be established. 
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Background 
Congenital thrombotic thrombocytopenic purpura (TTP), also known as Upshaw-
Schulman syndrome (OMIM accession number 274150), is a rare, life-
threatening disease characterized by single or recurrent episodes of 
thrombocytopenia, microangiopathic haemolytic anaemia and widespread 
microvascular thrombosis, which leads to ischemic damage of multiple organs 
(mainly kidney, heart and brain).1, 2 Congenital TTP has an autosomal recessive 
inheritance and is caused by mutations in ADAMTS13 (OMIM gene accession 
number: MIM# 604134).3 The gene encodes a plasma zinc metalloprotease of the 
ADAMTS family (a disintegrin-like and metalloprotease with thrombospondin 
type 1 motif), responsible for the cleavage of von Willebrand factor (VWF). 
VWF is a large multimeric glycoprotein synthesized in vascular endothelial cells, 
stored in Weibel–Palade bodies, and secreted upon endothelial cell activation or 
injury into plasma, where it plays two main functions in hemostasis. First, it is 
essential for platelet-plug formation as an adhesion protein that diverts circulating 
platelets to the sites of vascular injury, particularly through multimers of 
ultralarge size (ULVWF).4 Second, it forms a noncovalent complex with 
coagulation factor VIII in plasma, protecting the latter from inactivation and 
clearance.5 In physiologic conditions, ADAMTS13 cleaves ULVWF as soon as 
this adhesive protein is released by endothelial cells.6 When ADAMTS13 activity 
is deficient, uncleaved ULVWF causes heightened platelet adhesion and 
aggregation in the microcirculation, resulting in platelet-rich thrombi that are 
responsible for the fragmentation of circulating erythrocytes (microangiopathic 
hemolytic anemia) and for signs and symptoms of organ ischemia and 
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dysfunction.7 ADAMTS13 deficiency may be due to the production of anti-
ADAMTS13 auto-antibodies (acquired) or to mutations in ADAMTS13 
(congenital).3, 8-10 Congenital disease accounts for no more than 5% of all TTP 
cases associated with ADAMTS13 deficiency, the incidence of which is 
2/1.000.000 person/year.11 The exact incidence of congenital TTP has not been 
established, but it is less than 1/1.000.000 person/year. Congenital TTP was 
originally described as a form of thrombocytopenia dramatically responsive to 
plasma infusion, that Schulman, who first described the disease in 1960, ascribed 
to the congenital deficiency of a “humoral regulator of thrombopoiesis”.2 The 
mechanism of the disease remained unclear until 2001, when Levy et al. by 
means of linkage analysis performed on 4 pedigrees with congenital TTP, 
demonstrated that mutations in the ADAMTS13 gene resulting in severely reduced 
VWF-cleaving protease activity in plasma are responsible for the autosomal 
recessive inheritance of the disease.3 ADAMTS13 spans 29 exons and ~37 kb and 
is located at chromosome 9q34. From its N-terminus, the encoded 
metalloprotease ADAMTS13 comprises a signal peptide domain, a propeptide 
domain, a metalloprotease domain, a disintegrin like domain, a 
thrombombospondin type 1 repeat (TSP1) domain, a cysteine-rich domain, a 
spacer domain, 7 additional TSP1 repeats and two terminal complement C1r/C1s, 
Uegf, Bmp1 (CUB) domains.12 
We hereby review ADAMTS13 gene variants associated with inherited 
ADAMTS13 deficiency and congenital TTP. The features of these variants 
pertaining to their type, their localization on the gene and their effect on amino 
acid residues are presented. The results of in vitro expression studies of 
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ADAMTS13 mutations and polymorphisms are also summarized. Finally, the 
potential relevance of the results of these studies to the attribution of genotype-
phenotype associations is discussed. According to the Human Genome Variation 
Society (HGVS) instructions, nucleotide numbering refers to cDNA numbering 
with the A of the ATG codon numbered as +1. NM_139025.3 was used as 
reference sequence for nucleotide changes. NP_620596.2 was used as protein 
reference sequence. The review was based on published articles found through 
web-based searches on PubMed (updated at July 2009), using “ADAMTS13 
mutation”, “ADAMTS13 genotype”, “ADAMTS13 polymorphism”, “congenital 
thrombotic thrombocytopenic purpura” as queries. 
 
Clinical features of the disease 
The spectrum of clinical phenotype in congenital TTP is wide. While many 
patients develop thrombocytopenia and microangiopathic hemolytic anemia soon 
after birth, others have their first disease episode in adulthood, during the second 
or the third decade of life.13 The clinical severity of disease episodes varies from 
asymptomatic episodes of thrombocytopenia and anemia to multi-organ failure 
that threatens patients’ life.14 In addition, after the first disease episode patients 
may undergo one or more relapses, and in some cases progressive organ failure 
develops, likely as a result of the accumulation of ischemic damage.15 Aspects of 
disease phenotype severity might not be always consistent. For instance, it has 
been reported that adult-onset patients may also die of the disease16 or develop 
relapsing disease after their first TTP episode13, 17, 18 as well as early-onset 
patients do.  
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Supplementary Material S1 summarizes the 89 cases with congenital 
ADAMTS13 deficiency reported in the literature. Patients were included on the 
basis of a diagnosis of inherited severe deficiency of ADAMTS13 (ADAMTS13 
activity <10% of normal with concomitant absence of anti-ADAMTS13 
autoantibodies) and presence of mutations on both alleles of ADAMTS13. There 
are three cases reported in the literature16, 19 of patients with TTP episodes and a 
laboratory pattern suggestive of inherited severe deficiency of ADAMTS13, in 
whom it was possible to identify only one ADAMTS13 mutation after gene 
sequencing by PCR and Sanger sequencing. The phenotype of these patients may 
have been caused by a combination of ADAMTS13 single nucleotide 
polymorphisms (SNPs), which can have a profound effect on ADAMTS13 
secretion and activity, or by a mutation localized in the non-coding areas of 
ADAMTS13, which are not routinely analyzed. However, it cannot be excluded 
that genetic variants in genomic areas other than ADAMTS13 are responsible for 
the peculiar pattern of these patients. When the history of a patient was reported 
in more than one publication, the patient was included only once in the Table. 
Cross-references between studies were examined to avoid inclusion of the same 
patient more than once. Of the 89 reported cases, 84 had episodes of TTP, while 5 
reached adult age without developing TTP episodes, in spite of their severe 
ADAMTS13 deficiency. These individuals were siblings of patients with 
congenital TTP. For as many as 78 individuals with congenital ADAMTS13 
deficiency information was provided on disease onset, ranging from neonatal to 
35 years (median: 1,3 years). Of the 78 patients, 45% (n=35) had neonatal disease 
onset, 29% (n=23) intermediate onset (spanning from 2 months to 18 years), 20% 
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(n=15) adult onset (>18 years) and 6% (n=5) reached adulthood without 
developing TTP, in spite of undetectable ADAMTS13 activity and TTP-causing 
mutations. Information on other features of the disease phenotype was difficult to 
obtain from published cases and was available for a limited number of patients 
only. 
 
Genetic variants of ADAMTS13 
Since 2001, when ADAMTS13 mutations were first discovered to be associated 
with congenital TTP, 76 ADAMTS13 mutations have been reported (Table 1). 
These include: 45 missense mutations (59% of all reported mutations), 10 
nonsense mutations (13%), 10 deletions (13%), 4 insertions (6%) and 7 splice site 
mutations (9%). The majority of reported congenital TTP cases (64%) are 
compound heterozygous, while only 36% of patients were homozygous for 
ADAMTS13 mutations, making it difficult to identify genotype-phenotype 
associations. Figure 1 shows a linear map of the localization of ADAMTS13 
missense mutations on the gene. Of 45 missense mutations, 33 (73%) localize in 
the 5' half of the gene encoding the N-terminal half of the protein where the 
domains essential for ADAMTS13 specific activity (metalloprotease through 
spacer domains) are located. No missense mutation has been described in exons 
1, 2, 11, 14, 15, 18, 20, 23, 29. 
The geographic distribution of all ADAMTS13 mutations as established from the 
country of birth of the patients (available for 55% of all reported mutations) is 
shown in Table 1. Congenital TTP cases have been reported in all continents. 
Haplotype analyses of patients carrying c.4143dupA, the most frequently reported 
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ADAMTS13 mutation, revealed a common genetic background, suggesting of the 
existence of a common ancestor in Central Europe.15 
Nineteen non-synonymous SNPs of ADAMTS13 are recorded in dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/). Eight of them have also been 
reported in patients with congenital TTP. Two additional SNPs (c.1016C>G 
leading to p.T339R and c.2708C>T leading to p.S903L) were reported in 
Japanese patients with congenital TTP and confirmed to have minor allele 
frequency above 1% in the Japanese population,20, 21 but were not included in 
dbSNP. Notably, in dbSNP, there are 3 polymorphisms (a nonsense SNP, one 
insertion and one deletion) that are predicted to result in the truncation of 
ADAMTS13. Table 2 summarizes nonsynonymous polymorphisms of the coding 
area of ADAMTS13. 
 
Biological relevance: effect of ADAMTS13 mutations on the encoded protein 
ADAMTS13 mutations affect the metalloprotease, the disintegrin, the TSP1-1, the 
cysteine-rich, the spacer, the TSP1-2, TSP1-3, TSP1-5, TSP1-6, TSP1-7, TSP1-8, 
CUB-1 and CUB-2 domains (Table 1). No mutations affecting the signal peptide, 
the propeptide and the TSP1-4 have been reported as yet. Two SNPs of 
ADAMTS13 (c.19C>T leading to p.R7W and c.2494G>A leading to p.V832M) 
localize in the propeptide and in the TSP1-4 domain, respectively, so that genetic 
variants of ADAMTS13 affecting each of the ADAMTS13 protein domains, with 
the exception of the small signal peptide domain, have been described.  
N-terminal ADAMTS13 domains (metalloprotease through spacer) are highly 
conserved among ADAMTS proteins22 and are all required for ADAMTS13-
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mediated cleavage of VWF.23-25 C-terminally truncated mutations that lack the 
spacer domain indeed result in a protein unable to cleave VWF in vitro.23 The C-
terminal TSP1 domains, which are conserved among ADAMTS proteins, and the 
CUB domains, uniquely present in ADAMTS13 among ADAMTS proteins, are 
dispensable for ADAMTS13 activity under static conditions.23 However, the 
cooperative activity between C-terminal TSP1 domains and CUB domains is 
necessary for ADAMTS13-VWF interaction in conditions of shear stress that 
resemble those of the small vessels in which VWF cleavage takes place.26, 27  
The conservation of ADAMTS13 amino acid residues was evaluated through a 
comparison of ADAMTS13 amino acid sequence alignments in 5 species (Homo 
sapiens, Bos taurus, Mus musculus, Rattus norvegicus, and Gallus gallus), using 
Multiple Sequence Alignment (MUSCLE). Human ADAMTS13 showed the 
highest sequence identity with ADAMTS13 of Bos taurus (~75% of amino acid 
sequence identity), and the lowest with ADAMTS13 of Gallus gallus (~34%). 
Reported ADAMTS13 missense mutations determine amino acid changes in 
residues that are highly conserved across species (at least in 3/4 of the non-human 
species analysed), which confirms the importance of these residues for 
physiological function of ADAMTS13 (Table 3). Of 45 missense mutations, only 
4 were located in less conserved residues (p.I79M, p.A606P, p.R692C and 
p.R1060W). 
Twenty-six ADAMTS13 mutations, representing one third of those reported, were 
expressed in cultured cells to evaluate in vitro the mechanisms by which they 
induce ADAMTS13 deficiency (Table 4). In vitro studies differed in the design 
and methods adopted, so that it is not easy to compare results of different reports. 
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However, when mutations were evaluated in more than one study, results were 
generally concordant.16, 28, 29 The two main mechanisms leading to ADAMTS13 
deficiency are reduced secretion and reduced catalytic activity of mutant 
ADAMTS13. Of 26 mutations expressed, 9 result in severe reduction of 
ADAMTS13 secretion in culture medium. Of the remaining 17, 6 had no catalytic 
activity, while 11 conserved some degree of cleaving activity towards VWF. 
Nonsense mediated mRNA decay has been also described as a mechanism 
responsible for ADAMTS13 deficiency, in addition to impaired secretion and 
activity.30 
Six ADAMTS13 polymorphisms have been expressed in cell cultures. Notably, 
two of them (c.1423C>T leading to p.P475S, and c.1852C>G leading to 
p.P618A) result in a significant reduction of in vitro ADAMTS13 catalytic 
activity compared to wild type (Table 4).20, 31 This effect of SNPs on 
ADAMTS13 activity and secretion might be particularly relevant in patients 
carrying ADAMTS13 mutations. During in vitro experiments on the ADAMTS13 
mutation p.R1336W, found in 2 patients with congenital TTP, the combined 
presence of such SNPs and this mutation did indeed cause ADAMTS13 
deficiency in vitro, while the mutation or the SNPs alone did not.31   
 
Clinical relevance: does ADAMTS13 genotype influence the clinical features 
of the disease? 
Probably owing to the rarity of patients homozygous for ADAMTS13 mutations 
and to the paucity of in vitro expression studies, no genotype-phenotype 
association has been firmly established in congenital TTP. In Figure 2 the 
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ADAMTS13 genotypes that occurred more than once in the considered case 
material were plotted against the age of onset of the corresponding patients, 
which is the only phenotypic parameter for which enough information can be 
retrieved in the literature. We observed that in patients with a given ADAMTS13 
genotype, the age of disease onset was similar (Figure 2), suggesting the 
existence of a genotype-phenotype association. A concordance of age of onset 
could also be observed when patients came from different case series (patients 
with homozygous mutations c.4143dupA, p.R692C and p.R1060W). All 5 
patients (patients 33, 67, 68, 76, 88 in Table 1) with ADAMTS13 deficiency who 
reached adulthood without developing symptoms of TTP were siblings of patients 
with adult or intermediate (15 years) disease onset. In addition, mutation 
p.R1060W, a frequently reported ADAMTS13 mutation, was found in 4/15 
patients with adult-onset congenital TTP and in two asymptomatic siblings of 
congenital TTP patients, but not in early or intermediate-onset cases. Only one of 
the patients was homozygous for p.R1060W.19 In this study, we report an 
additional Italian patient carrying p.R1060W in homozygosis, who developed two 
TTP episodes at 18 and 19 years old, in occasion of her two pregnancies. These 
suggest the existence of a genotype-phenotype association in congenital TTP. 
The mechanisms of the association between ADAMTS13 mutations and disease 
phenotype are unknown. Since the catalytic activity of mutant recombinant 
ADAMTS13-R1060W is fully conserved (compared with wild type 
ADAMTS13), it has been postulated that a partial conservation of ADAMTS13 
activity in patients' plasma, which is undetectable with current ADAMTS13 
activity assays, is perhaps responsible for the milder phenotype of late onset 
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patients.19, 32, 33 An association of the results of in vitro studies with patients’ 
laboratory and clinical phenotype has been reported in a few families with 
congenital TTP and homozygous ADAMTS13 mutations.33 Using data available 
from the literature it is difficult to obtain a confirmation of these results. No clear 
association was found in the available data between age of disease onset, in vitro 
expression study results and conservation of mutated amino acid residues across 
species (Table 3). 
 
Molecular diagnosis, animal models and disease modifiers 
Congenital TTP should be suspected in patients who present with severe 
ADAMTS13 deficiency and absence of anti-ADAMTS13 auto-antibodies (severe 
congenital deficiency of ADAMTS13). In these patients, genetic analysis carried 
out by PCR amplification and sequencing of the exon areas and the intron-exon 
boundaries of ADAMTS13, is used to identify disease-causing genetic defects. 
Although congenital severe deficiency of ADAMTS13 is a specific laboratory 
marker of congenital TTP, both clinical and experimental evidence indicates that 
the deficiency is not sufficient to determine acute TTP episodes. More than 50% 
of patients with a severe deficiency have their first TTP episode well after the 
neonatal period, during infancy or even adulthood, after years of apparent well-
being and absence of disease manifestations. Consistent with these clinical 
observations the ADAMTS13 knock-out mouse was viable and exhibited normal 
survival. Only the introduction in the animal of a genetic background associated 
with high levels of VWF resulted in chronic spontaneous hemolysis and 
thrombocytopenia. A TTP-like syndrome could be elicited in the latter animal 
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model only after treatment with E coli-derived shigatoxin.34 Since genetic defects 
of ADAMTS13 cannot entirely explain the variable clinical features of congenital 
TTP, an effect on clinical phenotype of genetic defects other than those that cause 
ADAMTS13 deficiency has been postulated. The role of possible disease 
modifiers has not been the object of systematic investigations. However, Noris et 
al. reported that the pattern of clinical presentation of congenital TTP in a family 
carrying mutations p.G1239V and p.V88M was influenced by a mutation in 
complement factor H gene, a gene the mutations of which are associated with the 
familial form of hemolytic uremic syndrome.35 
Environmental modifiers may as well explain part of the variability of the 
phenotype of congenital TTP. The onset of acute TTP episodes in individuals 
with congenital ADAMTS13 deficiency is often associated with conditions and 
events such as pregnancy, infections, traumas, and surgical procedures.16, 18, 21 It 
is possible that these conditions and events precipitate the onset of acute episodes 
by inducing the release of the pro-thrombotic ULVWF forms by endothelial cells. 
However, such triggering conditions are not always present or clinically overt. 
 
Future perspectives 
The discovery that ADAMTS13 mutations cause congenital TTP has led to 
improvements in the knowledge of this rare but life threatening disease. The rare 
patients with homozygous ADAMTS13 mutations are particularly suitable to 
study genotype-phenotype relationships. From a clinical point of view clinical 
studies are needed to characterize, in a uniform way, disease-related clinical 
features, such as age and severity of presentation and the tendency to relapse. 
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Finally, while fresh frozen plasma infusion is established as the treatment of 
choice of acute disease episodes, it is important to establish which patients are 
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Figure 1. Linear map of the distribution of ADAMTS13 missense mutations on 
the gene and on the protein. Number within boxes indicate exon number, 




§ p.[C322G (+) T323R (+) F324L]. 
SP, signal peptide domain; TSP, thrombospondin-like domain; Cys, cysteine-rich domain; 
CUB, complement C1r/C1s, Uegf, Bmp1 domain. 
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Figure 2. Relationship between ADAMTS13 genotype and age of TTP onset. 
Genotypes are ordered on the basis on the mean age of onset of patients with each 
genotype. Circles represent patients who had neonatal TTP onset, triangles, 
patients with intermediate (2 months-18 years) onset,  closed squares, patents 
with adult onset  (>18 years), open squares, patients with no episodes of TTP at 








Table 1. Mutations of ADAMTS13. When available, the geographic origin of the 
patients carrying the mutations is indicated. The geographic origin of the parents 
of the patients with a given mutation is also indicated in brackets. Nucleotide 
numbering reflects cDNA numbering with +1 corresponding to the A of the ATG 
translation initiation codon in the reference sequence (www.hgvs.org/mutnomen). 
The initiation codon is codon 1. 
 
Location DNA Effect (protein or mRNA) Domain Ethnicity Reference 
Splice site      
Int 3 c.330+1G>A r.[330_331ins105, 
330_331ins27] 
 Japan/Korea Uchida et al. [2004] 
Int 4 c.414+1G>A r.spl?  Japan Matsumoto et al. [2004] 
Int 6 c.686+1G>A   Japan Matsumoto et al. [2004] 
Int 6 c.687-2 A>G   Turkey Studt et al. [2005] 
Int 10 c.1244+2T>G r.spl?  Japan Matsumoto et al. [2004] 
Int 11 c.1309-?G>A   France Veyradier et al. [2004] 
Int 13 c.1584+5G>A       Levy et al. [2001] 
Deletion      
Ex 3 c.291_319del p.E98PfsX31 Metalloprotease* Turkey Garagiola et al. [2008] 
Ex 7 c.718_724del p.S240AfsX7 Metalloprotease*   Assink et al. [2003] 
Int.8_Ex.8 c.825-?_?del     France Veyradier et al. [2004] 
Ex 10 c.1095_1112del p.W365_R370del Disintegrin USA Tao et al. [2006] 
Ex 15 c.1783_1784del p.L595GfsX19 Spacer* USA (Yemen) Savasan et al. [2003]  
Ex 19 c.2279del p.G760AfsX18 TSP1-3*   Assink et al. [2003] 
Ex 19 c.2376_2401del p.A793PfsX43 TSP1-4*   Levy et al. [2001] 
Ex 20 c.2549_2550del p.D850GfsX7 TSP1-5*   Schneppenheim et al. [2003] 
Ex 23 c.2930_2935del p.C977_R979delinsW TSP1-6 Iran Palla et al. [2009] 
Ex 25 c.3254_3255del p.S1085CfsX12 TSP1-8* France (Haiti) Veyradier et al. [2004] 
Insertion      
Ex 1 c.82dupT p.W28LfsX111 Metalloprotease*   Donadelli et al. [2006] 
Ex 4 c.372_373insGT p.R125VfsX6 Metalloprotease*   Fujimura et al. [2009] 
Ex 27 c.3770dupT p.L1258VfsX36 CUB-1*   Levy et al. [2001] 
Ex 29 c.4143dupA p.E1382RfsX6 CUB-2* Multiple countriesd Schneppenheim et al. [2003] 
Nonsense      
Ex 2 c.130C>T p.Q44X Propeptide*   Antoine et al. [2003] 
Ex 10 c.1169G>A p.W390X Disintegrin*   Schneppenheim et al. [2003] 
Ex 12 c.1345C>T p.Q449X Cysteine-rich* Japan Kokame et al. [2002] 
Ex 21 c.2728C>T p.R910X TSP1-5* Germany Schneppenheim et al. [2003] 
Ex 22 c.2785C>T p.Q929X TSP1-5*   Fujimura et al. [2009] 
Ex 24 c.3047G>A p.W1016X TSP1-7*   Donadelli et al. [2006] 
Ex 24 c.3100A>T p.R1034X TSP1-7* Germany  Schneppenheim et al. [2003] 
Ex 26 c.3616C>T p.R1206X CUB-1*   Shibagaki et al. [2006] 
Ex 27 c.3735G>A p.W1245X CUB-1* Germany  Licht et al. [2004] 
Ex 28 c.3904C>T p.Q1302X CUB-2*   Fujimura et al. [2009] 
Missense      
Ex 3 c.237C>G p.I79M Metalloprotease France (Haiti) Veyradier et al. [2004] 
Ex 3 c.262G>A p.V88M Metalloprotease Italy Bestetti et al. [2003] 
Ex 3 c.286C>G p.H96D Metalloprotease   Levy et al. [2001] 
Ex 3 c.304C>T p.R102C Metalloprotease   Levy et al. [2001] 
Ex 4 c.356C>T p.S119F Metalloprotease Tunisia Meyer et al. [2008]a 
Ex 5 c.533T>C p.I178T Metalloprotease   Fujimura et al. [2009] 
Ex 6 c.577C>T p.R193W Metalloprotease Japan Matsumoto et al. [2004] 
Ex 6 c.587C>T p.T196I Metalloprotease Australia (Germany) Levy et al. [2001] 
Ex 6 c.607T>C p.S203P Metalloprotease France (Haiti) Veyradier et al. [2004] 
Ex 7 c.695T>A p.L232Q Metalloprotease Turkey Schneppenheim et al. [2003] 
Ex 7 c.702C>A p.H234Q Metalloprotease   Shibagaki et al. [2006] 
Ex 7 c.703G>C p.D235H Metalloprotease   Assink et al. [2003] 
Ex 7 c.749C>T p.A250V Metalloprotease Japan Uchida et al. [2004] 
Ex 7 c.788C>G p.S263C Metalloprotease Germany  Schneppenheim et al. [2003] 
Ex 7 c.803G>C p.R268P Metalloprotease Japan/France (Haiti) Kokame et al. [2002] 
Ex 8 c.911A>G p.Y304C Disintegrin   Fujimura et al. [2009] 
Ex 8 c.932G>A p.C311Y Disintegrin   Assink et al. [2003] 
Ex 8 ‡ § Disintegrin Japan Kokame et al. [2008] 
Ex 9 c.1039T>A p.C347S Disintegrin Croatia Schneppenheim et al. [2006] 
Ex 9 c.1045C>T p.R349C Disintegrin   Fujimura et al. [2009] 
Ex 9 c.1058C>T p.P353L Disintegrin Germany Schneppenheim et al. [2003] 
Ex 10 c.1170G>C p.W390C TSP1-1 Germany  Licht et al. [2004] 
Ex 10 c.1193G>A p.R398H TSP1-1   Levy et al. [2001] 
Ex 12 c.1370C>T p.P457L Cysteine-rich   Assink et al. [2003] 
Ex 13 c.1520G>A p.R507Q Cysteine-rich France/Norway Veyradier et al. [2004] 
Ex 13 c.1523G>A p.C508Y Cysteine-rich Japan Kokame et al. [2002] 
Ex 13 c.1574G>A p.G525D Cysteine-rich   Fujimura et al. [2009] 
Ex 13 c.1582A>G p.R528G Cysteine-rich   Levy et al. [2001] 
Ex 16 c.1787C>T p.A596V Spacer France/France (Haiti) Veyradier et al. [2004] 
  34 
Ex 16 c.1816G>C p.A606P Spacer   Fujimura et al. [2009] 
Ex 17 c.2012C>T p.P671L Spacer Sweeden Schneppenheim et al. [2006] 
Ex 17 c.2017A>T p.I673F Spacer   Matsumoto et al. [2004] 
Ex 17 c.2074C>T p.R692C TSP1-2   Levy et al. [2001] 
Ex 19 c.2272T>C p.C758R TSP1-3 France Veyradier et al. [2004] 
Ex 21 c.2723G>C p.C908S TSP1-5 France Veyradier et al. [2004] 
Ex 21 c.2723G>A p.C908Y TSP1-5 Japan Matsumoto et al. [2004] 
Ex 22 c.2851T>G p.C951G TSP1-5   Levy et al. [2001] 
Ex 24 c.3070T>G p.C1024G TSP1-7   Levy et al. [2001] 
Ex 24 c.3178C>T p.R1060W TSP1-7 USA/Italy/UK Tao et al. [2006] 
Ex 25 c.3367C>T p.R1123C TSP1-8 Japan Matsumoto et al. [2004] 
Ex 26 c.3638G>A p.C1213Y CUB-1   Levy et al. [2001] 
Ex 26 c.3650T>C p.I1217T CUB-1 Korea Park et al. [2008] 
Ex 26 c.3655C>T p.R1219W CUB-1   Donadelli et al. [2006] 
Ex 27 c.3716G>T p.G1239V CUB-1 Italy Noris et al. [2005] 
Ex 28 c.4006C>T p.R1336W CUB-2   Antoine et al. [2003] 
Ex 21 c.2723G>C p.C908S TSP1-5 France Veyradier et al. [2004] 
Ex 21 c.2723G>A p.C908Y TSP1-5 Japan Matsumoto et al. [2004] 
Ex 22 c.2851T>G p.C951G TSP1-5   Levy et al. [2001] 
Ex 24 c.3070T>G p.C1024G TSP1-7   Levy et al. [2001] 
Ex 24 c.3178C>T p.R1060W TSP1-7 USA/Italy/UK Tao et al. [2006] 
Ex 25 c.3367C>T p.R1123C TSP1-8 Japan Matsumoto et al. [2004] 
Ex 26 c.3638G>A p.C1213Y CUB-1   Levy et al. [2001] 
Ex 26 c.3650T>C p.I1217T CUB-1 Korea Park et al. [2008] 
Ex 26 c.3655C>T p.R1219W CUB-1   Donadelli et al. [2006] 
Ex 27 c.3716G>T p.G1239V CUB-1 Italy Noris et al. [2005] 
Ex 28 c.4006C>T p.R1336W CUB-2   Antoine et al. [2003] 
* The domain localization of these mutations refers to the localization of the stop codon. 
‡ c.[964T>G (+) 968C>G (+) 969C>A (+) 970T>C]. 
§ p.[C322G (+) T323R (+) F324L]. 
d Germany/Poland/Czech Republic/Norway/Sweden/Croatia/Australia 
(Germany)/Turkey 
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Table 2. Non synonymous polymorphisms of the coding area of ADAMTS13. 
 
Exon/intron DNA Protein Domain dbSNP ID number Reference 
Missense and 
nonsense 
     
Ex 1 c.19C>T p.R7W Signal peptide rs34024143 Levy et al. [2001] 
Ex 9 c.1016C>G p.T339R Disintegrin / Fujimura et al. [2009] 
Ex 12 c.1342C>G p.Q448E Cysteine-rich rs2301612 Levy et al. [2001] 
Ex 12 c.1368G>T p.Q456H Cysteine-rich rs36220239 / 
Ex 12 c.1370C>T p.P457L Cysteine-rich rs36220240 / 
Ex 12 c.1423C>T p.P475S Cysteine-rich rs11575933 Kokame et al. [2002] 
Ex 13 c.1451G>A p.R484K Cysteine-rich rs28375042 / 
Ex 16 c.1810G>A p.V604I Spacer rs34256013 / 
Ex 16 c.1852C>G p.P618A Spacer rs28647808 Levy et al. [2001] 
Ex 16 c.1874G>A p.R625H Spacer rs36090624 Levy et al. [2001] 
Ex 16 c.1879G>T p.E627X Spacer* rs60398774 / 
Ex 16 c.1900G>A p.E634K Spacer rs34569244 / 
Ex 18 c.2195C>T p.A732V TSP1-2 rs41314453 Levy et al. [2001] 
Ex 19 c.2218G>A p.E740K TSP1-2 rs36221451 / 
Ex 20 c.2494G>A p.V832M TSP1-4 rs34104386 / 
Ex 21 c.2699C>T p.A900V TSP1-5 rs685523 Levy et al. [2001] 
Ex 21 c.2708C>T p.S903L TSP1-5 / Kokame et al. [2007] 
Ex 23 c.2944G>A p.G982R TSP1-6 rs36222275 / 
Ex 24 c.3097G>A p.A1033T TSP1-7 rs28503257 Levy et al. [2001] 
Ex 25 c.3287G>A p.R1096H TSP1-8 rs61751476 / 
Ex 26 c.3677C>T p.T1226I CUB-1 rs36222894 / 
Indels      
Ex 17 c.2059_2060insG p.V687GfsX158 TSP1-4* rs34245610 / 
Ex 29 c.4190del p.A1397VfsX35 CUB-2* rs35876612 / 
* The localization of these polymorphisms refers to the localization of the stop codon. 
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Table 3. Localization, results of in vitro studies, associated age of disease onset 












Conservation     
A_B_C_D_E 
p.I79M Metalloprotease       I _V_ I _ I _V 
p.V88M Metalloprotease ++ ++   V_V_V_V_A 
p.H96D Metalloprotease       H_H_H_H_H 
p.R102C Metalloprotease       R_R_R_R_R 
p.S119F Metalloprotease     Intermediate S_S_S_S_S 
p.I178T Metalloprotease       I _ I _ I _ I _V 
p.R193W Metalloprotease ++ -   R_R_R_R_R 
p.T196I Metalloprotease       T_T_T_T_T 
p.S203P Metalloprotease ++ -   S_S_S_S_S 
p.L232Q Metalloprotease     Neonatal L_L_L_L_ I 
p.H234Q Metalloprotease       H_H_H_H_H 
p.D235H Metalloprotease     Neonatal D_D_D_D_D 
p.A250V Metalloprotease ++ -   A_A_A_A_G 
p.S263C Metalloprotease       S_S_S_S_S 
p.R268P Metalloprotease ++ -   R_R_R_R_E 
p.Y304C Disintegrin       Y_Y_Y_F_Y 
p.C311Y Disintegrin     Intermediate C_C_C_C_C 
‡ Disintegrin       § 
p.C347S Disintegrin       C_C_C_C_C 
p.R349C Disintegrin       R_R_R_R_R 
p.P353L Disintegrin +++ +   P_P_P_P_P 
p.W390C TSP1-1       W_W_W_W_W 
p.R398H TSP1-1       R_R_R_R_R 
p.P457L Cysteine-rich +++ +   P_P_P_P_P 
p.R507Q Cysteine-rich - -   R_R_R_R_R 
p.C508Y Cysteine-rich       C_C_C_C_C 
p.G525D Cysteine-rich       G_G_G_G_G 
p.R528G Cysteine-rich       R_R_R_R_R 
p.A596V Spacer ++ + Neonatal A_A_A_A_ / 
p.A606P Spacer       A_A_A_S_ / 
p.P671L Spacer       P_P_P_P_ / 
p.I673F Spacer - -   I _ I _ I _ I _ / 
p.R692C TSP1-2     Neonatal R_Q_R_R_ / 
p.C758R TSP1-3       C_C_C_C_C 
p.C908S TSP1-5       C_C_C_C_ / 
p.C908Y TSP1-5 - -   C_C_C_C_ / 
p.C951G TSP1-5       C_C_C_C_ / 
p.C1024G TSP1-7       C_C_C_C_C 
p.R1060W TSP1-7 + ++++ Adult R_Q_R_R_K 
p.R1123C TSP1-8 - +++ Neonatal R_R_R_R_R 
p.C1213Y CUB-1 ++ +++   C_C_C_C_C 
p.I1217T CUB-1       I _ I _ I _ I _ I 
p.R1219W CUB-1 - +++ Adult R_R_R_R_R 
p.G1239V CUB-1 - +++   G_G_G_G_G 
p.R1336W CUB-2 ++ ++   R_R_R_R_H 
* Secretion and activity of the recombinant mutant proteins in comparison to wild type 
(WT) ADAMTS13 are presented by means of semi quantitative symbols:- indicates 
not detectable; + severely reduced; ++ reduced; +++ slightly reduced; ++++ similar to 
WT. 
# The age of disease onset associated with a certain mutation was reported when the 
mutation was reported in the homozygous state. 
‡ p.[C322G (+) T323R (+) F324L]. 
§ C322G: C_C_C_C_C; T323R: T_T_T_T_T; F234L: F_F_F_F_F. 
A, Homo sapiens; B, Bos Taurus; C, Mus musculus; D, Rattus norvegicus; E, Gallus 
gallus. 
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Table 4. Results of in vitro expression studies of ADAMTS13 mutations and 
single nucleotide polymorphisms (SNPs). 
 
Position DNA Protein System Secretion Activity Reference 
Missense       
HEK293 40% 18% Peyvandi et al. 
[2006] Ex 3 c.262 G>A p.V88M HEK293/Drosophila
-S2 
30% 40%*# Donadelli et al. 
[2006] Ex 6 c.577C>T p.R193W HeLa Reduced Not 
detectable 
Matsumoto et al. 
[2004] HeLa 21% / Hommais et al. 
[2007] Ex 6 c.607T>C p.S203P COS-7 18% Not 
detectable 
Hommais et al. 
[2007] Ex 7 c.749 C>T p.A250V HEK293 Reduced Not 
detectable 
Uchida et al. [2004] 
HeLa Not detectable Not 
detectable 
Kokame et al. 
[2002] HeLa 38% / Hommais et al. 
[2007] 
Ex 7 c.803G>C p.R268P 
COS-7 25% Not 
detectable 
Hommais et al. 
[2007] Ex 9 c.1058C>T p.P353L COS-7 69% 3% Manea et al. [2007] 
Ex 12 c.1370C>T p.P457L COS-7 70% 4% Manea et al. [2007] 
HeLa Not detectable / Hommais et al. 
[2007] Ex 13 c.1520 G>A p.R507Q COS-7 1% Not 
detectable 
Hommais et al. 
[2007] Ex 13 c.1523G>A p.C508Y HeLa Not detectable Not 
detectable 
Kokame et al. 
[2002] HeLa 17% / Hommais et al. 
[2007] Ex 16 c.1787 C>T p.A596V COS-7 20% 25%* Hommais et al. 
[2007] Ex 17 c.2017A>T p.I673F HeLa Not detectable Not 
detectable 
Matsumoto et al. 
[2004] Ex 21 c.2723 G>A p.C908Y HeLa Not detectable Not 
detectable 
Matsumoto et al. 
[2004] HeLa 11% 35%* Tao et al. [2006] 
Ex 24 c.3178 C>T p.R1060W 
HEK293 Severely 
reduced 
100%* Camilleri et al. 
[2008] HeLa Not detectable Not 
detectable 
Matsumoto et al. 
[2004] Ex 25 c.3367 C>T p.R1123C HEK293/Drosophila
-S2 
Not detectable 64%*# Donadelli et al. 
[2006] Ex 26 c.3638G>A p.C1213Y HEK293 29% 80%* Zhou et al. [2009] 
Ex 26 c.3655C>T p.R1219W HEK293/Drosophila
-S2 
Not detectable 62%*# Donadelli et al. 
[2006] HEK293 Not detectable 6% Peyvandi et al. 
[2006] Ex 27 c.3716G>T p.G1239V HEK293/Drosophila
-S2 
Not detectable 66%*# Donadelli et al. 
[2006] Ex 28 c.4006C>T p.R1336W HEK293 23% 12%* Plaimauer et al. 
[2006] Other 
types 
      
Ex 2 c.130C>T p.Q44X HEK293 Not detectable / Plaimauer et al. 
[2006] Ex 12 c.1345C>T p.Q449X HeLa Conserved Not 
detectable 
Kokame et al. 
[2002] Ex 27 c.3735 G>A p.W1245X HeLa 24% 100%* Zhou et al. [2009] 
COS-7 14% 85%* Pimanda et al. 
[2004] Ex 29 c.4143dupA p.E1382RfsX6 HEK293 4% 10% Garagiola et al. 
[2008] Ex 27 c.3770dupT p.L1258VfsX36 HeLa 8% 100%* Zhou et al. [2009] 
Ex 3 c.291_319del p.E98PfsX31 HEK293 Not detectable Not 
detectable 
Garagiola et al. 
[2008] Ex 10 c.1096_1113d
el 
p.C365-C370del HeLa 7% Not 
detectable 





HEK293 5% 6% Palla et al. [2009] 
SNPs       
Ex 1 c.19C>T p.R7W HEK293 99% 86%* Plaimauer et al. 
[2006] HeLa Conserved Conserved Kokame et al. 
[2002] Ex 12 c.1342C>G p.Q448E HEK293 95% 75%* Plaimauer et al. 
[2006] Ex 12 c.1423C>T p.P475S HeLa Conserved Reduced Kokame et al. 
[2002] Ex 16 c.1852C>G p.P618A HEK293 27% 14%* Plaimauer et al. 
[2006] Ex 18 c.2195C>T p.A732V HEK293 60% 71%* Plaimauer et al. 
[2006] Ex 24 c.3097G>A p.A1033T HeLa Conserved 80% Tao et al. [2006] 
* Activity expressed as ‘specific activity’, normalized for equal amounts of wild type 
protein. 
° The localization of these mutations refers to the localization of the stop codon. 
# Donadelli et al, 2006 used a BiP promoter and Drosophila cell lines to obtain secretion 
of mutant ADAMTS13 that were not secreted in eukaryotic cell lines. The activity of 
mutant proteins was then measured. 
System indicates the type of cells used for the experiments. 
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Supplementary Material S1. Patients with inherited ADAMTS13 deficiency 
reported in the literature. In all patients mutations have been identified on both 
alleles of ADAMTS13. Only one mutation is reported in the table for patients with 
homozygous mutations, whereas both mutations are reported for compound 
heterozygotes. Nucleotide numbering reflects cDNA numbering with +1 
corresponding to the A of the ATG translation initiation codon in the reference 
sequence. The initiation codon is codon 1. 
 
Patients Mutation Mutation effect Age of onset Reference 
Individuals with two 
mutations 
    
1 c.2074C>T p.R692C Neonatal 
2 c.2074C>T p.R692C Neonatal 
3 c.2074C>T p.R692C Neonatal 
c.286C>G p.H96D 4 
c.2851T>G p.C951G 
Neonatal 
c.286C>G p.H96D 5 
c.2851T>G p.C951G 
8 years 
c.1582A>G p.R528G 6 
c.3770dupT p.L1258VfsX36 
Neonatal 
c.1193 G>A p.R398H 7 
c.3070T>G p.C1024G 
Neonatal 
c.304C>T p.R102C 8 
c.587C>T p.T196I 
Neonatal 
c.2376_2401del p.A793PfsX43 9 
c.3638G>A p.C1213Y 
Neonatal 
10 c.1584+5G>A   4 years 
Levy 2001 
c.803G>C p.R268P 11 
c.1523G>A p.C508Y 
Neonatal 
12 c.1345C>T p.Q449X Neonatal 
Kokame 2002 
c.1169G>A p.W390X 13 
c.2549_2550del p.D850GfsX7 
Neonatal 
c.2728C>T p.R910X 14 
c.4143dupA p.E1382RfsX6 
3 years 
c.1058C>T p.P353L 15 c.4143dupA p.E1382RfsX6 4 years 
16 c.695T>A p.L232Q Neonatal 
c.3100A>T p.R1034X 17 
c.4143dupA p.E1382RfsX6 
Neonatal 
c.1058C>T p.P353L 18 
c.2728C>T p.R910X 
2 years 




c.130C>T p.Q44X 20 
c.4006C>T p.R1336W 
21 years 




22 c.1783_1784del p.L595GfsX19 Neonatal Savasan 2003 
23 c.932G>A p.C311Y 23 months 
24 c.703G>C p.D235H Neonatal 
25 c.703G>C p.D235H Neonatal 
c.1058C>T p.P353L 26 
c.1370C>T p.P457L 
20 months 
c.718_724del p.S240AfsX7 27 
c.2728C>T p.R910X 
Neonatal 
28 c.718_724del p.S240AfsX7 Neonatal 
 c.2728C>T p.R910X  
29 c.2279del p.G760AfsX18 7 months 
30 c.4143dupA p.E1382RfsX6 Neonatal 
31 c.4143dupA p.E1382RfsX6 64 months 
Assink 2003 
c.262G>A p.V88M 32 
c.3716G>T p.G1239V 
22 years 
c.262 G>A p.V88M 33 
c.3717 G>T p.G1239V 
No episodes 
at 53 years  
c.262 G>A p.V88M 34 c.3717 G>T p.G1239V 23 years 
Bestetti 2003 
35 c.414+1G>A r.spl? 4 years 





c.577C>T p.R193W 37 
c.1244+2T>G r.spl? 
Neonatal 
c.2017A>T p.I673F 38 
c.2723G>A p.C908Y 
Neonatal 
39 c.686+1G>A   Neonatal 
 
c.1309-?G>A   40 
c.2723G>C p.C908S 
Neonatal 
c.1520G>A p.R507Q 41 
c.1787C>T p.A596V 
Neonatal 
c.825-?_?del   42 
c.2272T>C p.C758R 
Neonatal 
c.237C>G p.I79M 43 
c.803G>C p.R268P 
Neonatal 
44 c.1787C>T p.A596V Neonatal 




c.1170G>C p.W390C 46 c.3735G>A p.W1245X 3 years Licht 2004 
c.749C>T p.A250V 
47 
c.330+1 G>A r.[330_331ins1055, 330_331ins127] 
N.A. Uchida 2004 
48 c.2074C>T p.R692C 2 months Snider 2004 
49 c.687-2A>G   Neonatal Studt 2005 
c.702C>A p.H234Q 50 
c.3616C>T p.R1206X 
3 months Shibagaki 2006 
c.1095_1112del p.W365-R370del 51 
c.3178C>T p.R1060W 
N.A. Tao 2006 
c.3178C>T p.R1060W 52 c.4143dupA p.E1382RfsX6 N.A. 
53 c.4143dupA p.E1382RfsX6 14 years 
c.587C>T p.T196I 54 
c.4143dupA p.E1382RfsX6 
1.5 years 
c.2012C>T p.P671L 55 
c.4143dupA p.E1382RfsX6 
6 years 
56 c.4143dupA p.E1382RfsX6 N.A. 
c.1520G>A p.R507Q 57 
c.4143dupA p.E1382RfsX6 
N.A. 
c.1039T>A p.C347S 58 
c.4143dupA p.E1382RfsX6 
N.A. 
59 c.4143dupA p.E1382RfsX6 4 years 
60 c.4143dupA p.E1382RfsX6 4.5 years 
61 c.4143dupA p.E1382RfsX6 Neonatal 
Schneppenheim 2006 
62 c.3367C>T p.R1123C Neonatal 
63 c.3655C>T p.R1219W 35 years 
64 c.3655C>T p.R1219W 28 years 
c.82dupT p.W28LfsX111 65 c.3178C>T p.R1060W 19 years 
c.82dupT p.W28LfsX111 66 
c.3178C>T p.R1060W 
21 years 
67 c.82dupT p.W28LfsX111 
 c.3178C>T p.R1060W 
No episodes at 25 
years 
c.82dupT p.W28LfsX111 68 c.3178C>T p.R1060W 
No episodes at 25 
years 
Donadelli 2006 
69 c.4143dupA p.E1382RfsX6 Neonatal Manea 2007a 
70 c.4143dupA p.E1382RfsX6 3 years Manea 2007b 
‡ § 71 
c.2723G>A p.C908Y 
3 years Kokame 2008 
72 c.3178C>T p.R1060W 33 years Camilleri 2008 
c.330+1G>A r.[330_331ins1055, 330_331ins127] 73 
c.3650T>C p.I1217T 
15 months Park 2008 
74 c.356C>T p.S119F 17 years Meyer 2008a 
c.291_319del p.Q97fsX31 75 c.4143dupA p.E1382RfsX6 15 years 
c.291_319del p.Q97fsX31 76 
c.4143dupA p.E1382RfsX6 
No episodes at 22 
years 
Garagiola 2008 
c.911A>G p.Y304C 77 
c.1574G>A p.G525D 
N.A. 
c.911 A>G p.Y304C 78 c.1574G>A p.G525D Neonatal 
c.372_373insGT p.R125VfsX6 79 
c.3904C>T p.Q1302X 
27 years 





c.577C>T p.R193W 81 
c.1045 C>T p.R349C 
33 years 
c.577C>T p.R193W 82 
c.1045 C>T p.R349C 
30 years 
c. 533 T>C p.I178T 83 c.2785 C>T p.Q929X 26 years 
c.577C>T p.R193W 84 
c.1816G>C p.A606P 
N.A. 
85 c.577C>T p.R193W N.A. 
 
86 c.2930_2935del p.C977_R979delinsW 23 years 
87 c.2930_2935del p.C977_R979delinsW 29 years 
88 c.2930_2935del p.C977_R979delinsW No episodes at 24 years 
Palla 2009 
89 c.3178C>T p.R1060W 18 years This study 




c.3047G>A p.W1016X 90 
Not found   
5 years Donadelli 2006 
c.3178C>T p.R1060W 91 
Not found   
21 years  
c.3178C>T p.R1060W 92 
Not found   
31 years 
Camilleri 2008 
‡ c.[964T>G (+) 968C>G (+) 969C>A (+) 970T>C]. 
§ p.[C322G (+) T323R (+) F324L]. 
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The quantification of residual plasmatic ADAMTS13 activity in congenital 
thrombotic thrombocytopenic purpura (TTP) patients is constrained by 
limitations in the sensitivity and reproducibility of commonly used assays at low 
levels of ADAMTS13 activity, blunting efforts to establish genotype-phenotype 
associations in the disease. In this study, the residual plasmatic activity of 
ADAMTS13 was centrally measured by SELDI-TOF mass spectrometry (limit-
of-detection=0.5%) in 29 patients with congenital TTP. The results were used to 
study the correlations between ADAMTS13 genotype, residual plasmatic activity 
and the clinical phenotype of the disease. ADAMTS13 activity above 0.5% was 
measured in 26 (90%) patients and lower levels of activity were associated with 
earlier age of onset, more frequent recurrences and prescription of fresh frozen 
plasma prophylaxis. At receiver operating characteristic curve analysis, activity 
levels of less than 2.7% were discriminative of severe disease, i.e., age of onset 
<18 years, annual rate of TTP episodes >1, and use of prophylaxis. Mutations 
affecting the highly-conserved N-terminal domains of the protein were associated 
with lower residual ADAMTS13 activity and more severe disease phenotype in 
an allelic-dose dependent manner. Our results show that residual ADAMTS13 
activity is associated with the severity of clinical phenotype in congenital TTP 
and provide insights into genotype-phenotype relationships. 
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Introduction 
Congenital thrombotic thrombocytopenic purpura (TTP) (also known as Upshaw-
Schulman syndrome, OMIM #274150) is a rare, recessively inherited thrombotic 
microangiopathy. The disease is characterized by the congenital severe deficiency 
of ADAMTS13 plasmatic activity caused by mutations in the ADAMTS13 gene.1-
6 The phenotype of congenital TTP is variable in its severity. Some patients 
present with the disease in the neonatal period, while others have an adult 
disease-onset. Moreover, patients may experience only a few isolated episodes of 
TTP, whereas others have frequent recurrences leading to the prescription of 
fresh frozen plasma (FFP) prophylaxis.5-8 A recent review of the ~100 published 
cases of congenital TTP showed that patients carrying the same ADAMTS13 gene 
mutations develop their first disease episode at a similar age.9 This observation 
suggests that different ADAMTS13 mutations may influence the severity of 
clinical phenotype, probably by determining different levels of residual plasmatic 
activity of ADAMTS13. However, the quantification of residual ADAMTS13 
activity in congenital TTP patients is blunted by limitations in the analytical 
sensitivity and performance in the low-end of ADAMTS13 activity distribution 
(i.e. activity below 6%) of the commonly used ADAMTS13 activity assays.10-13 A 
recently described method, based on surface-enhanced laser desorption/ionization 
time-of-flight (SELDI-TOF) mass spectrometry, is able to accurately measure 
ADAMTS13 plasmatic activity with high analytical sensitivity (limit of detection 
of 0.5%, i.e. 5- to 10-fold higher sensitivity than most commercially available 
assays).14, 15 
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In this study, we measured the residual activity of ADAMTS13 by SELDI-TOF 
mass spectrometry in a cohort of 29 patients with congenital TTP and studied the 
relationships between ADAMTS13 genotype, residual plasmatic activity and the 
clinical phenotype of the disease. 
 
Patients and Methods 
Patients 
Patients registered between 2000 and 2010 in four European TTP registries, the 
Milan TTP registry (Milan, Italy),16, 17 the Southeast England TTP registry 
(London, UK)18, the International Registry for HUS and TTP (Bergamo, Italy),19 
the TMA Registry of the French Reference Center for the management of 
thrombotic microangiopathies (Paris, France),20 were evaluated for study 
eligibility. Inclusion criteria were: (a) history of at least one episode of TTP 
(defined by the presence of thrombocytopenia and microangiopathic Coombs 
negative hemolytic anemia with signs of red blood cell fragmentation), (b) severe 
deficiency of ADAMTS13 with activity <6%, measured by collagen binding 
assay10 or fluorescence resonance energy transfer11, (c) absence of anti-
ADAMTS13 autoantibodies, searched for by western blotting21 or ELISA17-20 (d) 
documented mutations of ADAMTS13 after sequencing of the protein coding area 
of the gene by PCR and Sanger sequencing (e) availability of 100 µL of citrated 
plasma collected during remission at least 20 days from the last infusion of FFP 
or any other blood-derived products. A total of 29 patients were included in the 
study (Milan, n=12; UK, n=7; Bergamo, n=5; France, n=5). The disease histories 
of 16 patients had already been described elsewhere,9, 22-29 whereas 13 are 
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presented here for the first time. For each patient, phenotypic data were retrieved 
including: age at last follow up and sex, ethnicity, age at first TTP episode (in 
order to minimize misclassification, the age of onset was adjudicated on the basis 
of the first disease episode that required FFP infusion), lifetime and annual 
frequency of TTP episodes, use of regular FFP prophylaxis, history of neonatal 
jaundice or thrombocytopenia and presence of renal or neurological damage, 
defined as presence of chronic renal failure and persistence of neurological deficit 
during remission. Individual clinical and genetic information are reported in 
Supplementary Material S1. The study was approved by the Institutional Review 
Boards of the participating centers and all subjects gave informed consent. 
Measurement of ADAMTS13 activity 
All samples were shipped in dry ice to the Hematology laboratory at Department 
of Pathology, Ohio State University, Columbus, OH (USA) for centralized 
measurement. ADAMTS13 activity was determined in this central laboratory 
using a SELDI-TOF mass-spectrometer-based method.14 The laboratory 
personnel was unaware of the clinical features of the patients. ADAMTS13 
activity was determined by mixing patient plasma with the enzyme substrate 
VWF73 containing a 6XHis tag. The cleavage product was enriched by IMAC 
ProteinChip and then quantified using SELDI-TOF mass spectrometry.14, 15 An 
internal control was generated by cleaving recombinant-6×His-tagged human 
VWF73 by PreScissionTM Protease (Amersham Biosciences), as described 
before.14 Briefly, 10 µL of patient plasma were mixed with 30 µL buffer (5 mM 
Tris HCl, 5 mM NaCl, 1 mM BaCl2, pH 7.5) containing 2.5 µg of 6×His tagged 
human VWF73 (D1596-R1668).  The cleavage reaction was performed for 16 
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hours at 37 °C and then terminated by boiling the samples at 100 °C for 2 min. 
Each experiment included a standard curve performed under identical conditions 
except that the plasma sample was replaced by pooled normal plasma (PNP) 
diluted at 7.5%, 5%, 3.5%, 2.5%, 1.5%, 1% and 0.5% in 100 mM NaCl 
containing 0.1% bovine serum albumin (BSA) (Figure 1). Following the cleavage 
reaction, 40 µL internal control (0.01 µg/ µL) was mixed with 35 µL reaction 
sample from each patient on the corresponding IMAC ProteinChip spot. After 
incubation for 30 min at room temperature with constant shaking, each spot was 
washed five times with 200 µL of washing buffer. This was followed by one 
quick wash with 1 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), pH 7.0. Finally, 1 µL of energy absorbing molecule (EAM) solution 
(100% saturated sinapinic acid in 50% acetonitrile and 0.5% trifluoroacetic acid) 
was added to each spot. The cleavage products on the IMAC ProteinChips were 
analyzed by PCS4000 SELDI-TOF mass spectrometer (Vermillion Inc). In order 
to evaluate the test reproducibility in the lower analytical range, two external 
controls (two TTP patients with their plasma samples aliquoted and frozen at -
80C) were tested repeatedly over time and by different operators. The 
ADAMTS13 activity levels obtained (mean ± 2SD) for these two patients were 
1.8%±0.2% and 4.8%±0.8%, respectively, indicating good test reproducibility. 
The coefficient of variation for those two controls was 6.8% and 7.8%, 
respectively.  
Mutation analysis and annotation 
In keeping with the Human Genome Variation Society (HGVS) instructions, 
nucleotide numbering for reported mutations refers to cDNA numbering with the 
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A of the ATG codon numbered as +1. According to new instructions, stop codons 
were designed as “*” instead of “X”. NM_139025.3 was used as a reference for 
nucleotide changes. NP_620596.2 was used as protein reference sequence. The 
review of ADAMTS13 mutations associated with congenital TTP was based on 
published articles found through searches on PubMed (updated to July 2011), 
using “ADAMTS13 mutation”, “ADAMTS13 genotype”, and “congenital 
thrombotic thrombocytopenic purpura” as queries. Polymorphisms of 
ADAMTS13 were searched for on dbSNP. As suggested by the HGVS, the 
accuracy of nucleotide change for reported mutations was verified by Mutalyzer 
2.0 software (URL http://www.mutalyzer.nl/2.0/). Annotation of genetic variants 
was performed on dbSNP131 (URL:http://www.ncbi.nlm.nih.gov/projects/SNP), 
1000Genomes (URL:www.1000genomes.org) databases (used as databases of 
common genetic variation), and Polyphen 2 (URL: 
http://genetics.bwh.harvard.edu/pph2/) and SIFT (URL:http://sift.jcvi.org/) 
software, (used to predict the effect of aminoacid changes on protein function). A 
list of all the proteins used in the SIFT alignment to determine aminoacid 
conservation is provided in Supplementary Material S2. Splicing mutations were 
annotated on NetGene2 and their effect on protein translation predicted by 
Expasy (URL: http://web.expasy.org/translate/). Annotation was performed either 
manually or by automated submission of mutation batches with custom scripts 
written in Perl programming language. Sequencing of ADAMTS13 in 99 control 
individuals free from TTP was performed in the frame of the DVT Milan Study, a 
study on deep vein thrombosis predisposing genetic variants. In these subjects, 
ADAMTS13 exons were sequenced by DNA target capture on NimbleGen 
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Custom Human Sequence Capture 2.1M Array chips followed by next-generation 
DNA sequencing on ABI SOLiD 4 platforms. Sequencing was performed at the 
Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 
(USA). ADAMTS13 sequence coverage was above an average of 20X per base in 
each of the sequenced individuals, providing enough coverage for confident 
variant calls. 
Genotype risk classification 
To study the relationship between mutation localization and clinical phenotype, a 
genotype classification was constructed considering N-terminal mutations as a 
risk factor for more severe disease. N-terminal mutations were mutations 
affecting ADAMTS13 aminoacid 1-714, C-terminal mutatons were mutations 
affecting aminoacid 715-1427. One point was added to the score for each 
missense mutation affecting the N-terminal of the ADAMTS13 protein. 
Mutations at the C-terminal (either missense or truncating mutations affecting C-
terminal domains only) did not add points to the score. Patients with splice-site or 
truncating mutations affecting both N- and C-terminal domains were excluded 
from analysis. The resulting scores were: genotype score=0 (i.e. a ‘mild 
genotype’) for patients with compound heterozygous or homozygous mutations 
both affecting the C-terminal of ADAMTS13, genotype score=1 (i.e. a ‘moderate 
genotype’) for compound heterozygous patients with one mutation affecting the 
N-terminal and one affecting the C-terminal of ADAMTS13, genotype score=2 
(i.e. a ‘severe genotype’) for patients with compound heterozygous or 
homozygous mutations both affecting the N-terminal of ADAMTS13 and 
‘unclassified genotype’ for patients who had at least one splice-site mutation or a 
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truncating mutation affecting both N- and C-terminal domains of ADAMTS13. 
Mutation and genotype score classification data for all patients are provided in 
the Supplementary Material S1. 
Statistical analysis  
Descriptive statistics are presented as medians (interquartile range [IQR]) and 
percentages. Bivariate associations between categorical variables were done using 
the Fisher’s exact test. Linear and logistic regression analysis were used to 
calculate estimates and 95% confidence intervals (CI) of the associations between 
plasmatic ADAMTS13 activity, the genotype risk score and clinical outcomes. 
Receiver operating characteristic (ROC) curve analysis was used to determine the 
ADAMTS13 activity levels that could discriminate patients who had severe 
clinical outcomes with the highest sum of sensitivity and specificity.  
 
Results 
Patients characteristics and SELDI-TOF based measurement of ADAMTS13 
activity 
The features of the 29 patients with congenital TTP included in this study are 
presented in Table 1. Residual plasmatic activity of ADAMTS13 was measured 
in a central laboratory on samples collected during remission at least 20 days after 
the last infusion of FFP or other blood-derived products. Measurements were 
carried out in two duplicates of the same sample, the median difference in the 
measurements between the two duplicates being 0.13% (IQR: 0.43%). Raw data 
on duplicate measurement results are available in the Supplementary Material S1. 
A total of 26 patients (90%) had measurable residual activity of ADAMTS13, 
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whereas three patients had activity <0.5%. Activity was below 10% in all patients 
confirming the previous diagnosis of severe deficiency of ADAMTS13. The 
median plasmatic ADAMTS13 activity was 3.08% (IQR: 4.17%; range: <0.5-
6.77%). In a few patients with multiple remission samples available for 
measurement, residual ADAMTS13 activity was similar in the different samples 
(Supplementary Material S3). 
ADAMTS13 mutations 
ADAMTS13 genetic analysis in the 29 congenital TTP patients revealed 31 
mutations (2 mutations of the splice site, 7 indels, 3 nonsense and 19 missense), 
of which 8 (1 splice site mutation and 7 missense) are novel. All identified 
mutations and their functional annotations are reported in Table 2. Support for the 
causal role of the newly identified ADAMTS13 mutations was sought for by 
annotation on databases of common genetic variation and sequencing of the 
ADAMTS13 gene in 99 healthy Caucasian individuals. None of the mutations 
were present in dbSNP131, in the 1000Genomes database or in 198 alleles from 
99 controls, enabling us to exclude that the identified variants were common 
polymorphisms. All the novel missense mutations were also annotated on SIFT 
and Polyphen 2 software for the prediction of the functional effect of protein 
changes (predicted to be damaging vs predicted to be benign) (Table 2). As a 
critical test of the utility of these annotations, we determined their ability to 
distinguish common from disease-associated variants of ADAMTS13. To estimate 
the sensitivity and specificity of each software, we used as positive controls 55 
missense mutations of ADAMTS13 found through a review of all congenital TTP 
cases reported in the literature and as negative controls 20 missense single 
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nucleotide polymorphisms (SNPs) of ADAMTS13 reported by dbSNP. Polyphen 
2 was the most sensitive software, with sensitivity of 95% and specificity of 60%. 
SIFT was the most specific software, with sensitivity of 71% and specificity of 
95%. Annotation of all ADAMTS13 missense mutations and SNPs is presented in 
Supplementary Material S4. All 7 newly identified missense mutations were 
predicted to be damaging for protein function by Polyphen 2 software. Only 
p.Q436H was predicted by SIFT to be tolerated. The mutation is a c.1308G>C 
nucleotide substitution located in the donor splice site of exon 11. In addition to 
the Q-->H aminoacid change, this nucleotide change was also predicted by 
NetGene 2 to result in a reduction of splicing efficiency providing further support 
to its causal role. The novel c.106-1G>C mutation, located at the acceptor splice 
site of in intron 1, was predicted by NetGene2 to result in a 2 base pair shift of the 
splice site. This splice shift is in turn expected to determine a deletion of 2 
aminoacid residues (S36 and C37) with a frameshift of protein translation and 
formation of a premature stop codon after 102 aminoacid residues. 
Association between residual ADAMTS13 activity and the severity of clinical 
phenotype in congenital TTP 
The associations between residual ADAMTS13 activity and the phenotypic 
features of congenital TTP are outlined in Table 3. A lower residual ADAMTS13 
activity was associated with earlier age of onset (Figure 2A). Lower levels of 
plasmatic ADAMTS13 were also associated with a higher annual rate of TTP 
episodes (Figure 2B) and with higher odds of regular FFP prophylaxis 
prescription. We used receiver operating characteristic curve analysis to 
determine the levels of residual ADAMTS13 activity that best discriminated 
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patients at risk for unfavorable clinical endpoints (i.e. age of onset below 18 
years, annual rate of TTP episodes greater than 1 and prescription of FFP 
prophylaxis). An ADAMTS13 activity <2.74% discriminated patients who had a 
disease onset below 18 years and those who had prescription of regular FFP 
prophylaxis, whereas an activity <1.61% discriminated patients who had an 
annual rate of TTP episodes greater than 1 (Table 4).  
Relationships between ADAMTS13 mutations, residual plasmatic activity of 
ADAMTS13 and clinical outcomes of congenital TTP 
Because patients with the same ADAMTS13 genotype were found to have similar 
age of onset,9 we hypothesized that ADAMTS13 gene mutations could influence 
the clinical phenotype of congenital TTP, by determining different patterns of 
residual ADAMTS13 activity. We plotted ADAMTS13 genotypes that occurred 
more than once in the study cohort against the residual ADAMTS13 activity and 
the age of onset of the corresponding patients (Figure 3). A clustering of both age 
of onset and residual ADAMTS13 activity in patients with the same genotype 
was observed, suggesting that ADAMTS13 mutations influence both the amount 
of residual ADAMTS13 activity and the clinical features of the disease. In order 
to identify the relationships between specific ADAMTS13 mutations and the 
clinical features of congenital TTP we studied the type and distribution of 
congenital-TTP-causing ADAMTS13 mutations on the ADAMTS13 protein 
domains. Including the 8 novel mutations, 121 mutations of ADAMTS13 have 
been described to date in congenital TTP patients. Of these, 62 (51%) are 
missense. Notably, 76% (n=47) of the missense mutations of ADAMTS13 
described in TTP patients localize in the N-terminal of the protein (binomial 
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probability, p=2.01x10-5), which is the area with the highest degree of 
evolutionary conservation9 and where the domains necessary for ADAMTS13 
catalytic activity are located.30, 31 In contrast to this, missense single nucleotide 
polymorphisms (SNPs) of ADAMTS13 included in dbSNP131, which are likely 
not all to be related to disease, do not show evidence of skewed distribution 
(p=0.14). We also evaluated the evolutionary conservation at the sites of all 
reported missense mutations of ADAMTS13 (only mutations of ADAMTS13 
reported in association with congenital TTP were considered). Mutations of the 
C-terminal end of ADAMTS13 occurred at aminoacid residues that are highly 
conserved across species (SIFT score below 0.05), whereas causal mutations of 
congenital TTP in the N-terminal domains of ADAMTS13 were also found at 
aminoacid residues that are less conserved (SIFT score >0.05) (Figure 4A) 
(Fisher’s exact test, p=0.006). All these analyses indicated that mutations at the 
N-terminal domains of ADAMTS13 are more severe than C-terminal domain 
mutations. In order to investigate whether mutations affecting different domains 
of ADAMTS13 were associated with variable degrees of clinical severity, we 
compared the residual plasmatic activity of study participants carrying mutations 
of the N-terminal domains of ADAMTS13 with that of patients with C-terminal 
domain mutations. Only patients with homozygous mutations were considered for 
analysis, to avoid confounding that in compound heterozygous patients derives 
from the coexistence of two different mutations. Patients with homozygous 
mutations at the N-terminal domains (n=4) displayed lower residual activity of 
ADAMTS13 and earlier age of disease onset than those with homozygous C-
terminal domain mutations (n=8) (Figure 4B). To further study the relationship 
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between mutation localization and clinical phenotype of congenital TTP, we 
grouped patients in three classes considering N-terminal mutations as a risk factor 
for more severe disease. In this grouping (see Methods section for details), 9 
patients had a ‘mild genotype’ (i.e., patient with compound heterozygous or 
homozygous mutations both affecting the C-terminal of ADAMTS13), 5 had a 
‘moderate genotype’ (i.e.,  compound heterozygous patients with one mutation 
affecting the N-terminal and one affecting the C-terminal of ADAMTS13), 7 had 
a ‘severe genotype’ (i.e., patients with compound heterozygous or homozygous 
mutations both affecting the N-terminal of ADAMTS13) and 8 patients were not 
classifiable in any of the group (i.e., they either had at least one splice-site 
mutation or a truncating mutation affecting both N- and C-terminal domains of 
ADAMTS13). On linear regression analysis, the residual plasmatic activity of 
ADAMTS13 decreased with increasing genotype severity (Figure 5A). On 
logistic regression analysis, patients with a moderate genotype were 2-times more 
likely (OR: 2.0; 95% CI: 0.1-41) to receive regular FFP prophylaxis, while 
patients with a severe genotype were 11-times more likely (OR 10.7, 95% CI: 
0.8-138) to receive regular FFP prophylaxis compared with patients with a mild 
genotype. The associations were attenuated when we adjusted for residual 
ADAMTS13 activity (moderate genotype: odds ratio [OR] 1.0 [95% CI 0.03-30] 
and severe genotype: OR 4.8 [95% CI: 0.2-91] compared with mild genotype). 
On linear regression analysis, there was a negative association between the 
genotype severity score and age of disease onset (Figure 5B). Moreover, there 
was a positive association between genotype severity and the annual rate of TTP 
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episodes (Figure 5C). Results remained unchanged when patients carrying 
truncating mutations at the C-terminal domains were excluded form the analysis. 
 
Discussion 
A new SELDI-TOF mass spectrometry-based method was used to measure the 
residual plasmatic activity of ADAMTS13 in 29 congenital TTP patients, with 
the aim of investigating the relationships between ADAMTS13 genotype, residual 
plasmatic activity and the clinical phenotype of the disease. Our main study 
findings were the following: (a) a residual plasmatic activity of ADAMTS13 was 
measurable by SELDI-TOF mass-spectrometry in 90% of the study participants; 
(b) the amount of residual plasmatic activity of ADAMTS13 measured by 
SELDI-TOF mass spectrometry was inversely associated with the clinical 
severity of the phenotype; (c) residual plasmatic activity levels below levels of 2-
3% identified patients with adverse clinical outcomes; (d) ADAMTS13 mutations 
were associated with activity levels and clinical severity, with N-terminal domain 
mutations being associated with lower activity and severe disease in an allele-
dosage dependent way. The existence of some degree of ADAMTS13 activity in 
the majority of congenital TTP patients was documented in this study for the first 
time. Previous case reports and case series reported the detection of a residual 
activity only in few patients. Because many of these studies adopted 
immunoblotting and collagen binding assay for the identification of severe 
ADAMTS13 deficiency, this result is not surprising in light of the high limit of 
detection and scarce reproducibility of these assays at low ADAMTS13 
concentrations.12, 13 Recently, a Japanese group reported a large cohort of 
  60 
congenital TTP patients in whom ADAMTS13 was measured by an ELISA 
method with a reportedly low limit of detection (i.e, 0.5%), finding a residual 
activity only in a minority of patients. Because limits of detection are calculated 
against different calibration curves with different reference samples, a formal 
comparison of the limits of detection of that assay with ours cannot be made 
unless both assays are tested against a common ‘standard’. However, we note that 
several proofs of the reliability and validity of our measurements were provided 
in this study, arguing against random or biased results. First, a calibration curve 
using calibrators with concentrations of ADAMTS13 <10% was calculated 
before each assay, showing the linearity of the method at very low concentrations 
(see Figure 1). Second, repeated measurements on the same sample (including 
duplicate measurements and two external controls repeated over time by different 
operators) and multiple samples of the same patient consistently produced similar 
activity results. Third, the detection method of the assay used in this study (i.e. 
mass spectrometry) is considered to be the ‘gold standard’ for protein detection, 
providing high analytical sensitivity and specificity for very tiny amounts of 
cleavage products. Decreasing levels of residual ADAMTS13 activity were 
associated with earlier age of onset, more frequent disease recurrences and 
prescription of FFP prophylaxis to prevent further recurrences. These results are 
consistent with the view that congenital TTP patients with a higher residual 
plasmatic activity of ADAMTS13 are protected from disease onset until they 
come across a strong challenge to their fragile ADAMTS13-VWF balance (e.g., 
pregnancy, which is often a triggering factor of TTP in women with adult-onset 
disease), whereas patients with low or no residual activity are vulnerable to 
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environmental challenges, developing early-onset disease and frequent 
recurrences that prompt caring physicians to prescribe FFP prophylaxis. We 
identified levels below 1.6-2.7% as levels of ADAMTS13 activity predictive of 
clinical endpoints of disease severity. An activity of ADAMTS13 below these 
levels identified patients with early disease-onset, frequent recurrences and the 
need for preventive FFP infusion with high specificity, suggesting that patients 
with low residual ADAMTS13 activity are unlikely to have mild disease.  
In this study, we also reported 8 novel mutations of ADAMTS13 associated with 
congenital TTP. A detailed analysis of the annotation, functional consequences 
and distribution on ADAMTS13 of these novel and of previously reported 
mutations revealed that mutations in the highly conserved N-terminal domains of 
ADAMTS13, which have been shown to be required for the catalytic activity of 
this enzyme, are more likely to be associated with congenital TTP, lower residual 
ADAMTS13 activity and earlier age of disease onset than those of C-terminal 
domains. The association of ADAMTS13 genotype with the clinical phenotype 
was attenuated by adjusting for ADAMTS13 plasmatic activity, confirming that 
ADAMTS13 genotype influences the disease severity at least in part through the 
residual plasmatic activity of ADAMTS13. Limitations of this study include that 
individual ADAMTS13 activity was measured once for the majority of patients 
and that clinical outcomes were ascertained some years after their occurrence. 
Both would have led to random misclassification – since neither mutations nor 
levels were known at the time – and hence an underestimation of actual 
differences. Serial measurements of ADAMTS13 would have been interesting, 
but were not feasible in this study with patients from different regions of different 
  62 
continents. However, by measuring ADAMTS13 in more than one sample of 
several patients we showed that residual ADAMTS13 activity during remission is 
likely constant in a given patient. Since the prevalence of congenital TTP is 
estimated to be ~1/1 million,32 prospective studies will rarely be feasible. In 
addition, the clinically relevant endpoints of the study (i.e. age of onset, rate of 
episodes, use of FFP prophylaxis) can be considered “hard” endpoints, unlikely to 
be misclassified. To further minimize subjectivity in age of onset definition, we 
required that the first disease episode warranting plasma infusion be considered 
as the first episode of the disease.  
In conclusion, we found that residual ADAMTS13 activity is associated with the 
phenotype severity of congenital TTP and that mutations affecting the 
evolutionary conserved N-terminal domains of the protein are associated with 
more severe clinical phenotype. This study identified a disease-severity 
biomarker of potential clinical relevance (i.e. residual plasmatic activity of 
ADAMTS13) and provides insights into genotype-phenotype associations in this 
rare, life-threatening disease. 
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Figure 1. Linearity of SELDI-TOF based measurements of plasmatic activity of 
ADAMTS13 at concentrations below 10%. The figure shows a representative 
example of the calibration curve that was prepared before each experiment to 




Figure 2. Relationship between residual ADAMTS13 activity and clinical 
features of congenital TTP. Panel A: association between residual ADAMTS13 
deficiency and age of disease onset in 29 patients with congenital TTP at linear 
regression analysis. Only a few outliers were detected. A patient from the Milan 
cohort with adult age of onset and residual activity below 2.74% and 3 from the 
French cohort with neonatal onset and activity above 2.74%. Panel B:  





Figure 3. Relationship between ADAMTS13 genotype, residual activity and age 
of disease onset. Age of disease onset and residual ADAMTS13 activity in 
multiple patients carrying the same mutations of ADAMTS13. A clustering of 
both the age of onset and the plasmatic activity of ADAMTS13 can be observed 
for patients with a given ADAMTS13 genotype. For each patient ADAMTS13 




Figure 4. Evolutionary conservation, associated ADAMTS13 plasmatic activity 
and age of disease onset of N- and C-terminal mutations of ADAMTS13. Panel 
A: evolutionary conservation of amino acid residues affected by missense 
mutations of ADAMTS13 associated with congenital TTP in all cases reported in 
the literature. Conservation was estimated using SIFT. Panel B: residual activity 
of ADAMTS13 and age of onset of patients with different C- and N-terminal 




Figure 5. Association between genotype severity score, plasmatic activity of 
ADAMTS13, age of disease onset and annual rate of TTP episodes. Increasing 
severity in the genotype score (i.e. an increasing number of N-terminal mutations; 
‘mild genotype’ = 2 C-terminal mutations, ‘moderate genotype’ = 1 C- and 1 N-
terminal mutations; ‘severe genotype’ = 2 N-terminal mutations) was associated 
with lower plasmatic activity of ADAMTS13 (Panel A), earlier age of onset 






Table 1. Patient characteristics (n=29). 
 
Variable Value 
Median age (IQR), years 27 (24) 
Male, n (%) 13 (45) 
Ethnicity, n (%)  
Caucasian 22 (83) 
Arab 4 (14) 
Caribbean 3 (10) 
Median age of disease onset (IQR), years 11 (23) 
Neonatal jaundice and/or thrombocytopenia, n (%) 11 (38) 
Persistence of renal/neurological damage, n (%) 3 (10) 
Median total number of lifetime TTP episodes (IQR) 5 (8) 
Multiple TTP episodes, n (%) 23 (79) 
Median annual rate of TTP episodes (IQR) 0.28 (0.67) 
Regular FFP prophylaxis, n (%) 12 (42) 
FFP, fresh frozen plasma; TTP, thrombotic thrombocytopenic purpura; IQR, interquartile 
range. 
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Table 2. Mutations of ADAMTS13 found in patients included in the study and 
their functional annotations. None of the mutations were found in dbSNP131 and 
1000Genomes study databases. 
 
DNA Location Predicted effect Domain Polyphen 2 SIFT Reference 
Splicing 
mutations 
      
c.106-1G>C Int 1 p.(S36_C37delfs*102) - - - Novel 
c.1309-?G>A Int 11 - - - - Ref 30 
Indels       
c.82dupT Ex 1 p.W28Lfs*111 Signal peptide - - Ref 23 
c.4143dupA Ex 29 p.E1382Rfs*6 CUB-2 - - Ref 5 
c.291_319del Ex 3 p.E98Pfs*31 Metalloprotease - - Ref 29 
c.825-?_?del Int8_ex8 -  - - Ref 30 
c.718_724del Ex 7 p.S240Afs*7 Metalloprotease - - Ref 24 
c.2930_2935del Ex 23 p.C977_R979delinsW TSP1-6 - - Ref 28 
c.3254-3255del Ex 25 p.S1085Cfs*12 TSP1-8 - - Ref 30 
Nonsense       
c.2728C>T Ex 21 p.R910* TSP1-5 - - Ref 5 
c.3047G>A Ex 24 p.W1016* TSP1-7 - - Ref 23 
c.3616C>T Ex 26 p.R1206* CUB-1 - - Ref 8 
Missense       
c.237C>G Ex 3 p.I79M Metalloprotease Ben Tolerated Ref 30 
c.262G>A Ex 3 p.V88M Metalloprotease Prod Affect Ref 27 
c.304C>T Ex 3 p.R102C Metalloprotease Prod Tolerated Ref 2 
c.428T>C Ex 5 p.I143T Metalloprotease Prod Affect Novel 
c.448T>C Ex 5 p.S150P Metalloprotease Prod Affect Novel 
c.578G>A Ex 6 p.R193Q Metalloprotease Prod Affect Novel 
c.607T>C Ex 6 p.S203P Metalloprotease Prod Tolerated Ref 30 
c.703G>T Ex 7 p. D235Y Metalloprotease Prod Affect Novel 
c.706G>T Ex 7 p.G236C Metalloprotease Prod Affect Novel 
c.803G>C Ex 7 p.R268P Metalloprotease Ben Tolerated Ref 3 
c.1308G>C Ex 11 p.Q436H TSP1-1 Prod Tolerated Novel 
c.1520G>A Ex 13 p.R507Q Cysteine-rich Prod Tolerated Ref 30 
c.1787C>T Ex 16 p.A596V Spacer Prod Tolerated Ref 30 
c.2272T>C Ex 19 p.C758R TSP1-3 Prod Affect Ref 30 
c.3178C>T Ex 24 p.R1060W TSP1-7 Prod Affect Ref 25 
c.3251G>A Ex 25 p.C1084Y TSP1-8 Prod Affect Novel 
c.3283C>T Ex 25 p.R1095W TSP1-8 Prod Affect Novel 
c.3367C>T Ex 25 p.R1123C TSP1-8 Prod Affect Ref 23 
c.3716G>T Ex 27 p.G1239V CUB-1 Prod Affect Ref 27 
Ben, predicted benign; Prod, predicted to be probably damaging. 
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Age of disease onset, yearsa  
beta (95% CI) 3.2 (1.4 to 5.1) 
R2 0.3 
p-value 0.001 
Total number of lifetime TTP episodesa  
beta (95% CI) -2.1 (-4.5 to 0.3) 
R2 0.1 
p-value 0.082 
Annual rate of TTP episodesa  
beta (95% CI) -0.3 (-0.5 to -0.1) 
R2 0.3 
p-value 0.003 
Multiple TTP episodesb  
OR (95% CI) 0.8 (0.5 to 1.2)c 
p-value 0.302 
Neonatal jaundice and/or thrombocytopeniab  
OR (95% CI) 0.9 (0.6 to 1.2)c 
p-value 0.478 
Persistence of renal/neurological damageb  
OR (95% CI) 2.0 (0.9 to 4.7)c 
p-value 0.105 
Regular FFP prophylaxisb  
OR (95% CI) 0.6 (0.4 to 0.9)c 
p-value 0.030 
a On linear regression analysis. 
b On logistic regression analysis. 
c Per 1% increase in ADAMTS13 activity. 
FFP, fresh frozen plasma; TTP, thrombotic thrombocytopenic purpura; OR, odds ratio; CI, 
confidence interval. 
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Table 4. Receiver operating characteristic curve analysis. 
 
Phenotype Age of disease 
onset <18 years 
Annual rate of 




activity cut-off, % 
<2.74 <1.61 <2.74 
Area under the 
curve (95% CI) 
0.88 (0.75-1.01) 0.93 (0.83-1.03) 0.75 (0.56-0.94) 
p-value 0.001 0.003 0.023 
Sensitivity 92.3% 78.3% 70.6% 
Specificity 81.3% 100% 75.0% 
OR (95% CI) 52 (4.7-570.5) NC 7.2 (1.3-38.3) 
FFP, fresh frozen plasma; TTP, thrombotic thrombocytopenic purpura; OR, odds ratio; CI, 




Supplementary Material S1. Individual clinical and genetic information on 
study participants. 
 
Part 1: ADAMTS13 mutations and genotype score. 
Cohort Patient number Mutation  
Mutation 














p.E1382Rfs*6   C 0 Bergamo 1 
p.E1382Rfs*6   C 0 
0 
p.R1123C C 0 Bergamo 2 
p.R1123C C 0 
0 
   p.W1016*    C 0 Bergamo 3 p.G236C  N 1 1 
  p.W28Lfs*111  Not classified NA Bergamo 4 
p.R1060W C 0 
NA 
  p.W28Lfs*111  Not classified NA Bergamo 5 
p.R1060W C 0 
NA 
p.R1060W C 0 UK 6 p.R1060W C 0 0 
p.R1206* C 0 UK 7 
p.R1060W C 0 
0 
p.R1060W C 0 UK 8 
p.R1060W C 0 
0 
p.R1060W C 0 UK 9 p.R1060W C 0 0 
p.S240Afs*7 Not classified NA UK 10 
p.R910* C 0 
NA 
p.S240Afs*7 Not classified NA UK 11 
p.R910* C 0 
NA 
p.S240Afs*7 Not classified NA UK 12 p.R910* C 0 NA 
p.R507Q N 1 France 13 
p.A596V N 1 
2 
 c.825-?_?del Not classified NA France 14 
p.C758R C 0 
NA 
p.I79M N 1 France 15 p.R268P N 1 2 
p.A596V N 1 France 16 
p.A596V N 1 
2 
p.S1085Cfs*12 C 0 France 17 
p.S203P N 1 
1 
p.V88M N 1 Milan 18 p.G1239V C 0 1 
p.E98Pfs*31  Not classified NA Milan 19 
p.E1382Rfs*6   C 0 
NA 
p.C977_R979delinsW C 0 Milan 20 
p.C977_R979delinsW C 0 
0 
p.I143T N 1 Milan 21 
p.I143T N 1 
2 
p.Q436H N 1 Milan 22 
p.Q436H N 1 
2 
p.R1060W C 0 Milan 23 
p.R1060W C 0 
0 
p.R102C N 1 Milan 24 
p. D235Y N 1 
2 
p.C977_R979delinsW C 0 Milan 25 
p.C977_R979delinsW C 0 
0 
p.R193Q N 1 Milan 26 
p.R1095W C 0 
1 
p.(S36_C37delfs*102) Not classified NA Milan 27 
p.(S36_C37delfs*102) Not classified NA 
NA 
p.S150P N 1 Milan 28 
p.S150P N 1 
2 
p.A596V N 1 Milan 29 
p.C1084Y C 0 
1 
  74 
Part 2: ADAMTS13 measurement by SELDI-TOF mass spectrometry. 
Cohort Patient number ADAMTS13         Activity°, % 
A13:Act         
Replicate 1, % 
A13:Act         
Replicate 2, % 
A13:Act         
Difference in the 
two replicates, % 
Bergamo 1 4.46 4.00 4.91 0.91 
Bergamo 2 6.77 6.04 7.49 1.45 
Bergamo 3 1.01 0.97 1.04 0.07 
Bergamo 4 3.47 3.73 3.20 0.53 
Bergamo 5 3.89 3.64 4.14 0.50 
UK 6 4.73 4.66 4.79 0.13 
UK 7 3.83 3.82 3.84 0.02 
UK 8 6.37 5.82 6.93 1.11 
UK 9 5.98 5.82 6.14 0.32 
UK 10 0.54 0.52 0.56 0.04 
UK 11 0.57 0.57 0.56 0.01 
UK 12 1.42 1.45 1.39 0.06 
France 13 3.49 3.34 3.65 0.31 
France 14 6.67 6.27 7.07 0.80 
France 15 2.39 2.16 2.61 0.45 
France 16 4.97 4.71 5.23 0.52 
France 17 2.39 2.47 2.31 0.16 
Milan 18 5.14 5.27 5.02 0.25 
Milan 19 1.96 1.96 1.96 0.00 
Milan 20 3.08 3.07 3.08 0.01 
Milan 21 0.25 0.25 0.25 0.00 
Milan 22 0.25 0.25 0.25 0.00 
Milan 23 5.94 5.89 5.98 0.09 
Milan 24 1 0.94 1.06 0.12 
Milan 25 1.79 1.71 1.87 0.16 
Milan 26 5.53 5.69 5.38 0.31 
Milan 27 0.67 0.65 0.70 0.05 
Milan 28 1.28 1.27 1.29 0.02 
Milan 29 0.25 0.25 0.25 0.00 
° Measured by SELDI-TOF mass spectrometry. 
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Part 3: Clinical phenotype. 
Cohort Patient number Gender Age of onset Annual Rate of TTP episodes FFP prophylaxis 
Bergamo 1 M 18 0.72 1 
Bergamo 2 M 21 Na* 0 
Bergamo 3 M 5 0.17 0 
Bergamo 4 F 20 0.11 0 
Bergamo 5 F 28 0.03 0 
UK 6 F 24 0.04 0 
UK 7 F 30 0.09 0 
UK 8 F 29 0.03 0 
UK 9 F 32 0.05 0 
UK 10 M 0.16 3.83 1 
UK 11 M 0.16 2.31 1 
UK 12 M 0.16 4 1 
France 13 F 0.16 0.37 1 
France 14 M 0.16 0.33 1 
France 15 F 0.16 0.77 1 
France 16 F 0.16 0.57 0 
France 17 F 0.16 0.33 0 
Milan 18 M 23 0.37 0 
Milan 19 F 15 0.09 1 
Milan 20 M 22 0.14 0 
Milan 21 M 11 0.23 0 
Milan 22 M 0.16 3.33 1 
Milan 23 F 18 0.07 0 
Milan 24 F 2 0.56 0 
Milan 25 M 29 0.03 0 
Milan 26 F 32 0.03 0 
Milan 27 F 0.16 0.75 1 
Milan 28 F 5 0.13 Na** 
Milan 29 M 1 2.57 1 
* Chronic jaundice and thrombocytopenia. 
** Current prophylaxis status unknown. 
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Supplementary Material S2. List of protein sequences, functionally related with 
ADAMTS13, used by SIFT to predict the weighted probability of aminoacid 
substitutions. 
 
gi16306598, gi355567362, gi296191110, gi332833255, gi355752956, gi332255397, gi335281186, 
gi354499351, gi301770673, gi47076321, gi76671947, gi348574536, gi334311967, gi351702668, 
gi291416170, gi337298368, gi301627601, gi47214646, gi170587999, gi327277760, gi324499880, 
gi312073463, gi341881902, gi187036667, gi189310657, gi308481215, gi194225985, gi344276566, 
gi224073646, gi326930462, gi345305489, gi363740569, gi291233410, gi293348901, gi156554461, 
gi307177515, gi242016083, gi326670284, gi317419046, gi156393647, gi348516300, gi115961217, 
gi297674911, gi208967601, gi328712328, gi332022171, gi340729183, gi350417726, gi221130399, 
gi328791471, gi307204909, gi157110122, gi198434768, gi241752359, gi229286595, gi125980875, 
gi195162497, gi270002066, gi347965338, gi321479334, gi195043400, gi195131919, gi195340560, 
gi281359911, gi195396533, gi194888962, gi194764322, gi195448967, gi55249587, gi195501264, 
gi357614481, gi157278173, gi313245795, gi34452244, gi170069658, gi195996845, gi112983432, 
gi268580489, gi195574509, gi6164595, gi290886119, gi13346812, gi256071138, gi170791244, 
gi358338697, gi339237895, gi312373041, gi301130834, gi322787488, gi218780434, gi320169775, 
gi307111205, gi340378441, gi323650036, gi226457552, gi146271971, gi110735379, gi139689701, 
gi339521865, gi13928546. 
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Supplementary Material S3. Multiple measurements in the same patients on 
different samples. Similar residual activity was measured in samples collected 
months apart from the same patients. 
 





A13:Act       
Replicate 1 
A13:Act       
Replicate 2 
9 5.98 5.82 6.14 
 5.19 4.97 5.41 
26 5.53 5.69 5.38 
 6.57 6.81 6.33 
27 0.67 0.65 0.70 
 0.58 0.58 0.59 
* Measured by SELDI-TOF mass spectrometry. 
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Supplementary Material S4. ADAMTS13 missense mutations and 
polymorphisms and their functional annotation. 
 
Protein SIFT Polyphen 2 PMut Align GVGD 
TTP associated 
mutations 
    
p.I79M T BEN NEUTRAL C0 
p.V88M A PROD NEUTRAL C15 
p.H96D A PROD NEUTRAL C65 
p.R102C T PROD NEUTRAL C65 
p.S119F A PROD NEUTRAL C65 
p.I178T A PROD NEUTRAL C65 
p.R193W A PROD PATHOLOGICAL C65 
p.T196I A PROD NEUTRAL C65 
p.S203P T PROD PATHOLOGICAL C65 
p.L232Q A PROD NEUTRAL C65 
p.H234Q A PROD NEUTRAL C15 
p.D235H A PROD NEUTRAL C65 
p.G236C A PROD NEUTRAL N/D 
p.A250V A PROD NEUTRAL C65 
p.S263C A PROD NEUTRAL C65 
p.R268P T BEN NEUTRAL C65 
p.Y304C T PROD NEUTRAL C65 
p.C311Y A PROD PATHOLOGICAL C65 
p.R312Q T PROD NEUTRAL C35 
p.C322G A PROD NEUTRAL C65 
p.T323R T PROD PATHOLOGICAL C65 
p.F324L T PROD NEUTRAL C15 
p.C347S A PROD NEUTRAL C65 
p.R349C A PROD NEUTRAL C65 
p.P353L A PROD NEUTRAL C65 
p.G385E A PROD PATHOLOGICAL C65 
p.W390C A PROD PATHOLOGICAL C65 
p.R398C A PROD NEUTRAL C35 
p.R398H A PROD PATHOLOGICAL C25 
p.C438S A PROD NEUTRAL C65 
p.R507Q T PROD PATHOLOGICAL C35 
p.C508Y A PROD PATHOLOGICAL C65 
p.G525D A PROD PATHOLOGICAL C65 
p.R528G T PROD PATHOLOGICAL C65 
p.G550R A PROD PATHOLOGICAL C65 
p.A596V T PROD NEUTRAL C65 
p.A606P T PROD PATHOLOGICAL C25 
p.P671L T PROD PATHOLOGICAL C65 
p.I673F T PROD NEUTRAL C15 
p.R692C T PROD NEUTRAL C65 
p.Q723K T BEN PATHOLOGICAL C45 
p.C758R A PROD PATHOLOGICAL C65 
p.C908S A PROD PATHOLOGICAL C65 
p.C908Y A PROD PATHOLOGICAL C65 
p.G909R A PROD PATHOLOGICAL C65 
p.C951G A PROD PATHOLOGICAL C65 
p.C1024R A PROD PATHOLOGICAL C65 
p.C1024G A PROD PATHOLOGICAL C65 
p.R1060W A PROD PATHOLOGICAL C65 
p.R1123C A PROD PATHOLOGICAL C65 
p.C1213Y A PROD PATHOLOGICAL N/D 
p.I1217T A PROD PATHOLOGICAL N/D 
p.R1219W A PROD PATHOLOGICAL N/D 
p.G1239V A PROD PATHOLOGICAL N/D 
p.R1336W A PROD PATHOLOGICAL N/D 
ADAMTS13 
polymorphisms 
    
p.R7W T BEN PATHOLOGICAL C65 
p.T339R T PROD NEUTRAL C65 
p.Q448E T BEN NEUTRAL C25 
p.Q456H A BEN NEUTRAL C15 
p.P457L T PROD NEUTRAL C65 
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Clinical case: drop of residual plasmatic activity of ADAMTS13 to 
undetectable levels during acute disease in a patient with adult-onset 
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Congenital thrombotic thrombocytopenic purpura (TTP) (also known as Upshaw-
Schulman syndrome, OMIM #274150) is a rare, recessively inherited thrombotic 
microangiopathy. The disease is characterized by a congenital severe deficiency 
of ADAMTS13 plasmatic activity caused by mutations in the ADAMTS13 gene.1-
4 Congenital TTP displays a heterogeneous clinical severity with respect to age of 
disease onset, frequency of acute disease episodes and need for fresh frozen 
plasma (FFP) prophylaxis.1-4 We recently found that residual ADAMTS13 
activity, measured by highly-sensitive surface-enhanced laser 
desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry,5 is 
inversely associated with the severity of the disease. Low residual activity 
measured during disease remission was associated with a history of early disease 
onset, a high annual rate of TTP episodes and prescription of FFP prophylaxis.5 
These results suggest that congenital TTP patients who have some residual 
plasmatic activity of ADAMTS13 (we found 2-3% to be the critical level) are 
protected from early disease and frequent recurrences, developing the disease 
only when the fragile balance between residual ADAMTS13 and its cleavage 
substrate, the pro-thrombotic ultralarge forms of von Willebrand factor (VWF), is 
shifted towards ultralarge VWF release by environmental perturbations (e.g. 
infections, traumas, pregnancy, etc.). According to this “two-hit” model, one 
would expect to see ADAMTS13 activity drop during acute disease even in 
patients who during remission have some degree of residual plasmatic activity. 
However, in the aforementioned study residual ADAMTS13 activity was 
measured only during disease remission.5 In this paper, we report the case of an 
Italian patient with congenital TTP who developed one single acute episode of 
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the disease in her adult life. The patient had been included in the study of residual 
ADAMTS13 during remission, but the clinical history of the patient is hereby 
presented in full and we also report the results of SELDI-TOF-based 
ADAMTS13 activity measurement during and after the acute disease episode. 
The patient provided informed consent and the study was approved by the 
institutional review board of the Fondazione IRCCS Ca’ Granda – Ospedale 
Maggiore Policlinico. 
At the age of 32, during the 19th week of her first pregnancy, the patient was 
admitted to the gynecology department of her local hospital with epigastric pain, 
fatigue and headache. Complete blood count showed anemia (hemoglobin: 8.7 
g/L) and thrombocytopenia (platelet count: 42 x 109/L) with increased 
reticulocyte count and presence of schistocytes at the blood smear. Lactate 
dehidrogenase and indirect bilirubin levels were also above the upper normal 
value, direct Coombs tests was negative. There was no sign of renal involvement 
(creatinine: 79 µmol/L). Both alanine and aspartate transaminases were elevated. 
While elevation of liver enzymes suggested a diagnosis of HELLP, the presence 
of schistocytes supported a diagnosis of TTP. Plasma exchange (PEX) was 
implemented, with rapid increase of platelet counts. A total of 5 daily PEX 
procedures were performed. After the 5th procedure the patient developed an 
allergic reaction with bronchospasm, which led to the administration of 
corticosteroids and to the temporary suspension of PEX. At this time, fetal 
distress developed and the patient agreed to the therapeutic termination of 
pregnancy. Platelet counts dropped to 59 x 109/L and PEX was resumed. A total 
of 7 procedures were carried out, with resolution of the disease symptoms and 
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correction of laboratory abnormalities. After remission was achieved, the patient 
was referred to the outpatient clinic for thrombotic microangiopathies of the 
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center. ADAMTS13 
assays hereby mentioned have been described elsewhere.6, 7 Measurement of 
ADAMTS13 plasmatic activity by collagen binding assay on plasma samples 
collected during the first and second visits to the clinic, as well as on a sample 
that had been collected at the time of acute disease showed severely deficient 
plasmatic activity of ADAMTS13 (i.e. activity below 10% of normal). 
ADAMTS13 antigen levels were severely reduced. No anti-ADAMTS13 
autoantibody was detectable by western blotting or ELISA in any of the samples, 
indicating congenital ADAMTS13 deficiency. ADAMTS13 gene analysis by PCR 
and Sanger sequencing identified two novel missense mutations, not present in 
the dbSNP database. The two mutations were a c.578G>A substitution in exon 6 
of ADAMTS13 leading to a p.R193Q protein change in the metalloprotease 
domain and a c.3283C>T substitution in exon 25 leading to a p.R1095W protein 
change in the eighth thrombospondin-1-like domain of ADAMTS13. Both 
changes were predicted to be potentially damaging for protein function by 
Polyphen 2 (URL:  http://genetics.bwh.harvard.edu/pph2/) and SIFT 
(http://sift.jcvi.org/) software and were not present in 198 alleles of thrombosis 
free individuals sequenced in the frame of the DVT-Milan study. A diagnosis of 
congenital TTP was made. The patient remained asymptomatic during follow-up, 
with no need for FFP prophylactic infusion. In order to assess whether or not the 
patient had measurable ADAMTS13 activity during acute disease and remission, 
the residual plasmatic activity of ADAMTS13 was quantified by SELDI-TOF 
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mass spectrometry.5 A detectable ADAMTS13 cleavage activity was found in the 
two samples collected during disease remission months after the last PEX 
procedure, whereas it was undetectable during acute disease before the 
implementation of PEX (Figure).  Herein, we have reported the measurement of 
residual plasmatic activity of ADAMTS13 by SELDI-TOF mass spectrometry in 
a patient with congenital TTP during both remission and acute disease. During 
remission, ADAMTS13 activity was detectable, with values above 5%. 
Consistent with the patient’s clinical history, similar residual activity levels were 
shown to be associated with adult-onset disease and low-tendency towards 
recurrence. By contrast, activity during acute disease was completely abolished, 
consistent with the hypothesis that onset of acute TTP is associated with a drop in 
ADAMTS13 levels. Pregnancy, a recognized TTP-triggering condition that is 
physiologically associated with reduction in ADAMTS13 and raise in VWF 
plasmatic levels, is likely to have precipitated the onset of acute disease in the 
patient. In conclusion, this case report of a patient with congenital TTP 
highlighted the reduction of ADAMTS13 activity to undetectable levels in a 
patient with otherwise detectable residual ADAMTS13. This case is consistent 
with the paradigm of a ‘two-hit’ model in TTP, whereby a triggering agent can 
cause the onset of acute disease by abrogating residual activity in patients with 




Figure 1. Residual ADAMTS13 activity measured by SELDI-TOF mass 
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Abstract 
Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening thrombotic 
microangiopathy characterized by acute episodes of widespread microvascular 
thrombosis. The discovery that the plasmatic activity of the von Willebrand factor 
(VWF) cleaving protease, ADAMTS13, is severely deficient in a great proportion 
of individuals with TTP partially clarified the pathophysiology of the disease. 
However, the finding of severe deficiency of ADAMTS13 alone is unable to fully 
explain the clinical heterogeneity of patients with TTP. The recent development 
of methods that measure ADAMTS13 activity with great analytical sensitivity 
and precision offers the opportunity to study the spectrum of ADAMTS13 
activity below 10% (herein defined as “residual ADAMTS13 activity”). Recent 
exploratory studies on residual ADAMTS13 activity suggest that the amount of 
residual activity of ADAMTS13 might be a major determinant of the clinical 
heterogeneity of TTP in patients with severe ADAMTS13 deficiency. In this 
article, we review the recent findings on residual ADAMTS13 activity and their 
implications for research and clinical practice in the field. 
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Introduction and scope of this review 
Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening thrombotic 
microangiopathy characterized by acute episodes of widespread microvascular 
thrombosis.1 The discovery that the plasmatic activity of the von Willebrand 
factor (VWF) cleaving protease, ADAMTS13, is severely deficient in a great 
proportion of individuals with TTP partially clarified the pathophysiology of the 
disease.2 Severe ADAMTS13 deficiency is defined as an activity of the protease 
below 10% of normal, with normal values usually ranging form 50% to 150%. 
Severe ADAMTS13 deficiency is either due to circulating anti-ADAMTS13 
autoantibodies (i.e. acquired deficiency)3 or, less frequently, to recessively 
inherited mutations of ADAMTS13 (i.e. congenital deficiency).4 Although not all 
of the patients with a clinically defined TTP present with severely reduced 
ADAMTS13, the finding of severe ADAMTS13 deficiency has been consistently 
shown to define a distinct subgroup of the disease, with peculiar behavior and 
clinical features.5-7 In these patients, the pathologic presence in the circulation of 
ultralarge VWF multimers that remain uncleaved is regarded as the mechanism 
responsible for VWF-mediated platelet aggregation and thrombosis.8 The peculiar 
clinical characteristics of TTP with severe ADAMTS13 deficiency include a 
relatively mild acute-disease prognosis, with better response to plasma exchange 
(PEX) and lower episode-fatality rate, and high tendency to recur.6, 9 In spite of 
the recognized importance of measuring ADAMTS13 activity at acute disease 
presentation, the finding of severe deficiency of ADAMTS13 alone is unable to 
fully explain the clinical heterogeneity of patients with TTP. For example, 
patients with auto-antibody mediated severe deficiency of ADAMTS13 may 
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remain in remission for years, in spite of unmeasurable or very low ADAMTS13 
activity and persistence of anti-ADAMTS13 autoantibodies.9 Also, some patients 
with congenital severe deficiency of ADAMTS13 develop their first disease 
episode in their adult age, whereas others have early-onset disease and frequent 
recurrences.10, 11 The recent development of methods that measure ADAMTS13 
activity with great analytical sensitivity and precision offers the opportunity to 
study the spectrum of ADAMTS13 activity below 10%.11, 12 Residual 
ADAMTS13 activity is herein used to define the amount of activity below 10% 
that is detectable in patients with severe ADAMTS13 deficiency. Recent 
exploratory studies found that patients with severe deficiency of ADAMTS13 
show a range of residual plasmatic activity and that residual activity is associated 
with clinically relevant endpoints.13-16 This suggests that the amount of residual 
activity of ADAMTS13 might be a major determinant of the clinical 
heterogeneity of TTP in patients with severe ADAMTS13 deficiency. In this 
article, we review the recent findings on residual ADAMTS13 activity and their 
implications for research and clinical practice in the field. The review will focus 
only on TTP with severely deficient ADAMTS13 activity.  
 
TTP with severe deficiency of plasmatic ADAMTS13 activity as a distinct 
subtype of the disease 
TTP was originally described by Eli Moschcowitz in 1924 as a syndrome with a 
pentad of clinical manifestations: thrombocytopenia, microangiopathic hemolytic 
anemia, neurologic symptoms, renal involvement and fever.17 It was later 
recognized that fever, neurologic symptoms or renal involvement are not always 
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present during TTP, so that TTP is currently defined by the presence of 
thrombocytopenia and microangiopathic hemolytic anemia and by the exclusion 
of an alternative diagnosis.18 The pathophysiology of TTP remained unexplained 
for many decades until studies in the early 1980s demonstrated that patients with 
chronic relapsing TTP had a defect in their ability to cleave unusually large VWF 
multimers.19 Subsequently, in the late 1990s it was found that the plasma of 
patients with the disease was severely deficient of von Willebrand factor (VWF) 
cleaving protease activity.8 Further studies identified anti-ADAMTS13 
antibodies3 and mutations in ADAMTS134 as causes of severely reduced 
ADAMTS13 activity. The discovery of the role of ADAMTS13 sparked 
investigations on laboratory measurements related to the protease. A number of 
observational studies demonstrated that ADAMTS13 deficiency is not invariably 
present in patients with a diagnosis of TTP, but also that patients with severe 
deficiency of ADAMTS13 have distinct clinical characteristics and prognosis.5-7, 
9, 20-22 Severe ADAMTS13 deficiency in TTP patients is associated with 
idiopathic rather than secondary disease (i.e., disease associated with clinical 
conditions such as cancer, bone marrow transplantation or use of certain drugs), 
lower platelet count at presentation and lower prevalence of renal involvement.5, 6, 
9, 22 Patients with severely reduced ADAMTS13 activity at acute disease 
presentation have milder acute disease prognosis with better response to PEX and 
lower episode fatality rate than those with ADAMTS13 above 10%.5, 6, 9 This 
association is caused by the poor prognosis of secondary TTP forms in which 
severe ADAMTS13 deficiency has low prevalence (e.g., bone-marrow 
transplantation associated TTP or cancer-associated TTP). Patients with severe 
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deficiency are also more prone to recurrence.9, 14, 20, 23 A recent study found a 41% 
percent recurrence risk at 7.5 years in TTP survivors who presented with severe 
ADAMTS13 deficiency, whereas survivors with activity above 10% had a 
recurrence rate of only 4%.9 Studies on ADAMTS13-related measurements as 
markers for recurrence are summarized in Table 1. Also ADAMTS13-related 
laboratory measurements other than ADAMTS13 activity were shown to be 
associated with disease outcomes. These markers include ADAMTS13 antigen 
levels and IgG titre, inhibitor titre, Ig subclass and specificity of anti-
ADAMTS13 antibodies.6, 9, 20, 23-26 However, the value of these markers as 
predictors after accounting for ADAMTS13 activity is uncertain. This prompted 
researchers to look for additional prognostic markers that could help predict the 
risk of acute disease morbidity and mortality and the imminence of disease 
recurrence.27 
 
Residual ADAMTS13 activity in congenital and acquired ADAMTS13 
deficiency 
Until recently the quantification of ADAMTS13 plasmatic activity relied on 
assays that were developed in order to distinguish patients with severely reduced 
from patients with normal or slightly reduced protease activity. Assays 
standardization, and limitations in sensitivity, linear behavior and reproducibility 
were well recognized issues affecting early-developed methods.28 The 
performance of ADAMTS13 assays improved through the years, with the 
development of new methods and improvement of existing ones.29 Recently, 
assays able to measure residual ADAMTS13 activity with great analytical 
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sensitivity (limit of detection [LOD] of up to 0.5%) have been developed.11, 12 In 
particular, a method based on SELDI-TOF mass spectrometry for the detection of 
cleavage product showed linear behavior for the measurement of activities below 
10% and great reproducibility.13 The assay was employed in a number of 
exploratory studies that sought for associations between residual ADAMTS13 
plasmatic activity and disease outcomes.13-16 
 
Residual ADAMTS13 activity in congenital TTP 
Congenital TTP (also known as Upshaw-Schulman syndrome, OMIM #274150) 
is caused by mutations in ADAMTS13 and accounts for less than 10% of all cases 
of TTP. As noted, the phenotype of congenital TTP is variable in its clinical 
severity.10, 11 A study was recently conducted in which the residual activity of 
ADAMTS13 was measured by SELDI-TOF mass spectrometry in a cohort of 29 
patients with congenital TTP.15 The study was designed to test the hypothesis that 
genetically-determined patterns of residual ADAMTS13 activity were responsible 
for the variable clinical phenotype. The study found that a residual plasmatic 
activity of ADAMTS13 was measurable in 90% of the study participants. It also 
showed that the amount of residual plasmatic activity of ADAMTS13 measured 
by SELDI-TOF mass spectrometry is negatively associated with the clinical 
severity of the phenotype (as assessed by the age of disease onset, the annual rate 
of TTP episodes and the prescription of FFP prophylaxis). Residual plasmatic 
activity levels below 2-3% pinpointed patients with adverse clinical outcomes 
(i.e. age of onset below 18 years, annual rate of TTP episodes greater than 1 and 
need for FFP prophylaxis). Although these discriminative levels should be 
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validated in an independent cohort before being introduced in clinical practice, 
the results of the study suggest that the use of a sensitive ADAMTS13 activity 
measurement could be used to tailor individual management, in particular 
concerning the decision of whether or not to implement long-term FFP 
prophylaxis. The results also provide pathophysiological insights. A model of 
congenital TTP is suggested whereby congenital TTP patients with a higher 
residual plasmatic activity of ADAMTS13 are protected from disease onset until 
they come across a strong challenge to their fragile ADAMTS13-VWF balance 
(e.g. pregnancy, infection, surgery). In contrast, patients with a low or with no 
residual activity are more vulnerable to environmental challenges, developing 
frequent disease episodes. Consistent with this model is the relationship between 
residual ADAMTS13 activity and the age of first disease episode of congenital 
TTP patients. Patients with higher residual activity had an older age of onset 
(Figure 1A), although a few patients had early age of onset in spite of relatively 
high residual activity. This may be due to the presence of genetic modifiers or to 
a varying impact of environmental triggering conditions (Figure 1B); most 
importantly, none of the patients with low residual activity had adult age of onset 
(Figure 1C). Additional support for this model came from the measurement of 
residual activity during acute TTP and remission in a patient with congenital 
TTP.16 While activity was detectable in multiple remission samples, a drop to 
undetectable levels was observed during an acute disease episode. Overall, these 
studies highlight an important contribution of residual ADAMTS13 as a 
determinant of disease severity in congenital TTP. 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Residual ADAMTS13 activity in acquired TTP 
In patients with acquired TTP, the amount of residual ADAMTS13 activity in 
patients with severely deficient ADAMTS13 (activity below 10%) was associated 
with both subsequent TTP exacerbation (i.e. reappearance of disease within 30 
days of the remission of a previous event)14 and recurrence (i.e. reappearance of 
disease after 30 days).13 In the former study, mean ADAMTS13 activity at 
presentation was significantly lower in patients who suffered exacerbations than 
in those who did not (mean residual ADAMTS13 of 1.4% vs 2.9%). Receiver 
operating characteristic curve analysis of all study subjects indicated that the 
discriminative level of residual ADAMTS13 activity for the risk of exacerbation 
was 1.15%. In the latter study, the association between residual ADAMTS13 
activity and disease recurrence was obtained within a group of patients who 
already had a diagnosis of severely reduced ADAMTS13. This indicates that the 
measurement of ADAMTS13 in TTP patients is informative of the risk of 
recurrence also for activities below 10%. The relationship between ADAMTS13 
activity and risk for recurrence is characterized by an exponential curve (Figure 
2). This pattern confirms the importance of being able to measure low 
ADAMTS13 activity, as the risk of recurrence witnesses a steep increase for 
decreasing activity below levels of 20% and especially below 10%. Anecdotic 
reports on the risk of pregnancy-associated TTP support these results, showing 
that women who develop TTP associated with pregnancy have very low levels of 
ADAMTS13 activity (below 2.5%) at the beginning of their pregnancy. 
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Future directions 
The concept that the residual activity of ADAMTS13 in patients with 
ADAMTS13-deficient TTP is an important determinant of disease severity and of 
clinically relevant outcomes has implications for future research in the field. The 
development of a new generation of assays able to measure in a fast, cost 
effective and reproducible way ADAMTS13 activity at low concentrations is 
warranted in order to apply residual activity measurement to large-scale research 
and in clinical practice. Similarly sensitive and precise assays of ADAMTS13 
antigen levels might help calculating the specific activity of mutated ADAMTS13 
in congenital patients in whom residual plasmatic activity has been quantified. In 
this group of patients the benefit of measuring residual ADAMTS13 repeatedly 
and that of using the recently identified discriminative levels for clinical decisions 
will be the focus of future research. In the field of acquired TTP, the exponential 
increase of TTP recurrence risk for decreasing values of ADAMTS13 activity 
implies that much of predictive power of measuring ADAMTS13 activity may 
stand in a tail of the ADAMTS13 activity spectrum (which is poorly ascertained 
by most of the currently available assays).  The hypothesis merits further and 
thorough testing, as researchers in the field of TTP might happen to already have 
in hand the clinical marker they were looking for. 
  100 
Figures 
Figure 1. Relationships between residual ADAMTS13 activity and age of disease 
onset in congenital TTP. Increasing residual activity is associated with older age 
of onset (A). A few patients with high residual activity have early age of onset 




Figure 2. Exponential decay of the risk of thrombotic thrombocytopenic purpura 





Table 1. Studies that investigated ADAMTS13-related measurements in 
thrombotic thrombocytopenic purpura. 
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Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic disease 
characterized by episodes of thrombocytopenia and microangiopathic haemolytic 
anemia due to disseminated microvascular thrombosis. TTP was first described in 
1924 by Moschowitz as a disease presenting with a pentad of signs and symptoms 
(anaemia, thrombocytopenia, fever, hemiparesis and haematuria).1 Post-mortem 
examination showed widespread thrombi, mainly composed of platelets, in the 
terminal circulation of several organs. The description of von Willebrand factor 
(VWF) multimers of unusually large size in the plasma of patients with TTP 
represented a turning point for the understanding of the disease 
pathophysiology.2, 3 The presence in plasma of the highly platelet-adhesive 
ultralarge multimers of VWF provided a plausible explanation for the platelet- 
and VWF-rich thrombi observed in the small vessels of TTP patients. Then, 
studies in the late 1990s independently demonstrated the severe deficiency of a 
specific VWF cleaving-protease in the plasma of patients with recurrent TTP.4 
This protease was identified as the thirteenth member of the ADAMTS (a 
disintegrin and metalloprotease with thrombospondins 1 repeats) family of 
metalloproteases, ADAMTS13.5-7 Severe ADAMTS13 deficiency can be due to 
mutations in the ADAMTS13 gene (congenital TTP, see review8) or to anti-
ADAMTS13 autoantibodies (autoimmune TTP).9-11 The antibody-mediated 
severe deficiency of ADAMTS13 can be detected in most patients with idiopathic 
TTP (i.e. TTP occurring without associated clinical conditions/events), whereas 
its prevalence is much lower in the secondary forms of TTP (i.e. TTP associated 
with pregnancy, infections, autoimmune diseases and the use of drugs such as 
ticlopidine and clopidogrel).12 It should also be mentioned that there are 
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idiopathic TTP cases with only slightly deficient or even normal ADAMTS13 
levels at presentation, but these cases are not object of the present article and we 
will use idiopathic and autoantibody-mediated TTP as synonyms.  
 
Epidemiology and clinical course of idiopathic TTP 
The incidence of idiopathic TTP is estimated to be 4.5/1 million person/years, 
higher in blacks than in whites and Asians and with a male to female ratio of 1:2, 
similarly to other autoimmune diseases.13 Idiopathic TTP tends to have a less 
severe acute-disease prognosis, but much higher risk of recurrent disease in 
comparison to secondary forms.14, 15 The overall mortality of TTP was higher 
than 90%, but has decreased to 8-30% after the introduction of plasma exchange 
(PEX), which is the treatment of choice of acute TTP episodes.16, 17 
 The lower mortality of idiopathic TTP (21% vs 39% in the frame of the 
Oklahoma TTP registry)15 is probably due to the higher response to PEX of 
patients with auto-antibodies and to the mortality related to associated conditions 
in secondary cases.18 Up to 40% of patients with TTP develop recurrent episodes 
of the disease, with higher risk for recurrences in patients with severe 
ADAMTS13 deficiency and anti-ADAMTS13 autoantibodies during acute 
episodes. The cumulative risk for recurrence at 7.5 years from the first episode in 
patients with ADAMTS13 activity below 10% at presentation was estimated to be 
41%, 10 times that of patients with activity above 10% (4% risk at 7.5 years).16 
Persistence of ADAMTS13 deficiency and autoantibodies during disease 
remission is also associated with increased risk for recurrence.19, 20 
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Anti-ADAMTS13 antibody characterization 
Anti-ADAMTS13 autoantibodies have been the focus of several research efforts 
trying to characterize their immunoglobulin (Ig) subclass, specificity and 
mechanisms of action. Early studies distinguished two classes of anti-
ADAMTS13 autoantibodies: inihibitory and non-inihibitory antibodies. 
Inihibitory antibodies are present in 50-90% and their mechanism of action is the 
inihibition of ADAMTS13-mediated proteolyisis of VWF.21, 22 When non-
inhibitory antibodies are also measured, the anti-ADAMTS13 autoantibodies are 
detectable in the majority of patients.10 The core binding site for VWF, located in 
the spacer domain of ADAMTS13 and consisting of aminoacid residues Tyr572-
Asn579 and Arg657-Gly666, represents the target site of the autoantibodies found 
in the plasma of several TTP patients.23, 24 The mechanism of action of non-
inhibitory antibodies has been proposed to be the opsonisation and enhanced 
clearance of ADAMTS13, but this mechanism has never been proven.21 Studies 
on the class of anti-ADAMTS13 autoantibodies showed they are usually of IgG 
type, particularly IgG1 and IgG4 subtypes,10, 25 but in a few cases autoantibodies 
of IgA and/or IgM isotype were also found.19 Most anti-ADAMTS13 IgG found 
in TTP patients were demonstrated to be directed against the spacer domain, but 
additional antibodies against other ADAMTS13 domains were also detected.26, 27 
However, these studies were conducted in small patient cohorts. Zheng et al. in 
this issue of Haematologica report the first study of antibody specificity on a 
relatively large group of patients with TTP.28 They found that, although almost all 
patients with IgG had antibodies directed against the N-terminal ADAMTS13 
domains (Cys-rich through spacer), up to 46% of TTP patients also had 
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antibodies towards the C-terminal ADAMTS13 domains (TSP1-5 through CUB). 
Moreover, two patients had antibodies against the C-terminal domains of 
ADAMTS13, but not against the N-terminal domains. These findings suggest a 
functional role of C-terminal domains of ADAMTS13 in vivo, also in light of the 
importance of these domains in the VWF-ADAMTS13 interaction under fluid 
shear stress. Importantly, Zheng et al.29 combined antibody specificity with 
clinical data, showing that patients with antibodies against ADAMTS13 C-
terminal domains had lower platelet counts at presentation. This is not the first 
time anti-ADAMTS13 antibody features are found to correlate with clinical 
outcomes in TTP. Patients with IgG subclasses 4 were found to be more likely to 
have disease recurrence than patients with IgG subclass 1.28 Patients with high 
inhibitor titers were found to have worse acute-disease prognosis.29 Consistently, 
patients with high levels of IgG (both inhibitory and non-inhibitory) were found 
to have higher likelihood of developing cardiac involvement and, hence, poorer 
prognosis in comparison to patients with low IgG levels.30 All these findings 
indicate that different antibody features might be associated with clinical 
outcomes in TTP, but more comprehensive studies should be carried out before 
antibody characterization can be introduced in routine clinical practice of TTP. 
Moreover there remain other questions to be addressed. Acquired TTP is an 
autoimmune disorder, at least in those patients with an autoantibody-mediated 
severe ADAMTS13 deficiency, but the mechanisms involved in the loss of 
tolerance of the immune system against ADAMTS13 remain unknown. The 
higher incidence of autoimmune idiopathic TTP in specific ethnical groups such 
as Afro-Caribbeans, as well as the report of idiopathic TTP in two monozygotic 
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twins both developing anti-ADAMTS13 antibodies,31 strongly argues in favor of 
a genetic predisposition even in the acquired form of the disease. In the last year, 
two groups independently demonstrated an association between human leukocyte 
antigen (HLA) alleles and idiopathic TTP: HLA-DR and HLA-DQ typing 
suggests an underlying genetic risk for the development of TTP in Europeans.32, 33 
As for the antibody characterization, confirmation of these results in larger 
groups of patients and in other ethnic groups are required prior of the introduction 
of HLA typing in the control of the disease.  
 
Treatment and clinical trials in idiopathic TTP 
PEX remains the treatment of choice of acute episodes of TTP.34 As mentioned, 
its introduction greatly reduced the disease mortality and it has been proven 
superior to plasma infusion.17 Several different immunosuppressive drugs 
(corticosteroids, cyclosporine, azathioprine and, recently, rituximab) are added by 
many centers to PEX, with the rationale that they help stopping antibody 
production in autoimmune cases, but their efficacy has never been confirmed by 
large clinical trials. In addition to these treatments, novel drugs have been 
developed or are undergoing pre-clinical development that could potentially be 
used in idiopathic TTP along with PEX. These could tackle different aspects of 
TTP pathophysiology (Table 1).  First, it is possible to reduce or abolish the 
production of anti-ADAMTS13 autoantibodies with anti-CD20 monoclonal 
antibodies that target B-lymphocytes (e.g. rituximab, but other more potent 
compound are being developed).35 Second, it could be in principle possible to 
restore VWF cleavage in patients with severe ADAMTS13 deficiency with the 
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use of recombinant ADAMTS13. Third, novel compounds that inhibit VWF 
binding to platelet glycoprotein Ib-alpha have been developed that could block 
VWF-mediated platelet activation. There is hope in the TTP community that 
these novel therapeutic strategies be able to reduce the persistently high disease 
mortality. However, the availability of these new options generates new 
challenges for clinicians who have to deal with TTP patients. These include 
uncertainties on the safety of the drugs in this delicate clinical setting and on the 
subgroup(s) of patients (idiopathic, secondary, TTP with prominent renal 
impairment, etc.) that could benefit from the treatment. The efficacy and safety of 
these novel therapeutic strategies will need to be assessed in the frame of large 
clinical trials, a challenge for clinical scientists who work on this rare disease. 
Idiopathic TTP incidence is such that anyone willing to carry out a 3-year clinical 
trial involving roughly 100 patients would need to be able to cover a population 
of approximately 7 million people (assuming an incidence of 4.5/1 million 
person/years). The choice of the clinical end-point will similarly be a challenge: 
mortality is ~10-20% which makes it a hardly targetable end-point with small 
sample sizes. Such surrogate endpoints as the incidence of stroke, renal failure, 
myocardial infarction, time to platelet recovery or clinical remission may be 
adequate for the definition of therapeutic efficacy but there are few data available 
from cohort studies that could inform the design of clinical trials employing these 
endpoints. The picture is made even more complicated by the heterogeneity in the 
pathophysiologic background of TTP. The inclusion in a TTP trial of secondary 
cases, patients with atypical hemolytic uremic syndrome, patients at first TTP 
episodes or recurrence may in principle conceal the effect of a treatment which is 
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highly effective in a subgroup of TTP patients (e.g. only those with anti-
ADAMTS13 autoantibodies). Recently, a phase 2 double-blind, placebo-
controlled, clinical trial of intravenous ARC1779, an inhibitor of VWF binding to 
platelet glycoprotein Ib-alpha, was stopped due to slow recruitment 
(clinicaltrials.gov identification number NCT00726544). New trials are 
nonetheless being designed and carried out. These will be critical to the efforts of 
translating preclinical achievements in improvements in the care of this rare, but 
still life-threatening thrombotic disease. 
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Table. Novel drugs developed or undergoing pre-clinical development that could 
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Abstract 
The clinical course of thrombotic thrombocytopenic purpura (TTP) is 
characterized by recurrent disease episodes in up to 50% of the cases. The clinical 
presentation and severity of different TTP episodes have not been systematically 
compared. Laboratory and clinical information from 51 patients with recurrent 
disease, stemming from 136 patients with TTP included in the Milan TTP registry 
(URL: http://www.ttpdatabase.org), were used to compare episode fatality, 
symptoms and disease-related laboratory measurements in different disease 
episodes. The prevalence of severe neurological symptoms (coma, seizures, and 
focal neurological defects) was significantly lower in recurrences than in the first 
episode. Platelet counts and haemoglobin levels at presentation were higher in 
recurrences than in the first disease episode, and lactate dehydrogenase levels 
were lower. Also episode fatality tended to be lower in the second and third 
disease episodes than in the first. Recurrences of TTP are generally milder than 
first episodes. These differences in severity should be taken into account in 
clinical research on TTP and in patient management. 
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Introduction 
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disease 
characterized by acute episodes of thrombocytopenia and microangiopathic 
hemolytic anemia due to disseminated microvascular thrombosis.1 The clinical 
presentation of TTP is variable in terms of type and severity of clinical 
symptoms.2-5 Before the introduction of plasma exchange (PEX) for the treatment 
of acute TTP episodes mortality reached 90%, but decreased to 8-30% following 
the adoption of PEX.3, 6, 7 Patients who survive the first acute episode of the 
disease may remain asymptomatic for the rest of their life or develop one or more 
recurrence. It has been estimated that approximately one third of TTP patients 
recur, with a higher risk of recurrence in those with severe deficiency of the von 
Willebrand factor cleaving-protease ADAMTS13 during acute episodes4, 8, 9 and 
remission.10-12 Few data are available on the clinical presentation and severity of 
recurrences. It is not uncommon in clinical practice to observe that TTP patients, 
aware of their condition and under close medical monitoring after the first 
episode, are diagnosed with recurrence before the development of such severe 
symptoms as coma or other signs of severe neurological involvement. 
Accordingly, Scully et al. observed that patients from the UK TTP registry 
needed less PEX procedures to reach remission during recurrences than during 
the first episode.3 However, the different severity of recurrent TTP episodes has 
never been the object of a systematic investigation. In addition, it is possible that 
a number of patients who die from a recurrence are not referred for recurrence to 
expert clinical centers which are the major source of studies on this disease, 
biasing the perception of the real severity of recurrent episodes. If confirmed, the 
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knowledge that recurrences are clinically milder than first disease episodes could 
be useful for those who design and carry out observational studies or clinical 
trials in TTP, in order to avoid lumping together patients with first episodes and 
recurrences. It would also help in clinical practice to better balance the risk of 
recurrent disease with that of side effects from potentially harmful preventive 
therapies such as the use of immunosuppressive agents. 
 
Patients and Methods 
Patients and definition of clinical categories 
Between 1999 and 2009 physicians from Italy and 10 additional countries 
(Hungary, Serbia, Canada, Germany, Iran, Lebanon, Romania, Russia, Slovenia 
and Turkey) referred patients who had a suspected diagnosis of TTP to the 
registry established at the Angelo Bianchi Bonomi Hemophilia and Thrombosis 
Centre and provided detailed clinical information and, when available, plasma 
samples. Information was collected using a standardized clinical questionnaire 
(available upon request). When necessary to fill gaps of information, clinicians 
were asked to provide additional clinical documentation and samples. Physicians 
in Milan (L.A.L. or F.P.) reviewed the cases and confirmed or excluded the 
diagnosis of TTP. Criteria for TTP diagnosis were the documentation of at least 
one episode of: (a) thrombocytopenia, (b) microangiopathic haemolytic anemia 
(c) exclusion of alternative explanations for thrombocytopenia (such as the 
enterohemorrhagic form of hemolytic uremic syndrome, catastrophic anti-
phospholipid antibodies syndrome, pre-eclampsia and related syndromes, sepsis, 
systemic inflammatory response syndrome, disseminated intravascular 
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coagulation, disseminated malignancy or bone-marrow transplantation associated 
TTP-like syndrome). Remission was defined as persistence of normal platelet 
counts and hemoglobin levels for at least 30 days after the most recent acute 
episode and freedom from new disease symptoms. The study was approved by 
the Institutional Review Board of the Fondazione IRCCS Ca’ Granda – Ospedale 
Maggiore Policlinico and all patients or their tutors gave informed consent. The 
first TTP episode was classified as secondary when associated to one or more of 
the following conditions: (1) pregnancy or post-partum, (2) use of drugs reported 
to be associated with TTP, (3) additional disease associated with TTP 
(autoimmune diseases or HIV infection). Patients who did not fit these categories 
were classified as having idiopathic disease. Presence of symptoms in each TTP 
episode was defined as prevalence of symptoms at presentation or during the 
acute phase of the disease before remission or death. Symptoms related to 
thrombocytopenia included petechiae (purpura), ecchymoses and superficial 
hematomas. Renal involvement included an increase in the serum level of 
creatinine (serum levels above the normal reference value of each laboratory) or 
presence of alterations of urinalysis such as proteinuria or hematuria. Severe 
neurological symptoms were coma, seizure and focal neurological signs 
(motor/sensory deficit or aphasia). Less severe symptoms (headache, amaurosis 
fugax, mild gait alterations) were included in the category “other neurological 
symptoms”. Cardiovascular involvement included acute myocardial infarction, 
other acute coronary syndromes, increase in cardiac troponin-T, T wave 
electrocardiographic alterations and severe hypertension. Gastrointestinal 
symptoms included abdominal pain, vomiting and diarrhea, whereas jaundice was 
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excluded from this category owing to the confounding effect of hemolysis. The 
category “other symptoms” included fatigue, dyspnea and other symptoms not 
included in the aforementioned categories. PEX procedures for each episode were 
calculated as the number of 1 volume PEX sessions carried out since diagnosis 
until remission or death; double volume exchanges were considered equivalent to 
2 single volume PEX sessions. According to Vesely et al.,4 laboratory data 
recorded as “at presentation” were the most abnormal findings recorded on the 
day of diagnosis ±7 days. To compare data from different laboratories, LDH 
values were normalized to an upper normal limit of 480 IU/L. The plasmatic 
activity of ADAMTS13 was measured centrally at the Angelo Bianchi Bonomi 
Hemophilia and Thrombosis Centre using collagen binding assay on citrated 
plasma as previously described.12 Activity of ADAMTS13 below 10% was 
considered severely deficient. The normal range for ADAMTS13 activity was 46-
160%. Data of all patients are included in a digital registry (URL: 
www.ttpdatabase.org). 
Study design 
Figure 1 provides a flow-chart of the study design. To assess the severity of 
different episodes mortality rates were compared. In addition, each disease 
episode was compared with the others in patients who had more than one episode. 
Indicators of disease severity used for comparison were the differences in the 
prevalence of symptoms, in laboratory values (platelet counts, hemoglobin, LDH, 
and creatinine), and in the number of PEX procedures carried out in the time span 
between diagnosis and remission or death. In this matched-pair analysis each 
individual served as a control for him or herself in different episodes. Patients 
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referred for only one episode were followed-up for vital status to assess how 
many of them had died of recurrent disease without notification to the caregiver 
physician and to our registry, because these events might bias the selection of 
patients with recurrent disease towards non-fatal, less severe cases. This check 
was carried out only for patients referred from Italian centres. Information on 
their vital status and (when applicable) cause of death was searched for by 
different methods: (a) direct contact of the patient, (b) check against mortality 
registries, (c) postal follow-up through the vital statistic offices of the city of birth 
or last residence of the patient.  
Statistical analysis 
Wilcoxon signed-rank test was used to compare continuous variables in the two 
disease episodes. Categorical variables were compared by McNemar test. P 
values <0.05 were considered significant. STATA 11 software was used for the 
analysis (StataCorp. 2009. Stata Statistical Software: Release 11. College Station, 
TX: StataCorp LP) 
 
Results 
After exclusion of patients who did not match the diagnostic criteria and those 
with insufficient information to establish the diagnosis (n=167), 136 patients with 
TTP were included in the cohort (number updated at July 2009). The general 
features of the cohort and clinical information on the first disease episode are in 
Table 1. Twelve patients died of the disease (9% of all patients), 10 during the 
first disease episode (7.3% of 136 patients with a first disease episode), 2 during 
the second episode (3.5% of 57 patients referred for more than one episode). 
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None of the 33 patients who had 3 or more disease episodes died of the disease. 
Of the 12 patients who died, 9 had severe deficiency of ADAMTS13 (activity 
below 10%). Plasma samples for the centralized measurement of ADAMTS13 
activity were available for 135 patients (99%): for 36 (27%) patients only acute 
disease samples were available, for 53 (39%) only remission samples and for 46 
(34%) both acute and remission samples. The prevalence of severe ADAMTS13 
deficiency was higher in the group of patients with availability of acute disease 
samples (67%, 55/82) than in those without, whereas it was lower in patients with 
only remission samples available (36%, 19/53). Among the symptom categories 
analyzed, cardiovascular symptoms had the lowest prevalence (Table 1): an acute 
coronary syndrome was diagnosed in only 5 patients, 3 of whom had an acute 
myocardial infarction. Eight of the 136 patients had an acute renal failure 
according to the RIFLE (Risk of renal dysfunction, Injury to the kidney, Failure 
of kidney function, Loss of kidney function, End-stage renal disease) criteria for 
the definition of renal failure in critically ill patients.13 Two of these 8 patients 
had severe ADAMTS13 activity, three (one with severe ADAMTS13 deficiency) 
died  of the disease at the first episode and only one, who had relapsing episodes, 
was included in the paired analysis of disease severity. Of 57 patients who had 
two or more disease episodes, clinical information on the first two episodes of the 
disease was available for 51 (90%). Their general features and clinical 
information pertaining to the two episodes are summarized in Table 2. The 
general characteristics and the clinical features at first episode in patients with 
recurrence were not different from those in patients without recurrence (not 
shown), but a severe deficiency of ADAMTS13 activity was more prevalent 
  128 
among patients who had recurrences (65%, 37/57) than those without (43%, 
29/68). In patients with multiple disease episodes, the prevalence of severe 
neurological symptoms and fever was lower during the second than the first 
episode (Table 2). Among disease-related laboratory measurements, platelet 
counts and hemoglobin levels were higher in the second episode, whereas serum 
LDH was lower (Table 2). Creatinine levels did not significantly differ between 
the two episodes. Finally, the number of PEX procedures carried out between 
diagnosis and hospital discharge was smaller for the second episode. Subgroup 
analyses were performed in groups of recurrent patients with (n=36) or without 
(n=15) severe deficiency of ADAMTS13. In the group of patients with severe 
deficiency of ADAMTS13 statistically significant differences were found for 
prevalence of severe neurological symptoms, fever, hemoglobin levels, platelet 
counts, LDH values and number of PEX until remission/death. In the group of 
patients in whom severe deficiency of ADAMTS13 was not found in the 
available samples (n=15) significant differences in the two episodes were found 
for platelet counts, hemoglobin and LDH levels. All statistically significant 
differences found in subgroup analyses were in the same direction of those 
observed in the primary analysis.  Thirty-three (65%) of the 51 patients included 
in the paired analysis of disease severity comparing the first and second episode 
in patients with recurrent disease had at least a third disease episode that 
developed at a median time of 1.3 years (range: 0.3-8 years) after the second 
episode. The third episode generally displayed milder clinical and laboratory 
features in comparison to the first and even to the second episode (Figures 2 and 
3). The prevalence of purpura (p=0.004, McNemar’s test, prevalence at first vs 
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third episode), of severe (p=0.001) and other (p=0.007) neurological symptoms, 
and of fever (p=0.002) were lower in the third than in the first episode (Figure 2). 
Hemoglobin was largely influenced by episode number (p<0.001, Wilcoxon 
signed rank test, levels at first vs third episode) and smaller but statistically 
significant effects were also observed for platelet number (p=0.004) and LDH 
(p=0.03), whereas creatinine levels were not influenced by recurrence (p=0.85) 
(Figure 3). Vital status information were requested for Italian patients reported to 
have survived the first TTP episode and not known to have had additional disease 
episodes (n=52, 75% of the 69 survivors of the first TTP episode not referred for 
recurrence) (Figure 1). Vital status information through October 2009 was 
collected for all 52 patients: by phone calls or e-mail contact with the patients 
(n=13, 25%), through mortality registries (n= 16, 31%), or from the vital statistic 
office of the birth or residence city (n=23, 44%). Only one of the 52 patients had 




The results of this study show that TTP recurrences usually have a milder clinical 
course than first episodes of the disease. Neurological involvement, the degree of 
anemia and thrombocytopenia, which were previously shown to be predictors of 
6-month mortality in TTP patients,14 were less severe in the second and third 
disease episodes than in the first. PEX sessions employed during second episodes 
were significantly less than those of the first, corroborating the other study 
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findings. The third disease episode displayed even milder clinical course than the 
first two episodes.  
There are several plausible explanations for TTP recurrences to be less severe 
than first episodes. A first argument is that recurrences are more rapidly 
diagnosed and treated. Indeed, many recurrences were diagnosed on the occasion 
of complete blood counts, in the presence of the laboratory features of TTP 
(microangiopathic hemolytic anemia and thrombocytopenia), but with mild or no 
clinical manifestations. A low prevalence of neurological symptoms, relatively 
high platelet counts and low number of PEX needed to achieve remission in TTP 
recurrences were previously reported by Bohm et al. in a study evaluating the 
course of ADAMTS13 activity during acute TTP, including 11 patients with 
relapsing TTP and 14 with a first disease episode.15 However, only two of the 
relapsing patients of that study were also evaluated during the first episode 
rendering a direct comparison impossible. Secondly, patients who tend to 
experience the most severe episodes have the highest risk of death during the first 
episode, so that survivors as a group tend to have less severe disease. Thirdly, 
selection of survivors of recurrence might have occurred; this, however, was 
ruled out by follow-up. An advantage of our study is that 51 patients with 2 or 
more TTP episodes could be directly compared during their different episodes. 
This paired-comparison design minimizes the influence of individual 
determinants of disease severity, which might arise when different individuals are 
compared in different episodes. The design of this study also allowed minimizing 
heterogeneity in the ascertainment of clinical characteristics of different episodes 
in the same patient, because patients were usually referred to the same centre for 
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first episode and recurrences. Limitations of this study were missing information 
on some patients and the small absolute number of patients studied. However, 
given the rarity of TTP and the difficulties of gathering detailed clinical 
information on clinical episodes we believe that the number and quality of data 
available for analysis were sufficient to enable the comparison of disease severity 
described in the study. The overall prevalence of fatal TTP in the TTP cohort of 
this study was 9%, with lower mortality in relapsing episodes (unmatched 
analysis). This proportion of fatal disease is consistent with the rate of mortality 
reported for other cohorts. However, because ours is a tertiary care centre for TTP 
patients offering free ADAMTS13 testing and medical assistance and counseling, 
it is possible that recruitment of our patients is biased towards survivors of TTP 
episodes. Patients who died during the first episode without being referred to our 
registry do not affect the findings of this study, which is focused on survivors of 
the first episode who developed recurrences, but may have attenuated the contrast 
in severity between first and second events. Instead, we reasoned that deaths for 
TTP occurring during recurrences, not reported to our registry, might have biased 
this study towards the recruitment of survivors of TTP recurrence, i. e., a less 
severe subpopulation of recurrent patients. To exclude the presence of this 
potential distortion of the results, patients referred for a first TTP episode were 
followed-up to assess whether or not they had died of the disease without notice 
to the Hemophilia and Thrombosis Centre. The result of this evaluation showed 
no evidence of this bias, with the only death that occurred not being causally 
related to TTP. The knowledge that recurrences are generally milder than first 
disease episodes should be considered in the design and analysis of observational 
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studies and clinical trials in TTP. An unbalance in the prevalence of patients with 
recurrent episodes in groups with a risk factor under evaluation or in two different 
treatment groups might indeed confound the ascertainment of the effect of an 
exposure or a treatment on acute disease clinical outcomes. The results of this 
study also have clinical relevance. Although recurrent episodes of TTP should 
always be regarded as a potentially fatal condition, the relatively less severe 
clinical course of recurrences should be taken into account when potentially 
harmful preventive therapies, like long-term immunosuppression, are being 
planned in patients considered at risk for TTP recurrence. 
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Figure 2. Prevalence of clinical symptoms in different episodes for patients with 




Figure 3. Disease-related laboratory measurements in different episodes for 






Table 1. General, clinical and laboratory features at first episode of the patients 
included in the study. 
 
 Variable Value 
n= 136 
GEOGRAPHIC ORIGIN  
Italy 107 (79%) 
Other countrya 29 (21%) 
REFERRED DURING:   
Acute disease 56 (41%) 
Remission  80 (59%) 
MALE SEX  29 (21%) 
AGE AT FIRST EPISODE, years   37 (28-50) 
DIED OF THE DISEASE  12 (9%) 
IDIOPATHIC DISEASE  107 (79%) 
SECONDARY DISEASE  29 (21%) 
Pregnancy  13 (9%) 
Autoimmune disease b  9 (7%) 
Drug induced c  5 (4%) 
More than one condition d  2 (1%) 
SEVERE DEFICIENCY OF ADAMTS13 ACTIVITY e  74 (54%) 
REFERRED FOR MORE THAN ONE EPISODE  57 (42%) 
CLINICAL SYMPTOMS AT FIRST EPISODE 
(n=130)   
Severe neurological  64 (49%) 
Other neurological   69 (53%) 
Cutaneous manifestations of thrombocytopenia  71 (55%) 
Bleeding   15 (12%) 
Renal involvement  47 (36%) 
Cardiovascular symptoms  15 (12%) 
Gastrointestinal symptoms  49 (38%) 
Fever  47 (36%) 
Other symptoms  50 (38%) 
LABORATORY MEASUREMENTS AT FIRST 
EPISODE (n=117)   
Platelet counts (x109/l)(n=117)  14 (7-22) 
Hemoglobin (g/l) (n=117) f  80 (65-93) 
Lactate dehydrogenase (IU/l) (n=113)  1571 (953-2330) 
Creatinine (µmol/l) (n=107)  79 (70-106) 
TREATMENT AT FIRST EPISODE (n=129)   
Plasma exchange  118 (92%) 
Number of plasma exchanges (n=105)  11 (7-19) 
Other transfusional therapy  81 (63%) 
Immunosuppressive treatment  118 (92%) 
Continuous variables were expressed as median (interquartile range). 
a Hungary (n=11), Serbia (n=10), Canada, Germany, Iran, Lebanon, Romania, Russia, 
Slovenia and Turkey (n=1 each). 
b Autoimmune thyroid disease (n=5), systemic lupus eritematosus (n=3), myasthenia 
gravis (n=1). 
c Ticlopidine (n=4), clopidogrel (n=1). 
d Pregnancy and autoimmune thyroid disease (n=1), pregnancy and systemic lupus 
eritematosus (n=1). 
e Measured during acute disease or during remission. 
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Table 2. General and clinical features at their first two episodes of the 51 
recurrent patients included in paired analysis of disease severity. 
 




Other country  10 (20%) 
MALE SEX  11 (21%) 
AGE AT FIRST EPISODE, years  35 (26-44) 
AGE AT SECOND EPISODE, years  38 (30-48) 
TIME TO FIRST RELAPSE  1.7 (0.5-3.7) 
IDIOPATHIC DISEASE  37 (73%) 
SEVERE DEFICIENCY OF 
ADAMTS13 ACTIVITYa  36 (70%) 
REFERRED FOR MORE THAN 
TWO EPISODES  33 (64%) 
   FIRST EPISODE  SECOND EPISODE 
CLINICAL SYMPTOMS (n=51)     
Severe neurological  25 (49%)  9 (18%) 
Other neurological  35 (68%)  25 (49%) 
Cutaneous manifestations of  
thrombocytopenia  33 (65%)  29 (56%) 
Bleeding  9 (18%)  3 (6%) 
Renal involvement  15 (41%)  18 (35%) 
Cardiovascular symptoms  2 (4%)  2 (4%) 
Gastrointestinal symptoms  18 (35%)  10 (20%) 
Fever  21 (41%)  8 (16%) 
Other symptoms  17 (33%)  11 (22%) 
LABORATORY FEATURES (n=47)     
Platelet counts (x109/l)  15 (8-20)  20 (10-34) 
Hemoglobin (g/l)  77 (62-97)  10 (81-117) 
Lactate dehydrogenase (IU/l)  1691 (940-2379)  1110 (563-1900) 
Creatinine (µmol/l)  70 (70-97)  79 (53-114) 
NUMBER OF PLASMA 
EXCHANGES (n=37)b  12 (7-19)  7 (5-12) 
Continuous variables were expressed as median (interquartile range).  
a Measured during acute disease or during remission. 
b Information available on n=37 patients for both episodes; information was not 
available for the first episode in n=6 patients, for the second in n=2 patients, n=6 
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Abstract 
Binding of von Willebrand factor (VWF) multimers of ultralarge size to platelets 
is considered the triggering mechanism of microvascular thrombosis in 
thrombotic thrombocytopenic purpura (TTP). We assessed the potential of VWF-
related measurements as markers of disease activity and severity in TTP. VWF 
antigen (VWF:Ag), platelet glycoprotein-Ib-α binding-conformation (GPIb-
α/BC) and multimeric pattern were investigated in 74 patients with acquired TTP 
and 73 healthy controls. VWF ristocetin co-factor activity (VWF:RCo) and 
collagen binding (VWF:CB) were also measured in a subgroup of patients. 
VWF:Ag and VWF-GPIb-α/BC were higher in TTP patients than controls. 
However, there was no apreciable difference in VWF-GPIb-α/BC between 
samples obtained during acute TTP and remission. Larger VWF multimers were 
frequently lacking in acute TTP patients, who displayed ultralarge multimers at 
remission. The degree of loss of larger VWF multimers was associated with the 
degree of abnormality of hemoglobin, platelet counts and serum LDH and was 
also associated with low levels of both VWF:RCo/Ag and VWF:CB/Ag ratios. In 
TTP, the platelet-binding conformation of VWF is not exclusively present in 
acute disease, nor is it associated with its clinical and laboratory severity. The 
loss of larger VWF multimers, accompanied by low VWF:RCo/Ag and 
VWF:CB/Ag ratio values, represents an index of disease activity and severity of 
acute TTP in patients with severe ADAMTS13 deficiency. 
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Introduction 
Thrombotic thrombocytopenic purpura (TTP), a rare disease characterized by 
single or multiple episodes of disseminated microvascular thrombosis, is 
associated with the severe plasmatic deficiency of the von Willebrand factor 
(VWF)-cleaving metalloprotease ADAMTS13.1 In patients with TTP the 
presence in plasma of highly platelet-reactive VWF forms of ultralarge (UL) 
molecular weight (ULVWF), which in physiological conditions are cleaved by 
ADAMTS13 into regular-sized multimers,2 is the main mechanism of 
intravascular platelet adhesion/aggregation and disseminated thrombosis in the 
microcirculation.3-6 A nanobody (i.e., a single domain antibody) with specificity 
towards the platelet glycoprotein Ib-α binding conformation of VWF (GPIb-
α/BC) enables to measure by immunoassay the proportion of plasma VWF which 
is highly reactive with this platelet glycoprotein.7 In TTP, VWF-GPIb-α/BC 
(measured as the ratio of VWF in its platelet-binding conformation to the whole 
circulating mass of the protein) was 2-fold (acquired TTP) to 8-fold (congenital 
TTP) higher than normal in 17 patients with acute disease,7 but only 1.5-fold 
higher in 22 patients in clinical remission.8 The higher amounts of VWF-GPIb-
α/BC suggest that a change in the conformation of circulating VWF is responsible 
for the heightened platelet reactivity that leads to disseminated microvascular 
thrombosis.  
In this study, we sought to replicate these findings and to evaluate in a large 
cohort of patients the relationship between the amount of platelet-reactive VWF 
and different clinical and laboratory presentations of acquired TTP (acute 
disease/remission, with and without ADAMTS13 deficiency). Antigen 
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(VWF:Ag) levels, ristocetin cofactor activity (VWF:RCo), collagen binding 
(VWF:CB) and the multimeric pattern of VWF were also investigated.  
 
Patients and Methods 
Patient and sample selection 
The 74 patients investigated in the study were  selected from a larger group of 
136 patients with TTP included in the Milan TTP registry (URL: 
www.ttpdatabase.org). The features of the registry and the clinical definitions 
adopted have been described elsewhere.9, 10 A patient selection flow-chart is in 
Figure 1. Selected patients with acute TTP were those with available plasma 
samples, after excluding those transfused with blood products during the 10 days 
preceding sampling. Plasma samples were also available from patients during 
disease remission. Patients included in the study with acute phase samples were 
excluded from the choice of remission samples in order to respect the 
independence of observations. A summary of the study design is in Figure 2. 
Study measurements were investigated in four primary subgroups (a-d) chosen 
according to the following criteria (see below “Rationale for subgroup 
selection”): (a) 18 patients with a first episode of acute TTP and severe 
ADAMTS13 deficiency (<6%) at presentation; (b) 16 patients with a recurrent 
episode of acute TTP (second through eighth episode) and severe ADAMTS13 
deficiency at the time of recurrence; (c) 20 patients with previous acute TTP 
currently in remission, with severe ADAMTS13 deficiency at the time of 
remission; (d) 20 patients with previous acute TTP, currently in remission with 
normal plasma levels of ADAMTS13 (46-160%). Each patient was included in 
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only one of the four primary subgroups. Additional analyses of the study results 
were carried out in subgroups formed by combining in various ways primary 
subgroups a-d: (e) 34 patients with acute TTP (group a + b, i. e., patients with 
first acute episodes plus patients during acute recurrence, all with severe 
ADAMTS13 deficiency); (f) 40 patients with previous acute TTP currently in 
remission (group c + d, i. e., those with severe deficiency (<6%) plus those with 
normal ADAMTS13 (>46%); (g) 54 patients with severe ADAMTS13 deficiency 
(group a + b + c, i. e., those with first acute episodes plus those with recurrences 
plus those in remission, all with ADAMTS13 levels <6%). For 17 of the 34 
patients with acute TTP (group e) samples collected both during acute disease 
and remission were also available and used for paired comparisons of the study 
measurements at different times of the clinical course in the same individuals. In 
this subgroup, VWF:RCo and VWF:CB were also measured and the 
VWF:RCo/Ag and VWF:BC/Ag ratios calculated. 
Rationale for subgroup selection 
Patients with first acute episodes and those with acute recurrences (n=34) were 
included in two distinct primary subgroups (a and b) because recurrences are 
usually diagnosed earlier and are milder than first acute episodes of TTP in terms 
of clinical and laboratory abnormalities, creating a possible source of 
confounding.10 We chose to analyze separately 54 patients with ADAMTS13 
<6%, whether in the acute phase or during disease remission, in order to 
investigate patients with a similar disease mechanism, i.e., the severe deficiency 
of the VWF-cleaving protease. The subgroup of 20 patients with normal 
ADAMTS13 during remission was chosen in order to allow comparison of the 
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VWF-related measurements in patients with and without severe ADAMTS13 
deficiency.  
Control group selection 
Controls for VWF:Ag and VWF-GPIb-α/BC measurements were 73 blood donors 
at the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, 
similar in age and sex with the whole group of TTP patients and with each study 
subgroup.  
Study measurements 
The multimeric pattern of plasma VWF was analyzed by sodium dodecyl sulfate 
agarose gel electrophoresis followed by luminographic visualization of 
multimers. EDTA plasma samples were diluted in order to obtain final VWF:Ag 
concentrations of 10%. Gel systems of 1% high gelling temperature agarose 
(HGT-Seakem) were chosen for low-resolution multimeric analysis. After 
electrophoresis, proteins were electrotransferred to an immobilon polyvinylidene 
fluoride membrane (Millipore, Billerica, MA) overnight and multimers visualized 
using a rabbit polyclonal anti-human VWF antibody (Dako Cytomation, 
Glostrup, Denmark) and a goat anti-rabbit IgG peroxidase conjugated antibody 
(BioRad Laboratories, Hercules, CA). The filters were stained with a luminol-
iodophenol solution, covered with transparent film, and densitometry of 
multimers was then carried out with Typhoon 8600 Variable Mode Imager 
(Image Quant TM Software; Amersham Biosciences, Uppsala, Sweden). The 
multimeric patterns of patient and control samples were compared with that of a 
reference pooled plasma run on the same gel. Densitometric analysis was 
performed on the blotted membrane using the graph line obtained by the single 
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lane of the gel and plasma samples with similar VWF concentrations in order to 
obtain comparable area values. According to Budde and Scheneppenheim,11 the 
reference plasma lane was divided into small (1-5), intermediate (6-10) and larger 
(>10) multimers of regular size. The proportion of larger multimers in the sample 
was calculated by dividing the area corresponding to larger multimers by the total 
area of the lane. The ultralarge VWF (ULVWF) ratio was calculated as the ratio 
of (i) the proportion of large multimers in the test sample to (ii) the corresponding 
area in the reference plasma within the same gel. A normal range was established 
by calculating the ULVWF ratio in 36 healthy subjects. VWF-GPIb-α/BC was 
measured using an immunoadsorbent assay,7 based upon the nanobody 
AU/VWF-a11 that specifically recognizes the VWF-GPIb-α/BC. Antibodies were 
provided by P. G. de Groot and P. J. Lenting. Before incubation, serial dilutions 
of VWF:Ag were obtained (4 dilutions with concentrations ranging from 250 
ng/ml to 31 ng/ml). The same pooled normal plasma used for the VWF:Ag assay 
was used as reference in each experiment. The VWF-GPIb-α/BC was calculated 
as the ratio of the slope of the close response curve of plasma samples to the 
slope of normal plasma pool (set to a value of 1). Plasma from a patient with type 
2B von Willebrand disease was included in all the experiments as a positive 
control, because these patients have higher amounts of VWF-GPIb-α/BC in their 
plasma.12 ADAMTS13 activity was measured using the collagen binding assay, 
anti-ADAMTS13 antibodies were searched for by western blotting.9 The lower 
laboratory limit of sensitivity of the collagen binding assay is 6%, so that 
ADAMTS13 deficiency was arbitrarily defined as severe when plasma levels 
were lower than 6%. VWF:Ag was quantified using the ACL TOP Analyzer and 
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pooled normal plasma as reference. VWF:RCo was measured by the Siemens 
Healthcare Diagnostics BC von Willebrand Reagent assay using lyophilized 
platelets in the presence of ristocetin. The test was performed in an automatic 
coagulometer (BCS, Siemens Healthcare, Milano, Italy). VWF:CB was measured 
on plasma using a solution of 95% type I and 5% type III collagens (Horm®, 
Nycomed Austria GmbH, Linz, Austria) as described previously.13 
Statistical analysis 
The chi-square or Fisher’s exact tests and Mann-Whitney U- or Student t-tests 
were used when appropriate to compare categorical and continuous variables in 
different primary and secondary study groups. The Wilcoxon signed-ranks test 
was used for paired comparisons of continuous variables. Pearson’s correlation 
was used to assess the relationships between the VWF-related measurements and 




The general features and results of VWF and ADAMTS13 measurements in the 
whole group of TTP patients and controls are shown in Table 1. Median values of 
VWF:Ag and VWF-GPIb-α/BC were higher in TTP patients than controls 
(Mann-Whitney U test, p<0.001 and p=0.004), whereas there was no statistically 
significant difference pertaining to ULVWF multimers, which, however, showed 
a much wider range of ratio values in cases than in controls. 
Among study subgroups, VWF:Ag was higher during acute TTP (first and 
recurrent episodes combined) than during remission (median value in 34 acute 
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cases 202% vs 130% in 40 remission cases, p=0.002). VWF-GPIb-α/BC values 
were not significantly different in 34 cases with acute TTP (first and recurrent 
episode combined) compared with 40 cases in remission (median values 1.20 vs 
1.31, p=0.28). There was also no difference in the paired analysis of the 17 cases 
with both acute and remission samples available (Table 2). In patients with first 
acute disease episode and remission with severe ADAMTS13 deficiency, VWF-
GPIbα/BC values were higher than in those with recurrent episodes, those with 
normal protease levels and controls (see Table 1). Owing to the lack of large 
VWF multimers, the ULVWF multimer ratio was markedly decreased in patients 
with first acute episodes, whereas it was higher than normal (due to the presence 
in plasma of ultralarge multimers) during remission in patients with severe 
ADAMTS13 deficiency (Table 1 and Figure 3A). The marked changes of the 
multimeric pattern of VWF from defective to ultralarge are shown in Figure 3B, 
which compares the ratio values during acute episodes and remission obtained in 
paired samples from 17 TTP cases.  These changes occurred particularly in 
patients who had low ULVWF ratio at the time of their acute episode and severe 
ADAMTS13 deficiency at remission (Figure 3B). The multimeric structure was 
not different from normal in patients during acute recurrences and during 
remission in patients with normal ADAMTS13 activity (Table 1 and Figure 3A). 
Figure 4 shows representative examples of VWF multimer patterns in the 
aforementioned patient subgroups. In the 17 patients with both acute and 
remission samples available, antigen-normalized values of VWF:RCo and, 
particularly, VWF:CB correlated with ULVWF ratio (VWF:RCo/Ag: r=0.71, 
p=0.01; VWF:CB/Ag: r=0.88, p=0.0006). Similarly to what observed for 
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ULVWF ratio, the VWF:CB/Ag ratio was reduced in acute TTP compared to 
remission (Table 2). The VWF:RCo/Ag ratio was reduced in the first acute 
episodes of TTP compared to the corresponding remissions (0.47 vs 0.78; n=10; 
p=0.01), but not in recurrent episodes compared to their remissions (1.03 vs 0.75; 
n=7; p=0.13). ABO blood groups influenced both VWF:Ag and VWF-GPIb-
α/BC, because both in patient and controls plasma levels were higher in carriers 
of non-O blood groups (Table 3). However, the associations of high levels of 
VWF:Ag and VWF-GPIb-α/BC with TTP remained statistically significant after 
stratification for O/non-O blood group (Table 3). The ULVWF multimer ratio 
was independent from blood groups (not shown). In patients, VWF:Ag and VWF-
GPIb-α/BC levels did not correlate with the ULVWF ratio. Finally, we chose to 
evaluate whether or not during acute TTP there was a correlation between the 
aforementioned VWF-related measurements, the degree of abnormality of 
laboratory markers of disease activity and severity (platelet count, hemoglobin, 
serum lactate dehydrogenase) and the prevalence of clinical symptoms 
(neurological, renal, cardiovascular, hemorrhagic). While there was no 
correlation between these laboratory measurements of TTP activity and VWF:Ag, 
VWF:RCo and VWF-GPIb-α/BC levels (data not shown), the ULVWF multimer 
ratio was positively correlated with the degree of anemia (r=0.48; p=0.007), 
thrombocytopenia (r=0.59; p<0.001) and negatively correlated with serum LDH 
levels (r=-0.54; p=0.003). VWF:CB/Ag and VWF:RCo/Ag ratio were similarly 
correlated with TTP-related laboratory measurements at presentation. 
VWF:CB/Ag displayed statistically significant correlations with platelet counts 
(r=0.65, p=0.01) and LDH (negative correlation with r=-0.57 and p=0.05) and a 
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trend towards correlation with hemoglobin (r=0.47, p=0.09). VWF:RCo/Ag 
showed a statistically significant correlation with platelet counts (r=0.74; 
p=0.003) and a trend towards negative correlation with LDH (r=-0.53; p=0.07). 
There was no statistically significant association with hemoglobin (r=0.37; 
p=0.19), perhaps due to the smaller sample size and lower correlation of 
VWF:RCo/Ag with ULVWF ratios compared with VWF:CB/Ag (see above). 
None of the study measurements was associated with the prevalence and type of 
clinical symptoms (data not shown). 
 
Discussion 
This study aimed to investigate the relationships between VWF-related properties 
and different clinical and laboratory presentations of acquired TTP (acute disease 
or remission with or without ADAMTS13 deficiency). In previous studies,7, 8 
plasma levels of VWF in its platelet-binding conformation (VWF-GPIb-α/BC) 
were high during acute TTP,7 suggesting that this rise might be associated with, 
or even be responsible of, the formation of platelet-rich thrombi in the 
microcirculation, and hence of disease activity. In our cohort, platelet-reactive 
VWF was indeed increased in the acute phase of the first disease episode 
(subgroup a) in comparison to controls, but during remission the plasma levels of 
this conformation of VWF were not different from those measured during the 
first acute episode. Moreover, even in patients during the acute phase there was a 
large overlap of values between them and controls. No correlation was found with 
the degree of abnormalities of such laboratory markers of TTP activity and 
severity as platelet count, hemoglobin and LDH levels. Hence, platelet-reactive 
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VWF appears to be a weak index of disease activity in these patients. Its presence 
in plasma was closely associated with the presence of severe ADAMTS13 
deficiency, indicating that the rise in the platelet-reactive conformation of VWF 
is among the prothrombotic changes induced by the deficiency of the VWF-
cleaving protease. 
There were striking differences in the multimeric structure of VWF between 
patients in the acute phase of the first disease and those in remission. The largest 
multimeric fraction of VWF was markedly reduced on electrophoresis in patients 
with a first acute episode of TTP, and this reduction was correlated with the 
degree of impairment of laboratory markers of disease activity and severity. The 
defect of larger VWF multimers was pronounced in patients during their first 
acute episode but not in those with recurrences, consistent with the views that 
recurrences are generally less severe than first disease episodes in terms of 
clinical and laboratory measurements, perhaps because they are diagnosed and 
managed earlier.4 During remission, the multimeric pattern changed dramatically, 
with the fresh appearance in plasma of ultralarge VWF multimers similar to those 
present in vascular endothelial cells and platelets, in agreement with the 
pioneering observations made by Moake et al in 1982.14 The lack of larger VWF 
multimers in patients with acute TTP was previously described in the frame of 
case reports and small case series.15-17 In this study the correlation between the 
degree of defect of larger multimers of regular size and laboratory markers of 
TTP activity and severity suggests that the electrophoretic measurement of the 
ULVWF ratio is an index of disease activity and severity at presentation, at least 
in patients with ADAMTS13 deficiency. Lack of larger VWF multimers strongly 
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correlated with low VWF:CB/Ag and VWF:RCo/Ag ratios, suggesting that 
VWF:CB/Ag and VWF:RCo/Ag ratios, which are more easily measurable than 
the ULVWF ratio, may be candidate markers of acute disease severity in TTP. 
Pertaining to the striking differences in the multimeric structure of VWF 
observed during the first acute episode of TTP in comparison with the same 
patients during remission, we offer the following mechanistic explanations. 
During acute disease the plasmatic deficiency of the metalloprotease impairs the 
cleavage of the ultralarge multimeric forms of VWF secreted in plasma from 
markedly activated endothelial cells. However, these forms and the largest 
regular sized multimers are not seen in patient plasma because they avidly bind to 
platelets, thereby causing a multimeric defect that resembles that seen in acquired 
and type 2 von Willebrand disease. Perhaps this VWF defect adds to that of 
thrombocytopenia in causing the bleeding tendency sometimes observed in the 
acute phase of TTP. Indeed no association was found in this study between 
hemorrhagic symptoms and degree of multimeric effect, perhaps owing to the 
low prevalence in our patients of these symptoms, that tend to be overlooked and 
reported less frequently in TTP cases than the more striking ischemic symptoms. 
In contrast, during TTP remission, the degree of endothelial cell activation and 
the associated secretion of ultralarge multimers are likely to be much smaller, so 
that the balance between secretion of ultralarge VWF and platelet uptake is less 
turned towards the latter than during acute disease.  The same situation of relative 
balance does perhaps take place at the time of recurrence, because recurrent 
episodes are diagnosed earlier, before massive platelet uptake of VWF is large 
enough to cause the loss of larger multimers in plasma. In TTP cases 
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characterized by normal ADAMTS13 levels during remission, the normal 
multimeric pattern uniformly observed in this study is likely to be explained by 
the restoration of a physiological degree of secretion of ultralarge VWF from 
endothelial cells that are no longer abnormally activated, as well as by the 
capacity of plasma ADAMTS13 to process ultralarge multimers into smaller 
regular sized multimers. This study has a number of limitations. The selection of 
the case material is based upon a registry for information on clinical data, 
symptoms and routine laboratory parameters such as platelet count, hemoglobin 
and serum LDH. However, the ADAMTS13 and VWF-related measurements, 
i.e., the core of this study, were centralized in one laboratory. The criteria for the 
diagnosis of TTP in the acute phase and remission are those based upon the 
exclusion of other thrombotic microangiopathies usually adopted in the medical 
literature. The criteria chosen for the analysis of primary and secondary 
subgroups are arbitrary, but the rationale for their choice is explained. 
In conclusion, this study confirms that the platelet-reactive form of VWF as 
measured with the nanobody-based immunoassay is sometime present at 
increased concentrations during TTP. However, it also demonstrates that this 
measurement is not an accurate and sensitive index of disease activity and 
severity, being detectable also in several patients at the time of disease remission. 
The most striking and consistent finding was a defect of the large VWF 
multimers during the acute phase of TTP, accompanied by low VWF:CB/Ag and 
VWF:RCo/Ag ratios. The defect of VWF multimers was associated with disease 
activity and severity, as indicated by the degree of thrombocytopenia, anemia and 
organ damage measured by serum LDH. 
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Florence; R. Vallone, AO G. Rummo, Benevento; Zatoni and Spinzi, Valduce 
Hospital, Como; C. Cristofalo, A. Perrino Hospital, Brindisi; M. G. Mazzucconi 
and C. Santoro, La Sapienza University, Rome; P. Spedini and M. Tajana, AIO 
Cremona; L. Zighetti and G. Gerli, S. Paolo Hospital, Milan; L. Gatti, M. Agnelli, 
M. Colombi and A. Zanella, IRCCS Maggiore Hospital, Mangiagalli and Regina 
Elena Foundation, Milan; S. Morandi, Istituti Ospedalieri, Cremona; G. Rossi, 
Ospedali Civili, Brescia; S. Sammassimo, AO Senese, Siena; M. C. Refe and A. 
Gabrielli, Ospedali Riuniti, Ancona; M. Simoncelli, Infermi Hospital, Rimini; E. 
Venegoni and G. Fornaroli, Magenta Hospital, Magenta; M. C. Bertoncelli, S. 
Colombi, D. Rossi and G. Gaidano, AO Maggiore della Carità, Novara; M. 
Pizzuti, S. Carlo Hospital, Potenza; R. De Cristofaro, Catholic University School 
of Medicine, Rome; S. Bulgarelli, AO Arcispedale S.Maria Nuova, Reggio 
Emilia; A. Caddori, G. Brotzu Hospital, Cagliari; F. Marongiu and A. Solinas, 
Policlinico Universitario, Cagliari; L. Sottile, Policlinico Universitario, Messina; 
G Leopardi and C. Cecchini, S.Salvatore Hospital, Pesaro. 
International Centres: B. Andjelic and D. Vucelic, Clinical Centre of Serbia, 
Belgrade, Serbia; C. Mavragani, Medical School of Athens, Greece; M. B. 
Dolnicar, University Children Hospital Ljubljana; M. Tombuloglu and O. Taylan, 
Ege Universitesi Tip Fakultesi Dahiliye AD Hematoloji BD Bornova, Izmir, 
Turkey; G. Huseyin, Trakya University, Erdine, Turkey, Mehran Karimi, 








* Number updated at the beginning of the study (July 2009). One patient had no 
available samples. 
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Figure 2. This flow chart shows the criteria followed in the selection of the 
primary and secondary subgroups from the 74 patients selected from the Milan 




Figure 3. ULVWF multimer ratio in study subgroups (A) and according to paired 
samples analysis (B). In (A) box plots were used to describe the distribution of 
ULVWF ratio across study groups. Each box plot represents median, quartiles 
and range of ULVWF ratio. Panel (B) represents paired comparisons of ULVWF 
during acute disease (left) and remission (right). In (B) closed circles denote 
patients investigated at the time of their first TTP episode, open circles those 
investigated at the time of recurrences. All patients represented in (B) had 
severely deficient ADAMTS13 activity at the time of acute disease. During 
remission, only four of the patients represented in (B) had severe ADAMTS13 
deficiency, displaying ultralarge VWF multimers in plasma with an ULVWF 
ratio above 1.20. The other patients investigated during remission in paired 




Figure 4. Multimeric analysis in pooled normal plasma (A), patient at first TTP 
episode (B), patient at recurrent (third) episode (C), patient during remission with 
severe ADAMTS13 deficiency (D), patient during remission with normal 
ADAMTS13 activity (E). Low-, intermediate-, high and ultralarge molecular 







Table 1. General features and study results in TTP (all patients and primary 
subgroups a-d) and controls. 
 
Groups and 
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ADAMTS13 activity % 93  (46-160) <6 <6 <6 <6 
89  
(55-170) 
All continuous variables were expressed as median (with ranges between parentheses) 
unless specified. 
a Expressed as medians (interquartile ranges). 
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Table 2. Study measurements in 17 patients with available acute disease and 
remission samples (paired comparison). 
Acute vs remission values were compared by Wilcoxon signed ranks test. All values 
expressed as median (interquartile range). 
  Acute disease Remission P value 
VWF antigen, %  234 (144-311) 184 (150-263) 0.35 
ULVWF multimer 
ratio 0.85 (0.54-1.14) 1.14 (0.98-1.29) 0.005 
VWF-GPIb-α/BC 
ratio 1.05 (0.98-168) 1.46 (0.81-1.94) 0.30 
VWF:Rco, % 109 (77-180) 129 (92-119) 0.20 
VWF:Rco/Ag ratio 0.65 (0.38-0.93) 0.77 (0.60-0.92) 0.37 
VWF:CB, IU/dL 112 (74-250) 166 (136-220) 0.15 
VWF:CB/Ag ratio 0.75 (0.40-0.90) 1.01 (0.78-1.12) 0.005 
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Table 3. Results of VWF:Ag and VWF-GPIb-α/BC according to O/non-O blood 
groups. 
 
VWF:Ag, % Blood group Variable Cases Controls P= 
N= 32 30 O Median 118 85 <0.001 
N= 42 43 non-O Median 194 115 <0.001 
 
 
VWF-GPIb-α/BC ratio Blood group Variable Cases Controls P= 
N= 32 30 O Median 1.01 0.79 0.06 
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Thrombotic thrombocytopenic purpura (TTP) is a rare life-threatening disease. Of 
surviving patients, 45% develops an exacerbation or a late recurrence. Severe 
ADAMTS13 deficiency is a well-established predictor of recurrence. The 
predictive value of anti-ADAMTS13 antibodies, their inhibitory activity and Ig 
class subtype is still to be established. We sought to analyze ADAMTS13 related 
biomarkers (ADAMTS13 and anti-ADAMTS13 immunoglobulins, classes and 
subclasses) and their potential relationship with prognosis. In 115 patients with 
TTP, we assessed the association between levels of these biomarkers, the severity 
of acute episodes and the risk of recurrence. During acute TTP, higher IgA, IgG1 
and IgG3 titres showed the strongest association with acute episode severity. In 
the survival analyses, the presence of IgG at acute disease, the presence of 
ADAMTS13 inhibitor or IgG during remission were all associated with a higher 
hazard of recurrence. Both the Ig class and subclass are of predictive value for 
acute episode severity in patients with TTP. Although markers that could predict 
the risk of recurrence in the acute phase are limited, a thorough assessment of 
ADAMTS13 related parameters during remission is warranted. 
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Introduction 
Thrombotic thrombocytopenic purpura (TTP) is a rare disease characterized by 
widespread hyaline thrombi, composed primarily of platelets and rich in von 
Willebrand factor (VWF). TTP manifests in the terminal arterioles and capillaries 
of multiple organs, most extensively in the heart, brain, kidney, pancreas, spleen, 
mesentery and adrenal glands.1, 2 The disorder is associated with a severe 
deficiency of the VWF-cleaving protease ADAMTS13 causing persistence of 
highly adhesive ultralarge VWF (ULVWF).3-6 Within the microcirculation, 
unfolded ULVWF multimers spontaneously seize platelets and promote platelet 
thrombi formation, eventually leading to life-threatening microvascular 
thrombosis. In patients with acquired TTP, a deficiency of ADAMTS13 is caused 
by auto-antibodies against ADAMTS13.6 Neutralizing antibodies that inhibit 
proteolytic activity but also non-neutralizing antibodies that may enhance 
clearance or disturb interaction with physiologic binding partners have been 
described.7 In most cases, anti-ADAMTS13 autoantibodies are of the IgG 
isotype, with IgG4 as the most prevalent subclass followed by IgG1.8-10 IgM and 
IgA autoantibodies have also been identified.7 Exacerbation (within 30 days of 
remission) and late recurrences (after 30 days) are frequent complications, 
reported in up to 40% of TTP patients.11-13 Most recurrences occur during the first 
year, but they have also been documented to occur years after the first acute 
event.12, 14 Several studies assessed the potential utility of ADAMTS13-related 
laboratory measurements at different stages of the disease clinical course for the 
prediction of clinical outcomes in TTP, obtaining discordant results.9, 10, 12, 15-19 In 
this multicenter study, we analyzed the association between ADAMTS13-related 
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biomarkers and acute episode severity as well as risk of recurrence in patients 
with TTP. 
 
Patients and methods 
Patients and definition of clinical categories 
Clinical centers from seven countries (Italy, Hungary, Lebanon, Romania, 
Slovenia, Serbia and Russia) participated in the study. Data collection methods 
and clinical definitions were extensively described elsewhere.20 Data of all 
patients were included in a digital database (URL: http://www.ttpdatabase.org). 
Criteria for TTP diagnosis were the documentation of at least one episode of: (a) 
thrombocytopenia, (b) microangiopathic haemolytic anemia (c) exclusion of 
alternative explanations for thrombocytopenia (such as the enterohemorrhagic 
form of hemolytic uremic syndrome, catastrophic anti-phospholipid antibodies 
syndrome, pre-eclampsia and related syndromes, sepsis, systemic inflammatory 
response syndrome, disseminated intravascular coagulation, disseminated 
malignancy or bone-marrow transplantation associated TTP-like syndrome). 
Patients were classified as in remission when they became free of symptoms and 
had normal laboratory values (except for ADAMTS13 levels) for at least 30 days 
from the conclusion of plasma therapy. Recurrence was defined as the re-
emergence of clinical symptoms or laboratory criteria compatible with a 
diagnosis of an acute TTP episode (as described above) occurring at least 30 days 
or later after remission of the preceeding acute episode. 
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Laboratory measurements 
ADAMTS13 activity was measured using the residual VWF collagen binding 
activity (CBA) assay, as previously reported.16 ADAMTS13 antigen levels were 
measured by ELISA, as previously described by Feys and colleagues.21 The anti-
ADAMTS13 antibodies were quantified using an ELISA method. Microtiter plate 
wells were coated with mouse anti-V5 antibody (Invitrogen, Grand Island, NY, 
USA) at 4 µg/mL final concentration. The plate was incubated successively with: 
1) cell-culture conditioned media containing ADAMTS13 protein at a final 
concentration of 1µg/mL; 2) plasma samples at various dilutions (1/50, 1/100 and 
1/200); and, 3) HRP-labelled anti-human IgG/IgA/IgM/IgG1,2,3,4. Between each 
step, the plates were washed with phosphate-buffered saline containing 0.1% 
(v/v) Tween-20 (pH 7.4). Bound IgG/IgA/IgM/IgG1,2,3,4 was detected adding 
OPD substrate. The optical density (OD) values were read at 492 nm using a 
reference filter at 620 nm. For IgG, the concentration of autoantibody was 
calculated as a percentage of a curve of a patient’s plasma with a high inhibitor 
titre (arbitrarily assigned a value of 100%). Normal range was calculated on 40 
normal plasmas and values higher than 2 standard deviations were considered 
positive (IgG>1.18%; IgA>0.014; IgM>0.034; IgG1>0.006; IgG2>0.013; 
IgG3>0.019; IgG4>0.003). To normalize the OD values in patients with more 
than one IgG subclass of anti-ADAMTS13 autoantibodies, a normalization 
procedure was applied as previously described by Ferrari and colleagues with 
minor modifications.10 Purified human IgG 1-4 (lambda chain, Sigma-Aldrich, St 
Louis, MO, USA) antibodies were coated on an ELISA plate in a concentration 
range of 0.125–1 µg/ml and the OD values generated from the addition of HRP-
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anti-human IgG 1-4 were recorded every 5 min up to 75 min. For each IgG 
subclass and concentration, five independent experiments were performed and the 
means of the corresponding OD values were plotted against time and analyzed by 
linear regression for each IgG subclass. The regression coefficients obtained at a 
coating concentration of 0.5µg/ml (linear range) were used to calculate the OD 
value of each subclass. Setting the OD value of IgG4 to 1, the resulting 
normalization factors were 1.1, 0.94, 1.49 for IgG1, IgG2 and IgG3, respectively. 
OD values of TTP patients positive for anti-ADAMTS13 IgG subclasses were 
normalized by multiplying them by the corresponding normalization factor. To 
obtain the IgG subclass percentage distribution in a single patient, positive 
normalized OD values of each subclass were summed and the relative proportion 
of each individual subclass was calculated as a percentage of the total absorbance 
(set at 100%). 
Statistical analysis 
To take into account the intra-individual correlation of repeated measurements 
over time, linear regression random intercept models were fitted to assess the 
association between levels of ADAMTS13 and anti-ADAMTS13 
immunoglobulins and the severity of acute episodes, defined on the basis of 
platelets counts and on the number of plasma exchanges performed. Values 
below the limit of detection (LOD) were assigned a value equal to 50% of the 
LOD. When necessary, the dependent variables were transformed (logarithm or 
square-root) to get a normal distribution. Using Cox regression models we 
analysed the hazard ratio (HR) and 95% confidence interval (95% CI) of 
recurrence in association with levels of ADAMTS13 and anti-ADAMTS13 
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immunoglobulins retrieved at the previous acute episode or during remission. In 
these analyses, we categorized CBA levels and other biomarkers and 
immunoglobulins in two (low, high) according to standard thresholds. To take 
into account within-subject correlation, frailty models were fitted. Two separate 
analyses were performed, for measurements during acute episodes and remission, 
respectively. All the analyses were performed with Stata, version 11 (StataCorp 
LP, College Station, TX, USA). 
 
Results 
We identified 166 patients with a confirmed diagnosis of TTP over the study 
period (1994-2010). We excluded 11 patients with congenital TTP and 40 
patients with plasma samples that were inadequate for analysis (gathered during 
plasma therapy), leaving 115 patients for this analysis. The general and clinical 
characteristics of the patients are summarized in Table 1. Of the 115 patients, 43 
entered the study (first plasma sample collection) with a first acute TTP event and 
7 of them developed at least one recurrent event during follow-up. Eleven 
patients entered the study with a recurrent event and 3 of them developed at least 
one subsequent recurrent event. The remaining patients (n=61) had their first 
samples retrieved during remission and 20 of them had at least one subsequent 
acute episode of TTP. Moreover, 9 patients (8%, 7 women and 2 men, aged 21-66 
years, mean age 46 years) died during the study period. Of these, 7 died during an 
acute episode of TTP. The remaining two were a 34-year-old female patient who 
died of a cerebral tumor; and a 54-year-old female patient who died of an 
unknown cause. 
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Acute phase analysis 
Samples from 70 acute TTP episodes in 62 patients were analyzed. 43 samples 
were collected during the first acute episode, 27 during a recurrence (eleven 2nd 
episodes, four 3rd episodes, five 4th episodes, three 5th episodes, one 6th 
episode, one 9th episode, two 10th episodes). During the acute phase, higher IgA 
titres were associated with lower platelet counts, while  higher IgG titres were 
associated with an increased number of plasma exchanges required to obtain 
remission. Among the IgG subclasses, IgG1 had the strongest association with 
platelet count, while IgG3 was strongly associated with both platelet count and 
the number of plasma exchanges (Table 2). There was no association between 
severity of the acute phase and ADAMTS13 antigen, activity, or inhibitor levels. 
Survival analyses 
Patients with low levels of ADAMTS13 (<10%) during the acute episode did not 
have a significantly higher hazard of recurrence, but none of 5 patients with 
normal levels (≥46%) developed recurrences. Patients with presence of IgG 
during the acute episode had a high risk of recurrence (15/50=30%) although 
hazard ratio was not estimable (none of 10 patients with absence of IgG 
developed recurrence) (Table 3). Analyses considering only ‘first’ acute episodes 
led to the same results. Patients with low ADAMTS13 activity (<10%) or 
presence of IgG during remission had a five-fold increased hazard of recurrence 
(respectively HR=4.89, 95% CI 2.00 to 11.99 and HR=4.99, 95% CI 2.08 to 
12.00) (Table 4). Moreover, low ADAMTS13 antigen (<10%) and presence of 
inhibitor in blood drawn during remission were associated with a high hazard of 
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recurrence (respectively HR=5.66, 95% CI 2.10 to 15.24 and HR=4.30, 95% CI 
2.00 to 9.21) (Table 4). 
 
Discussion 
In recent years, several studies have investigated the role of biomarkers in 
predicting recurrence of episodic autoimmune disease. Particularly meaningful in 
this respect are studies about the distribution of the specific Ig subclasses in 
relation to a number of autoimmune diseases such as rheumatoid arthritis, celiac 
disease, type I diabetes and others.22-24 These studies showed how IgG subclasses 
have a distinct biologic properties with different actions on complement 
activation and immune functions. Published data suggest that patients with a 
reduced ADAMTS13 activity during the acute episode have a higher risk of 
recurrence.12 In the present study, conducted on a large number of TTP patients, 
we did not identify a higher hazard of recurrence for patients with severe 
ADAMTS13 deficiency (<10% of activity) during the acute phase compared with 
patients with intermediate or normal levels (≥10%), but none of 5 patients with 
normal levels (≥46%) developed recurrences. Conversely, patients with severe 
ADAMTS13 deficiency during remission had a 5-times higher hazard of 
recurrence (Table 5). 
In patients with acquired idiopathic TTP and in some secondary forms, the 
deficiency of ADAMTS13 depends on the presence of anti-ADAMTS13 
autoantibodies. The predictive value of disease recurrence offered by the presence 
of anti-ADAMTS13 antibodies, their inhibitory activity, Ig classes and subclasses 
is still contraversial.15, 16 Our data add to previous findings by showing that the 
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presence of anti-ADAMTS13 inhbitors during remission also predicts the risk of 
recurrence. They also confirm that presence of anti-ADAMTS13 IgG has a strong  
predictive value for recurrence both during acute phase and remission. However, 
we did not find any association between IgG subclasses and recurrence risk 
(Table 5). We did not find an association between ADAMTS13 activity or 
antigen level and acute disease severity in acquired TTP. Moreover, we did not 
observe an association between anti-ADAMTS13 inhibitor levels and acute 
episode severity which is in disagreement with previous reports.19 Our study also 
showed that during the acute TTP phase, IgA represented the Ig class which is 
most strongly associated with the clinical severity of the acute episode (estimated 
by the number of platelets at presentation). IgA could contribute to the severity of 
the clinical manifestations by activating the complement system through the 
mannose-binding lectin pathway, thus increasing complement-mediated 
inflammation.25 In fact IgA levels have been associated with increase mortality 
from acute phase TTP.9 In this study, we identified that the IgG class and 
subclasses are also predictive of the severity of acute TTP. High IgG titres were 
associated with a higher number of plasma exchanges; and of the IgG subclasses, 
IgG1 and IgG3 were associated with the clinical severity of the acute phase of 
disease. In fact high IgG1 levels were previously suggested to increase mortality 
risk in patients with TTP.10 Detailed knowledge about the pathogenicity of the 
different isotypes may be useful to develop subclass specific immunoaphereses 
and immunotherapies capable of redirecting the isotopic switch towards less 
pathogenic isotypes and of blocking complement and inflammatory cell 
activation by acting on specific IgG subclasses. The main limitation of our study 
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is related to the nature of data retrieval. This is not a formal cohort study, since 
we have identified patients from current local registries and patients records, and 
there is no inception cohort, leading to potential referral bias. The patients, 
referred to a tertiary center from many other regional centers, could be 
representing those with highest severity, or highest recurrence rate. Those with a 
first event long ago who never had a recurrence were less likely to be included 
than those with a recent recurrence, so we may have overestimated recurrence 
risk. Those who would have had a recurrence but died, were also not included. 
Survival analyses comparing groups by laboratory parameters and acute phase 
analyses, however, were not affected by these limitations. So, while our estimates 
of the proportion of patients with severe disease and the recurrence risk per se 
may be inaccurate, we believe the analyses that showed a preponderance of 
specific biomarkers in patients with severe events or recurrence is reliable. The 
large number of patients, the long observation time available for most patients 
and the centralized measurement of ADAMTS13-related biomarkers collocate 
ours among  the most precise estimates available in the literature. 
In conclusion, we undertook a comprehensive assessment of several biomarkers, 
retrieved both at acute phase and remission, to predict outcomes in patients with 
TTP. Disease recurrence seems to be only associated with the presence of IgG 
antibodies during the acute phase, while alterations in several ADAMTS13-
related biomarkers could predict recurrence risk when measured during disease 
remission. Hence, adequate laboratory workup in this setting could help identify 
patients at risk that require closer follow up.  Although the study of IgG 
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subclasses does not seem helpful in predicting disease recurrence, its value in 
identifying the severity of the acute episodes warrants further study. 
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Table 1. Characteristic of patients. 
 
 N % 
Total 115 100 
Geographic Origin   
Italy 92 80 
Other Country 23 20 
Sex   
Male 25 22 
Female 90 78 
Age at first acute 
episode, years 
  
<20 9 8 
20-30 26 23 
30-40 33 28 
40-50 17 15 
50-60 19 16 
60-70 10 8 
>70 2 2 
Died from the disease 7 6 
Idiopathic disease 92 80 
Secondary disease 23 20 
other autoimmune disease 4 3 
Pregnancy 9 8 
Ticlopidine use 4 3 
Surgery 3 3 
Herpes Virus Infection 2 2 
Malignant disease 1 1 
ADAMTS13 at acute 
episode (N=62) 
  
<10 43 69 
≥10,<46 14 23 
≥46 5 8 
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Table 2. Relationship between ADAMTS13 related biomarkers and clinical 
severity during the acute phase. 
 
Log Platelet count Variable Slope 95%CI P value 
ADAMTS13 activity 0.005 -0.001 to 0.011 0.12 
ADAMTS13 antigen 0.003 -0.002 to 0.008 0.27 
Inhibitor 0.003 -0.0001 to 0.005 0.06 
IgG -0.0005 -0.002 to 0.001 0.42 
IgM -0.188 -0.657 to 0.280 0.43 
IgA -0.262 -0.480 to -0.045 0.018 
IgG1 -0.708 -1.197 to -0.218 0.005 
IgG2 -0.096 -1.266 to 1.075 0.87 
IgG3 -0.478 -0.817 to -0.139 0.006 
IgG4 0.069 -0.073 to 0.212 0.34 
 √Plasma exchange 
ADAMTS13 activity 0.005 -0.021 to 0.031 0.73 
ADAMTS13 antigen 0.007 -0.010 to 0.024 0.43 
Inhibitor 0.006 -0.003 to 0.017 0.17 
IgG 0.005 0.0002 to 0.010 0.04 
IgM 0.71 -0.796 to 2.218 0.36 
IgA 0.59 -0.501 to 1.675 0.29 
IgG1 1.47 -1.021 to 3.964 0.25 
IgG2 0.63 -3.034 to 4.301 0.74 
IgG3 2.55 0.005 to 5.095 0.05 
IgG4 0.21 -0.565 to 1.740 0.38 
 CI, confidence interval. 
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Table 3. Cox regression analysis of hazard of recurrence in relation to biomarkers 









Ratio 95% CI P value 
ADAMTS13 activity (%)  
≥10 18 3 1.00 Reference Reference 
<10 22 4 1.68 0.43-6.59 0.45 
ADAMTS13 antigen (%)  
≥10 18 4 1.00 Reference Reference 
<10 16 2 0.86 0.23-3.23 0.83 
Inhibitor (U/ml)  
Absent 20 4 1.00 Reference Reference 
Present 15 3 0.70 0.19-2.63 0.60 
IgG (%)  
≤1.18 5 0 1.00 Reference Reference 
>1.18 27 6 ∞ - - 
IgM  
≤0.034 25 4 1.00 Reference Reference 
>0.034 6 1 1.37 0.24-7.97 0.72 
IgA  
≤0.014 17 3 1.00 Reference Reference 
>0.014 14 2 ne   
IgG1  
≤0.006 5 1 1.00 Reference Reference 
>0.006 24 4 1.24 0.21-7.23 0.81 
IgG2  
≤0.013 6 1 1.00 Reference Reference 
>0.013 23 4 1.09 0.22-5.46 0.92 
IgG3  
≤0.019 10 2 1.00 Reference Reference 
>0.019 19 3 0.65 0.20-20.6 0.46 
IgG4  
≤0.003 7 2 1.00 Reference Reference 
>0.003 22 3 0.49 0.12-2.12 0.34 
CI, confidence interval. 
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Table 4. Cox regression analysis of hazard of recurrence in relation to biomarkers 









Ratio 95% CI P value 
ADAMTS13 activity (%)  
≥10 71 18 1.00 Reference Reference 
<10 19 9 4.89 2.00-11.99 0.001 
ADAMTS13 antigen (%)  
≥10 77 19 1.00 Reference Reference 
<10 5 3 5.66 2.10-15.24 0.001 
Inhibitor (U/mL)  
Absent 43 9 1.00 Reference Reference 
Present 13 9 4.30 2.00-9.21 <0.001 
IgG (%)  
≤1.18 50 7 1.00 Reference Reference 
>1.18 26 11 4.99 2.08-12.00 <0.001 
IgM  
≤0.034 74 16 1.00 Reference Reference 
>0.034 2 2 2.67 0.39-18.44 0.32 
IgA  
≤0.014 59 16 1.00 Reference Reference 
>0.014 16 1 0.30 0.07-1.27 0.10 
IgG1  
≤0.006 25 6 1.00 Reference Reference 
>0.006 17 6 1.29 0.61-2.71 0.50 
IgG2  
≤0.013 30 6 1.00 Reference Reference 
>0.013 12 6 1.85 0.86-3.98 0.12 
IgG3  
≤0.019 29 7 1.00 Reference Reference 
>0.019 13 5 1.45 0.59-3.58 0.42 
IgG4  
≤0.003 11 2 1.00 Reference Reference 
>0.003 31 10 1.49 0.49-4.49 0.48 
CI, confidence interval. 
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Table 5. Studies that investigated ADAMTS13-related measurements in 
thrombotic thrombocytopenic purpura. 
 




Marker Endpoint Result 
62 Acute TTP ADAMTS13 activity Acute episode severity No association 
59 Acute TTP ADAMTS13 antigen Acute episode severity No association 
56 Acute TTP Anti-ADAMTS13 inhibitor level 
Acute episode 
severity No association 
52 Acute TTP Anti-ADAMTS13 Ig class 
Acute episode 
severity 





47 Acute TTP Anti-ADAMTS13 IgG subclasses 
Acute episode 
severity 
Higher IgG1 and 




62 Acute TTP ADAMTS13 activity Recurrence 




62 Acute TTP ADAMTS13 antigen Recurrence No association 
62 Acute TTP Anti-ADAMTS13 inhibitor Recurrence No association 
52 Acute TTP Anti-ADAMTS13 Ig class Recurrence 
Presence of IgG 
associated with 
recurrence 
47 Acute TTP Anti-ADAMTS13 IgG subclasses Recurrence No association 















74 Remission Anti-ADAMTS13 Ig class Recurrence 
Presence of IgG 
associated with 
recurrence 
This study Cohort 
61 Remission Anti-ADAMTS13 IgG subclasses Recurrence No association 
Coppo et al. 
















35 Acute TTP Anti-ADAMTS13 inhibitor level 
Acute disease 
mortality No association 
35 Acute TTP Anti-ADAMTS13 Ig class 
Acute disease 
mortality 
High IgA titres 
associated with 
death Ferrari et al. 
2007 Cohort 
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higher risk or 
recurrence 
Jin et al. 
2008 Cohort 
24 Remission Anti-ADAMTS13 Ig G Recurrence No association 
48 Acute TTP Anti-ADAMTS13 IgG subclasses 
Acute disease 
mortality 
High IgG1 titres 
associated with 




48 Acute TTP Anti-ADAMTS13 IgG subclasses Recurrence 
High IgG4 titres 
associated with 
recurrence 























37 Remission ADAMTS13 activity Recurrence No association 
Zheng et al. 





















40 Acute TTP ADAMTS13 antigen Acute disease mortality 
Lower antigen 
levels associated 











* Different analyses had different sample size. 
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Abstract 
Thienopyridines are commonly used anti-platelet drugs that may be associated 
with the development of secondary, drug-induced thrombotic thrombocytopenic 
purpura (TTP), a rare but potentially life-threatening condition. We report the 
case of a 70 year-old man with a history of recurrent idiopathic TTP episodes 
who was treated with clopidogrel and then ticlopidine for thromboprophylaxis 
after percutaneous coronary intervention. Treatment was successful with no signs 
of TTP recurrence. Platelet counts and ADAMTS13 activity levels remained 
normal for months after the initiation of anti-platelet therapy, with no 
reappearance of anti-ADAMTS13 autoantibodies. This report suggests that 
thienopyridines can be used in patients with a history of TTP who are in disease 
remission.   
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Introduction 
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disease 
characterized by single or multiple episodes of disseminated microvascular 
thrombosis, with thrombocytopenia, microangiopathic hemolytic anemia and 
damage of multiple organs.1-4 TTP can be idiopathic or secondary. Secondary 
TTP is defined when the disease develops in association with medical conditions 
(i.e. HIV infection, bone-marrow transplantation and disseminated malignancy) 
or with the use of certain drugs.1 Drug-induced TTP is very rare, accounting for a 
tiny proportion of all TTP cases.2 Drugs that have been reported in association 
with TTP include quinine and thienopyridines (ticlopidine and clopidogrel), a 
class of inhibitors of platelet ADP-receptor commonly used for anti-platelet 
therapy in patients with cardiovascular disease.5 Idiopathic TTP is associated with 
severe deficiency of the von Willebrand factor cleaving protease, ADAMTS13, 
due to the presence of circulating anti-ADAMTS13 autoantibodies. By contrast, 
secondary TTP is rarely associated with the presence of anti-ADAMTS13 
autoantibodies.1 However, case-series and reviews of reported cases of 
thienopyridine-induced TTP showed a high prevalence of anti-ADAMTS13 
autoantibodies, suggesting that the use of these drugs in genetically susceptible 
patients may elicit an anti-ADAMTS13 autoimmune response similar to that of 
idiopathic TTP patients.6, 7 There are no data on the use of thienopyridines in 
patients with a history of idiopathic TTP.  
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Case description 
A 70 year-old Italian man was admitted to the Cardiology unit for elective 
coronary angiography, after a recent stress-test had shown evidence of stress-
induced angina with reversible ischemia of the inferior surface. The patient had a 
history of idiopathic thrombotic thrombocytopenic purpura with severe 
deficiency of ADAMTS13 due to anti-ADAMTS13 autoantibodies. At the age of 
69 he was admitted to another hospital for the sudden appearance of fatigue, 
diarrhea and focal neurological signs (aphasia and right upper limb weakness and 
paresthesia). Laboratory tests showed severe thrombocytopenia (platelet counts: 
20 109/L), and Coombs-negative mechanical hemolytic anemia (hemoglobin: 7.6 
g/dL), increased lactate dehydrogenase (LDH: 1968 IU/L) and hemoglobinuria. A 
diagnosis of TTP was made and the patient was treated with corticosteroids 
(prednisone, 75 mg daily) and plasma exchange (PEX), achieving remission with 
normalization of the laboratory parameters after 4 PEX procedures. Two months 
later, a new TTP episode developed. Measurement of ADAMTS13 activity by 
collagen binding assay8, 9 on plasma sampled before the initiation of PEX 
revealed severe deficiency of ADAMTS13 (ADAMTS13 activity: <6%; normal 
values, n.v.: 46-160%) with presence of anti-ADAMTS13 IgG auto-antibodies at 
western blotting analysis and ELISA measurement (antibody titre: 18%; n.v.: 
<1%).8, 9 The second episode resolved after 12 plasma exchanges. Measurement 
of ADAMTS13 at 6 months after remission, when corticosteroid maintenance 
treatment was discontinued, showed normal ADAMTS13 activity (ADAMTS13 
activity: 85%; n.v.:46-160%) with absence of anti-ADAMTS13 autoantibodies. 
Table 1 summarizes ADAMTS13-related laboratory measurements at acute 
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disease and remission. After remission, the patient started regular follow-up at the 
out-patient clinic for thrombotic microangiopathies of the Angelo Bianchi 
Bonomi Hemophilia and Thrombosis Center (Milan, Italy), with regular 
measurement of ADAMTS13 activity and follow-up clinical visits every 3-4 
months. At coronary angiography, the patient showed coronary artery bivascular 
disease with 80% stenosis of the anterior descending and circumflex arteries. 
Bare metal stents were successfully placed after pre-dilatation. During the 
procedure, the patient was treated with clopidogrel (75 mg daily) and ASA (100 
mg daily). After the procedure, a cutaneous rash developed, which was treated 
with corticosteroids. Clopidogrel was precautionarily suspended. Dual anti-
platelet therapy with ticlopidine (250 mg twice a day) and ASA (100 mg daily) 
was prescribed for the duration of one year. Complete blood counts before, 
during and after the intervention consistently showed normal platelet counts. 
ADAMTS13 activity was normal in 4 measurements 2-weeks after the procedure, 




We reported the case of a 70 year-old patient with a history of autoimmune 
idiopathic TTP treated with thienopyridines after percutaneous coronary 
intervention. The development of drug-induced TTP is a rare side effect of 
treatment with thienopyridines with an incidence rate of 1/5000 treated patients 
for ticlopidine and 1/1 million treated patients for clopidogrel.6 Thienopyridine-
induced TTP has been reported to be associated with the presence of anti-
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ADAMTS13 autoantibodies in a large proportion of cases, suggesting the 
assumption of these drugs can elicit anti-ADAMTS13 autoimmune responses.6 
The still unexplained mechanisms leading to anti-ADAMTS13 autoimmune 
response in patients with thienopyridine-induced TTP could share 
pathophysiological pathways with autoimmune idiopathic TTP. There are no data 
on the use of thienopyridines in patients with a history of autoimmune TTP. In 
this case, thienopyridines were administered in a patient with a history of 
recurrent autoimmune TTP with severe ADAMTS13 deficiency and anti-
ADAMTS13 IgG autoantibodies. At the time of treatment the patient was in 
remission and had no evidence of anti-ADAMTS13 autoantibodies. 
Autoantibodies did not reappear and TTP did not develop after treatment with 
thienopyridine. This indicates that thienopyridines do not necessarily induce TTP 
when used in patients with a history of TTP who are in clinical remission and 
suggests that the mechanisms that lead to anti-ADAMTS13 autoimmunity in 




Figure 1. Platelet count and ADAMTS13 activity and antibody levels after the 







Table 1. ADAMTS13-related laboratory profile of the patient.  
 
Variable Normal values Acute disease - second episode 
Remission - 6 
months after the 
second episode 
A13:Activity, %a 46-160% <6 90 
A13:Antigen, %b 40-155% 40 85 




Absent 2 Absent 
IgG, %e <1.18% 18 0 
IgG1, %e <0.006% 0.012 0 
IgG2, %e <0.019% 0.109 0 
IgG3, %e <0.019% 0 0 
IgG4, %e <0.003% 1.161 0 
IgM, %e <0.034% 0 0 
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In this thesis, we reported original studies on the pathophysiology of TTP and on 
severe ADAMTS13 deficiency. The findings of these studies are accompanied by 
a review of previously published data which collocates the research in the context 
of available literature. Illustrative clinical cases of the disease are also presented. 
The work herein reported enables the elaboration of a revised model of the 
pathophysiology of this rare disease. The manuscript is organized in two 
Sections. Section I is on congenital TTP, Section II is on acquired TTP. Below 
we report a summary of the Sections and Chapters of the manuscript. 
 
Section I: congenital thrombotic thrombocytopenic purpura. 
Chapter 1: this chapter reports a systematic analysis of ADAMTS13 gene 
mutations and polymorphisms. This includes original analyses on the allele 
frequency and gene localization of variants occurring in the general population 
and in patients with congenital TTP. This was the first study to report a clustering 
of age of disease onset in patients with congenital TTP carrying the same disease-
causing mutations.  
Chapter 2: this chapter reports a study on the residual activity of ADAMTS13 in 
congenital TTP and its relationships with disease phenotype. The study is the first 
to (a) describe the presence of some residual activity in the majority of congenital 
TTP patients; (b) find that the residual activity is associated with the severity of 
the disease; (c) identify residual ADAMTS13 levels that discriminate patients 
with unfavorable prognosis; (d) describe a genotype-phenotype correlation in the 
disease, with mutations in the evolutionary conserved N-terminal domains of 
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ADAMTS13 being associated with severe disease in an allelic-dose dependent 
manner. 
Chapter 3: a clinical case is presented. Residual ADAMTS13 activity was 
measured in a patient with congenital TTP during acute disease and compared 
with levels at remission. Activity was reduced to undetectable levels (i.e. below 
0.5%) during the acute phase, whereas it was detectable and above 6% during 
multiple remission samples. This illustrate how onset of acute disease is 
characterized by a drop of residual activity, indicating that a “second 
condition/event” intervened to trigger acute disease in a patient with severe 
ADAMTS13 deficiency. 
Chapter 4: this chapter summarizes emerging evidence on residual ADAMTS13 
activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura and 
discusses its implication for clinical practice and future research. 
 
Section II: acquired thrombotic thrombocytopenic purpura 
Chapter 5: the knowledge on the pathophysiology of acquired TTP is reviewed, 
with particular emphasis on the role of anti-ADAMTS13 autoantibodies. The 
feasibility of clinical trials in TTP is also discussed.    
Chapter 6: this chapter describes the prevalence of clinical symptoms at TTP 
presentation, the disease-related laboratory measurement and the episode fatality 
rate of first episodes and recurrences of TTP. A milder clinical course with 
reduced fatality rate is observed for recurrences of TTP, suggesting that these are 
diagnosed and managed earlier than first episodes. The study also implies that 
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there is a time lag between the onset of thrombosis in TTP, the appearance of 
symptoms and the diagnosis. 
Chapter 7: this chapter describes the study of ADAMTS13 and VWF-related 
laboratory measurement in acute versus remission in TTP. The goal of the study 
was to discover whether changes in VWF conformation, amount or multimeric 
pattern were associated with the onset of thrombosis in TTP. The consumption of 
multimers of ultralarge size of VWF was found to be a marker of acute disease 
severity. This Chapter shows that changes in the amount and multimeric patterns 
of VWF may trigger acute thrombosis in ADAMTS13 deficient individuals.  
Chapter 8: this chapter describes the study of ADAMTS13- and anti-
ADAMTS13 autoantibody-related measurements and their association with acute 
disease severity and recurrence risk in patients with acquired TTP. The study 
shows that both the Ig class and subclass of anti-ADAMTS13 autoantibodies are 
of predictive value for acute episode severity in patients with TTP. 
Chapter 9: a clinical case of acquired TTP is presented. Two different 
thienopyridines, a class of drugs associated with the development of TTP, were 
safely used in a patient with a history of acquired idiopathic thrombotic 
thrombocytopenic purpura. This clinical case shows that drug-induced TTP 
develops with mechanisms that are likely distinct from those of idiopathic 
acquired TTP, in spite of the presence of anti-ADAMTS13 autoantibodies in both 
conditions. 
Below we discuss the implications of the results of these studies in the 
understanding of the pathophysiology of TTP. 
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The emerging concept of residual ADAMTS13 activity and the “two-hit” 
paradigm for the pathophysiology of thrombotic thrombocytopenic purpura 
 
The discovery that ADAMTS13 plasmatic activity is severely reduced in patients 
with TTP partially clarified the pathophysiology of the disease. Severe 
ADAMTS13 activity is associated with the appearance in the circulation of  
platelet-reactive ultralarge multimers of VWF (ULVWF).1 These are in turn 
responsible for platelet aggregation and disseminated microvascular thrombosis 
that characterize the acute episode of TTP. However, the finding of severe 
deficiency alone is not sufficient to explain the clinical heterogeneity of TTP.2, 3 
TTP patients with severe deficiency of ADAMTS13 may indeed remain 
asymptomatic for years, without active thrombosis in spite of the presence of 
ULVWF in the circulation. Studies on a mouse model of severe ADAMTS13 
suggested that a second event is probably required to trigger TTP in the presence 
of severe ADAMTS13 deficiency. Adamts13 knock-out mice do not 
spontaneously develop thrombotic microangiopathy, but they do develop a TTP-
like syndrome upon the injection of shiga toxin.4 This behavior resembles that of 
human congenital ADAMTS13 deficiency, in which environmental triggering 
events such as surgery or pregnancy are often associated with the development of 
acute episodes.3, 5 These conditions might precipitate the onset of acute 
thrombosis by triggering the release of ULVWF by activated endothelial cells. 
Consistently, TTP triggering conditions/events are all accompanied by 
endothelial activation and VWF release. 
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However, also the postulation of this second event needed to trigger TTP in 
predisposed patients incompletely explains the clinical heterogeneity of the 
disease. First, triggering conditions/events are not always apparent. Second, in 
spite of similarly reduced ADAMTS13 activity (activity below 10%) and of 
similarly distributed environmental exposures (as one may assume in a 
sufficiently large population) some patients with congenital or acquired TTP 
develop frequent recurrences, whereas others may remain thrombosis-free for 
years.2, 3, 5 The discovery of the importance of residual ADAMTS13 activity 
reconciles this clinical heterogeneity with the “two-hit” paradigm. Below we 
present a model that incorporates recent evidence. 
Environmental exposures (circadian variation, inflammation, infections, traumas, 
chemicals, etc.) cause ADAMTS13 activity to fluctuate around a genetically 
determined level. In healthy individuals, these fluctuations never reach the TTP-
triggering threshold (Figure 1A). This can be defined as the ADAMTS13 activity 
level below which ULVWF multimers accumulate to the point that disseminated 
microvascular thrombosis is eventually triggered. It is unclear which is the actual 
TTP-triggering threshold, but it is conceivable that this is close to 0% of activity 
and that it is individually variable. In patients with either congenital or acquired 
severe deficiency of ADAMTS13, the fluctuations of ADAMTS13 activity occur 
at a level that is much closer to the TTP-triggering threshold. How close this is 
depends on the residual activity of ADAMTS13. The type and location of causal 
ADAMTS13 mutations are a major determinant of residual plasmatic ADAMTS13 
activity in congenital TTP patients, with mutations affecting the evolutionary 
conserved N-terminal domains of the protein being associated with lower 
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plasmatic activity. Similarly, in patients with acquired TTP the titre and affinity 
of anti-ADAMTS13 autoantibodies may determine the residual activity of 
ADAMTS13. As a result, patients with some degree of conserved activity are 
more resistant to ADAMTS13 activity fluctuations even under mild challenges of 
their fragile VWF-ADAMTS13 equilibrium. In these patients, the tiny amount of 
residual ADAMTS13 may be sufficient to prevent the excessive accumulation of 
ULVWF, until strong challenges (e.g., pregnancy) overcome the residual activity 
and trigger acute TTP (Figure 1B). This results in later age of disease onset and 
less frequent episodes in congenital patients (Figure 1B, 2 and 3). Occasionally, a 
strong challenge or other disease modifiers may determine early disease onset 
also in these patients (Figure 2). In contrast, patients with low residual activity are 
exposed to early disease and frequent episodes, because ADAMTS13 activity 
fluctuations occur at a level that is very close to the TTP-triggering threshold 
(Figure 1C). In congenital disease, early-onset disease and frequent recurrences 
are observed (Figure 2 and 3). A similar scenario occurs in patients with acquired 
TTP, with the complication that severe ADAMTS13 deficiency is not present 
since birth and may be corrected by the implementation of plasma exchange 
(PEX) and immunosuppressive therapy. Another contribution to the greater 
complexity of acquired TTP comes from the fact that antibody amount fluctuates 
as well, conceivably resulting in changes in the residual activity of ADAMTS13 
of the patients. Nonetheless, a clear association between residual ADAMTS13 
activity and risk of recurrence is observed also in acquired TTP, consistent with 
the proposed model (Figure 4). 
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The measurement of residual ADAMTS13 activity may help improve the 
knowledge of TTP-triggering mechanisms, which is necessary to develop 
adequate preventive strategies. The proposed model also has clinical implications. 
Monitoring of residual activity may assist in deciding on the implementation of 
prophylactic therapies aimed at preventing recurrences and may constitute a 
valuable surrogate endpoint for the preliminary evaluation of preventive 
strategies in clinical trials. This may improve the predictive value of ADAMTS13 
beyond what currently attained by the detection of severe ADAMTS13 





Figure 1. Panel A: fluctuations of ADAMTS13 activity over time in the healthy 
individual. Fluctuations are spontaneous or determined by environmental 
challenges. Infections, traumas, local inflammation may determine small 
deflections (broken arrow); pregnancy, infections, surgery or other currently 
unknown factors may constitute stronger challenges and determine great 
deflections in the activity (full arrow). Broken horizontal line close to 0 indicates 
the thrombotic thrombocytopenic purpura (TTP)-triggering threshold. Panel B:  
fluctuations of ADAMTS13 activity over time in individual with severe 
ADAMTS13 deficiency and relatively high (>6%) residual activity. Minor 
fluctuations do not result in the onset of TTP, whereas major challenges result in 
TTP onset. Time to onset is relatively long (horizontal line) and TTP episodes 
infrequent (arrow). The number on top of the arrow indicates the number of TTP 
episode. Panel C: fluctuations of ADAMTS13 activity over time in individual 
with severe ADAMTS13 deficiency and relatively low (<3%) residual activity. 
Minor fluctuations result in the onset of TTP. Time to onset is relatively short 
(horizontal line) and TTP episodes frequent (arrows). Numbers on top of the 




Figure 2. Relationship between age of disease onset and residual plasmatic 
activity of ADAMTS13 in congenital TTP patients. Areas indicate three different 
scenarios corresponding to the models reported above the plot. A: low residual 
ADAMTS13 activity and early age of onset. B: high residual activity and early 




Figure 3. Relationship between frequency of TTP episodes and residual 
plasmatic activity of ADAMTS13 in congenital TTP patients. Areas indicate two 
different scenarios corresponding to the models reported above the plot. Dark 
grey: low residual activity and frequent recurrences. Light grey: high residual 




Figure 4. Relationship between risk of TTP recurrence and residual plasmatic 
activity of ADAMTS13 in acquired TTP patients. Increasing levels of plasmatic 
activity of ADAMTS13 are associated with exponentially decreasing risk of 
recurrence. Patients with low residual activity have the highest risk of recurrence 
(left), patients with high residual activity are at lower risk (middle), and patients 
with normal activity have virtually no risk (right). This is consistent with 






In dit proefschrift worden de resultaten van onderzoekingen gepresenteerd naar 
de pathofysiologie van Trombotische Trombocytopenische Purpura (TTP) en een 
ernstig tekort aan ADAMTS13. De resultaten gaan vergezeld van een overzicht 
van de reeds gepubliceerde literatuur en theoretische overwegingen die de nieuwe 
gegevens een plaats geven binnen wat reeds bekend was. Bovendien worden een 
aantal ziektebeschrijvingen opgevoerd ter illustratie. Het manuscript kent twee 
secties: sectie I betreft congenitale TTP, sectie II verworven TTP. Hieronder een 
korte beschrijving van de bevindingen in ieder hoofdstuk. 
 
Sectie I: congenitale Trombotische Trombocytopenische Purpura 
Hoofdstuk 1: dit hoofdstuk bevat een systematische analyse van ADAMTS13 
genvariaties. Dit betreft analyses van de allelfrequentie en genlocalisatie van 
varianten die voorkomen in de algemene bevolking en bij patiënten met 
congenitale TTP.  In dit hoofdstuk wordt aangetoond dat de leeftijd waarop acute 
TTP manifest wordt, geassocieerd is met bepaalde genvarianten. 
Hoofdstuk 2: hier wordt een onderzoek gepresenteerd naar de residuele activiteit 
van ADAMTS13 in congenitale TTP en de samenhang met ziekteverschijnselen. 
Hierbij bleek dat er enige ADAMTS13 activiteit is bij de meeste patiënten met 
TTP, dat de mate van activiteit samenhangt met de ernst van de aandoening, en 
dat dit gebruikt kan worden om patiënten te identificeren met een slechte 
prognose. Bovendien bleek hierbij een samenhang met het genotype, waarbij 
mutaties in het geconserveerde N-terminale domein van ADAMTS13 leidden tot 
de meest ernstige vorm van de aandoening. 
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Hoofdstuk 3: ADAMTS13 spiegels werden gemeten bij een patiënt met 
congenitale TTP, zowel tijdens een acute fase als tijdens remissie. Tijdens de 
acute fase was de ADAMTS13 activiteit gedaald tot onder de detectiegrens (0.5% 
van normaal), terwijl de spiegels meer dan zes procent waren in remissie. Deze 
bevinding laat zien dat een acute fase wordt geïnitieerd door een sterke 
vermindering van de residuele activiteit, wat aangeeft dat een bijkomende 
oorzaak aanwezig moet zijn die de acute fase luxeert bij een patiënt met een 
ernstig tekort aan ADAMTS13. 
Hoofdstuk 4: in dit hoofdstuk worden recente onderzoeksresultaten samengevat 
betreffende de rol van de residuele ADAMTS13 activiteit in TTP bij mensen met 
een erfelijk ADAMTS13 tekort, met de daaruit voortvloeiende implicaties voor 
de klinische praktijk. 
 
Sectie II: verworven  Trombotische Trombocytopenische Purpura 
Hoofdstuk 5: in dit overzicht van de epidemiologie en pathofysiologie van 
verworven TTP ligt de nadruk op de rol van anti-ADAMTS13 auto-antistoffen. 
Tevens wordt besproken in hoeverre klinisch experimenteel onderzoek in TTP 
haalbaar is, gegeven de lage incidentie. 
Hoofdstuk 6: in een groep patiënten met verworven TTP is nagegaan wat de 
prevalentie van de verschillende symptomen was ten tijde van de acute 
manifestatie van de ziekte, welke waarden in het laboratorium gevonden werden, 
en wat het overlijdensrisico was, zowel bij eerste TTP als bij recidieven. Hierbij 
bleek een milder klinisch beloop en een lagere sterfte bij recidieven van TTP dan 
bij een eerste acute manifestatie, hetgeen naar alle waarschijnlijkheid is terug te 
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voeren op snellere diagnostiek en een eerder aangevangen behandeling bij een 
tweede episode dan bij de eerste. Dit impliceert dat er met name bij een eerste 
episode enige tijd verstrijkt tussen het begin van stolselvorming bij TTP en de 
eerste symptomen, en het stellen van de diagnose. 
Hoofdstuk 7: in het onderzoek dat beschreven wordt in dit hoofdstuk was het 
doel na te gaan of veranderingen in von Willebrandfactor, hetzij in de ruimtelijke 
vorm, de concentratie of het multimerenpatroon, samenhangen met het optreden 
van acute TTP bij een ernstig verworven tekort aan ADAMTS13. Het bleek dat 
met name de afwezigheid van ultragrote multimeren van von Willebrandfactor 
samenhing met de ernst van de acute ziekte. Dit onderzoek heeft daarmee 
aangetoond dat veranderingen in de hoeveelheid en multimeerpatronen van von 
Willebrandfactor acute trombose kunnen initiëren bij patiënten met een tekort aan 
ADAMTS13. 
Hoofdstuk 8: dit hoofdstuk richt zich op metingen van verschillende auto-
antistoffen tegen ADAMTS13 en hun samenhang met de ernst van acute episoden 
en het herhalingsrisico bij patiënten met verworven TTP.  Hierbij bleek dat met 
name IGg klasse en subklassen van voorspellende waarde zijn voor de ernst van 
de acute episode. 
Hoofdstuk 9: een patiënt met verworven TTP wordt besproken bij wie twee 
verschillende thienopyridines als geneesmiddel gebruikt waren zonder dat dit tot 
complicaties leidde, terwijl van deze groep geneesmiddelen bekend is dat zij TTP 
kan induceren. Dit suggereert dat TTP in samenhang met het gebruik van 
bepaalde geneesmiddelen een andere ontstaanswijze kent dan idiopathische 
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verworven TTP, ondanks de schijnbare overeenkomst door de aanwezigheid van 
antistoffen tegen ADAMTS13 bij beide vormen. 
 
Het concept van residuele ADAMTS13 activiteit en het tweetrapsparadigma voor 
de pathofysiologie van trombotische trombocytopenische purpura 
De aanwezigheid van een ernstig tekort aan ADAMTS13 is niet voldoende om de 
klinische heterogeniteit van TTP te verklaren. Volgens het ‘tweetrapsparadigma’ 
fluctueren de concentraties van ADAMTS13 rond een genetisch bepaald niveau. 
In gezonde individuen leiden deze fluctuaties, die het gevolg zijn van 
omgevingsfactoren, nooit tot bloedspiegels onder de kritische drempel voor TTP - 
dat is, een activiteit van ADAMTS13 waarbij ultragrote von 
Willebrandfactormultimeren aanleiding geven tot microvasculaire thrombose. Bij 
patiënten met een aangeboren of verworven tekort aan ADAMTS13 vinden deze 
fluctuaties plaats rond een spiegel die al dicht tegen deze drempelwaarde aanligt. 
Hoe dicht hangt af van de residuele ADAMTS13 activiteit. Hierdoor zijn 
patiënten met enige residuele ADAMTS13 activiteit bestand tegen de fluctuaties 
die milde stimuli opwekken, en zullen zij ondanks hun fragiele VWF-
ADAMTS13 equilibrium nog geen TTP ontwikkelen. Daarentegen zijn patiënten 
met lage residuele activiteit zeer gevoelig voor een omgevingsstimulus (de 
“tweede trap”) en zullen zij daardoor veelvuldig recidieven van acute episodes 
van TTP doormaken. Dit alles impliceert dat het bijhouden van de residuele 
ADAMTS13 activiteit waardevolle prognostische informatie kan opleveren bij 
patiënten met TTP en een ernstig tekort aan ADAMTS13. 
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